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Abstract
Image Guided Intensity Modulated Radiotherapy (IG-IMRT) incorporates novel 
imaging strategies into IMRT planning and delivery. FDG-PET/CT imaging may
be used to identify potentially radioresistant tumour cell populations in head 
and neck cancer [HNC). Dose-painting w ith  IMRT is a novel technique which 
provides an opportunity to widen the therapeutic w indow by dose escalation to 
radioresistant subvolumes.
The purpose of this thesis was to evaluate the feasibility of this technique, to 
provide methodology for identification of the FDG-avid region and to inform on a 
reasonable dose level to use in a future phase I clinical study investigating dose- 
painting to the FDG-avid target volume. This technique requires confidence in 
the quality of geometric and dosimetric accuracy of delivery and this issue was 
investigated in this thesis.
Pre-clinical work included a comparison of five different FDG segmentation 
techniques. One of these techniques was used to identify the FDG-avid biological 
volume selected to receive dose-painting w ith  IMRT in a planning study. Four 
dose levels were tested. Radiobiological modelling was used to determine an 
optimal dose level as the basis for a future clinical study and to determine the 
impact of using different FDG segmentation techniques. A clinical study was 
performed in patients w ith  HNC to compare in-room volumetric imaging - cone 
beam computed tomography (CBCT) -  w ith  planar kilo voltage (kV) electronic 
portal imaging (EPl) for aspects of image guidance and to inform  on appropriate 
planning margins.
Pre-clinical work suggested that dose-painting w ith  IMRT to the FDG-avid 
subvolume would be associated w ith  increases in estimated tum our control 
probability (TCP) and w ith  acceptable increases in normal tissue complication 
probability (NTCP). Verification using CBCT provided accurate data to guide 
treatment delivery and appropriate planning margins. The findings reported in 
this thesis provide valuable information that w ill inform  the design of future 
clinical studies.
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Chapter 1: Introduction
Whilst radical radiotherapy is able to achieve high cure rates for early stage head
and neck squamous cell carcinomas (HNSCC), the cure rates in the locally 
advanced setting are considerably worse. Up to 50% of patients who present 
w ith  locally advanced disease w ill experience locoregional failure following 
radical treatment, with the majority of cases recurring w ith in  the high dose 
target volume.
Existence of a radiation dose-response relationship [1] has motivated attempts 
to increase cure rates by intensifying treatment. Escalation of the radiation dose 
is one potential strategy and dose-painting with intensity modulated
radiotherapy (IMRT) can be used to achieve this. Dose painting is a technique 
which exploits the heterogeneous dose distribution produced by IMRT by 
prescribing 'hot spots' of dose to carefully selected subvolumes usually lying 
w ith in  the high dose target volume (TV) [2].
Image guidance, in its simplest definition, describes any aspect of the patient 
pathway which incorporates the use of imaging technology [3]. Image guided 
intensity modulated radiotherapy (IG-IMRT) refers to the use of advanced 
imaging technology to identify the target volume to be treated with IMRT [4]. 
This may include functional imaging, such as i^F-fluorodeoxyglucose (FDG) 
positron emission tomography (PET), to guide selection of a dose painting target 
in radiotherapy planning. Further along the patient pathway, in-room volumetric 
imaging, such as cone beam computed tomography (CBCT), is a recent 
technological advance which can be used in the treatment verification [5].
Pre-clinical and phase I clinical study data suggest that dose-painting w ith  IMRT 
has the potential to improve the therapeutic ratio of radical radiotherapy to 
HNSCC [6, 7]. The w ork performed in this thesis explored aspects of these 
emerging technologies. In the firs t part of this thesis, a comparison of FDG-PET 
segmentation techniques to identify a suitable target for dose-painting (Chapter 
2), and a pre-clinical study to evaluate the potential advantages of dose-painting 
w ith  IMRT (Chapter 3), are presented. The second part of this thesis evaluates
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aspects of IMRT treatment delivery. A clinical study evaluating the potential of 
image guidance using CBCT to improve the geometric accuracy of IMRT delivery 
to HNSCC (Chapter 4) is reported. Pre-clinical work to evaluate how CBCT scans 
acquired during treatment could he used to guide adaptive radiotherapy 
strategies is also presented (Chapter 5). Finally, Chapter 6 summarises the 
findings presented in this thesis.
1.1. Epidemiology
Head and neck cancer (HNC) has an incidence of 3% of all malignancies and is 
the fifth  most common tumour worldwide. M ortality is high, w ith  more than 300 
000 deaths yearly worldw ide attributable to the disease [8, 9]. In the UK in 2008, 
8082 persons were diagnosed w ith  head and neck cancer (excluding paranasal 
sinus and nasopharyngeal disease). The incidence is predicted to rise by 500- 
1000 per year by 2012 [10]. Oral cancer (oral cavity and pharynx) [11] 
constitute the largest group of head and neck cancers, w ith  5790 newly 
diagnosed cases in 2008. The incidence of oral cancers is rising, w ith  the 
reported three year average incidence rate in men rising by 24% between 1997 
and 2008, and a sim ilar increase of 21% in women. Incidence in men aged in 
their 40s and 50s has more than doubled in contrast to incidence in older men 
aged in their 70s, which has remained relatively stable. W hilst the cure rate for 
early stage disease is high (above 80-90%), the m ajority of patients present w ith  
locally advanced disease which is associated w ith  lower cure rates of up to 50- 
6096 [12,13].
1.2. Treatment of Head and Neck Squamous Cell Carcinoma
Management of head and neck squamous cell carcinomas (HNSCCs) is
challenging. These tumours exhibit rapid growth and in filtra te  deeply. They are 
frequently found close to or in filtra ting critical structures, causing pain and 
functional loss. Radical approaches to treatment chiefly consist of surgery, 
radiotherapy or a combination of the two [9]. The principle advantage offered by 
radiotherapy compared to surgery is that of organ preservation. The addition of 
chemotherapy and biological agents to radiotherapy confers an absolute benefit 
in overall survival of 4.5% [14].
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Although radiotherapy offers a non-surgical treatment option, the risks of acute 
and late toxicities of treatment remain considerable. Intensity modulated 
radiotherapy (IMRT) is a highly conformai technique which facilitates a 
deliberately inhomogeneous dose distribution, allowing higher doses to be 
delivered to tumour volumes whilst minim ising dose to the nearby organs at risk 
[OARs] [15, 16]. The steep dose gradients produced by IMRT can be 
advantageous to the patient in terms of reducing m orbid ity but, w ith  
locoregional failure being the most common presentation of treatment failure 
following radical radiotherapy, the quality of target volume delineation becomes 
even more im portant than w ith  conventional 3D conformai radiotherapy 
techniques which by nature of the ir technique, deliver radiation to much larger 
volumes.
1.3. Patterns of treatment failure
Several groups have reported that the site of locoregional treatment failure is
frequently within the high dose target volume [Table 1.1).
Table 1.1. Reported patterns of locoregional failure following IMRT.
Author Year n Media LRF 
n
follow
up
Site of recurrence
Schoenfeld 2008 100 37.2m 10,10%
et a l [17]
Soto etc/ 2008 61 22m 9,15%
f ig ;
Huang et a/ 2008 71 33m 7,10%
f ip ;
Eisbruchet 2004 133 32m 21,16%
Lee eta/ 2003 107 25m 4,4%
/ 2 i ;
Chao et a/ 2003 126 26m 17,13%
8 high dose PTV, 2 marginal
9 high dose PTC
7 prim ary GTV
17 infield, 4 marginal
4 in GTV
9 CTVl, 1 marginal to 
CTVl/inside CTV2,1 CTV2,
5 matched lower neck field
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Dawson et 2000 58 27m 12,21% 9 GTV
a/f2g ;
n, number o f patients; LRF, locoregional failure. The high incidence of 
locoregional failure occurring w ith in  the high dose PTV suggests the following: 
a) that standard delineation techniques are selecting high risk regions 
adequately but b) a subset of tumour clonogens may exist w ith in  these selected 
high dose regions that appear relatively radioresistant to the tumorical effects of 
standard high doses equivalent to approximately 70Gy in 2Gy daily fractions.
Radioresistance describes the relative resistance of cells to the biologic effects of 
ionising radiation [24]. A number o f factors can influence the radiosensitivity of 
a tumour, including physical -  for example, tum our size or histopathological 
grade - and biological prim ary tumour characteristics such as intrinsic 
radiosensitivity, hypoxia or proliferation status.
1.4. Strategies to overcome treatment failure
Various strategies have been proposed to increase non-surgical cure rates in the
setting of locally advanced HNSCC. Existence of a radiation dose-response 
relationship in HNSCC suggests that intensification of the radiation dose may 
increase tumour cell k ill and thereby improve cure rates. Radiation dose 
intensification may be achieved by the addition of radiosensitisers such as 
platinum-based chemotherapy or biological agents such as cetuximab [14, 25- 
28]. Modification of the radiotherapy treatment schedule by acceleration or 
modified fractionation has also been shown to be beneficial in terms of tumour 
control and normal tissue toxicity [29-32]. Radiation dose escalation is another 
strategy that until the introduction of IMRT was lim ited by the risk of excessive 
increases in dose to surrounding normal tissues and associated toxicity.
Intensity modulated radiotherapy [IMRT] is a highly conformai treatment 
technique which produces heterogeneous dose distributions w ith  steep 
gradients of dose change. IMRT planning techniques such as simultaneous 
integrated boost [SIB] [33] or simultaneous modulated accelerated radiation 
therapy [SMART] [29] boost can be employed to 'steer' hot spots of radiation 
dose to subvolumes w ith in  the standard tum our target volume which have been 
carefully selected on the basis of functional characteristics relating to the
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tumour. This strategy has been termed dose painting w ith  IMRT [2] and offers an 
opportunity for radiation dose escalation.
1.4.1. Dose-painting with IMRT
Dose-painting w ith  IMRT is a novel approach to prescribing radiotherapy and
was firs t proposed in 2000 by Ling et al (figure 1.1] [2]. It involves 'painting' a 
boost dose of radiation to a volume which has been carefully selected on the 
basis of functional or biological imaging characteristics which may suggest 
radioresistance [34]. Metabolic activity, proliferation or hypoxia may be 
associated w ith  increased radioresistance in a tumour, leading to failure of local 
tumour control following radical radiotherapy at standard doses. Functional 
imaging modalities such as positron emission tomography [PET] can be used to 
image these behavioural characteristics and hence may facilitate identification of 
a population of relatively radioresistant tum our clonogens. These radioresistant 
cells can be dose painted in order to increase the chance of achieving total 
tumour cell kill.
Figure 1.1. Dose-painting with IMRT as proposed by Ling et al [2].
Biologieal Target Volume?
PTV
GTV
An idealized schematic illustrating the concept o f biological target volume (BTV). 
Whereas a t present the target volume is characterized by the concepts o f GTV, CTV,
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and PTV, biological images may provide information fo r  defining the BTV to 
improve dose targeting to certain regions o f the target volume. For example, 
regions o f low p02 level may be derived from  PET-lBF-misonidazole study, high 
tumor burden from  MRl/MRS data o f choline/citrate ratio, and high proliferation  
from  PET-1241UdR measurement [2].
Dose painting can be performed in one of two ways: dose-painting-by-contours 
[DPBC) or dose-painting-by-numbers [DPBN] [35-38]. DPBC is a more standard 
approach and uses a binary prescription of dose to a delineated target volume -  
either the entire volume receives the boost dose, or none of it  receives a boost 
dose. DPBN is a novel concept in dose and was firs t proposed by Bentzen in 2005 
[39]. The principle is to prescribe dose as a function of each voxel's signal 
intensity, thus delivering higher boost doses to the 'hotter' voxels thought to 
represent greater radioresistance and lower boost doses to those deemed to be 
at less risk.
Bentzen et al first proposed DPBN in the setting of prostate cancer [figure 1.2] 
[39]. Blood oxygen level-dependent magnetic resonance imaging [BOLD MRl] 
[shown on the right] was performed to produce a voxel map showing a range of 
hypoxic levels in the tumour. On the left, the non-linear scale shows the 
prescribed dose as a function of signal intensity.
Figure 1.2. Dose-painting by numbers [DPBN] as proposed by Bentzen et 
al in tbe setting of prostate cancer [39].
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BOLD MR image o f a patient with prostate cancer. The region o f interest was 
defined from  haematoxylin-eosin staining o f the prostate sections and transferred 
to the MR image. The distribution ofR2* values in the region o f interest covers the 
range o f oxygenation status from  normal to anoxic. Dose-painting by numbers 
involves the prescription o f a specific, physically absorbed dose o f radiation on a 
v o x e /-6 y -v o x e /  occorc^zn^ ùo a  d ^ z z e z f  p rescnp (:zozz /zzzzcfzozz znzyzcafecf 
the non-linear scale below the histogram. Courtesy o f N J Taylor, D Cornell, and A 
Padhani, Mount Vernon Hospital, UK[39].
The differences between DPBC and DPBN are summarised in Table 1.2.
Table 1.2. Comparison between dose-painting by contours (DPBC) and 
dose-painting by numbers (DPBN).
DPBC DPBN
Advantages
• Simple, binary • Elegant, may model tumour
biological properties better
• Potentially simpler to • May reduce volume of boost dose
interpret clinical outcomes and therefore may be associated
w ith  less m orbid ity than with
DPBC
• Phase 1 data lim ited • Phase 1 data even more lim ited
• No special software • May allow even higher dose
modifications required escalation due to smaller volume
sizes
Disadvantages
• May result in larger volumes • Custom software required
than necessary being given
boost dose
• May lim it size of volume to • Represents voxel-level conformity -
receive dose what is the relevance given
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temporal variation in uptake, 
treatment delivery constraints and 
what is the risk of inaccurate 
delivery
Uncertainty whether imaging •  Does the therapeutic gain balance
modality provides accurate the resources-intensive workload
representation of 
radiosensitivity
Optimal method of delineation • How to decide on most appropriate
as yet unresolved dose prescription function
The strategy of DPBC is a simpler and more w idely available tool than that of 
DPBN. Early clinical data in the setting of HNSCC has been reported for both 
approaches [6, 7]. Regarding DPBN, there are issues relating to the potential 
temporal changes at voxel level, constraints o f accurate IMRT calculation 
algorithm and accurate treatment delivery at sub-centimetre level, combined 
w ith  the need for custom software to be developed.
1.4.2. PET in radiotherapy planning to head and neck cancers
Conventional radiotherapy planning involves delineation of target volumes (TV)
and organs at risk (OAR) volumes using computed tomography (CT) images. CT
is w idely available, provides good quality images, particularly when intravenous 
contrast is added, and importantly, provides electron density data essential for 
dosimetric calculations in radiotherapy treatment planning. Limitations of CT 
include relatively poor definition w ith in  soft tissues which is a potential problem 
in a tum our site such as the head and neck region, in which typically mucosa- 
originating prim ary tumours, for example, tongue base tumours, often display 
sim ilar characteristics as the surrounding soft tissues.
PET is w idely available and a range of PET tracers are in use. PET can provide 
functional inform ation about a tumour which in turn  can be combined w ith  the 
anatomical detail provided by CT or magnetic resonance imaging (MRI). The 
incorporation of FDG-PET data has been shown to reduce inter-observer 
variab ility in target volume delineation [40, 41]. FDG-PET-based contouring
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alone has also been shown to correlate the closest w ith  'true' tumour extent 
compared w ith  CT and MRI, as measured on histopathological specimens [42].
Limitations of PET that must be acknowledged are as follows: poor resolution 
(approximately 5-7mm), low signal-to-background ratio associated w ith  some 
tracers and effects of partial volume. These issues may lead to either under- or 
over-estimation of lesion sizes [37]. PET scanning protocols differ between 
centres and therefore strict standardisation w ill be required i f  dose painting 
techniques are to be employed in the research setting. Finally, PET tracers are 
markers of functional activity and despite clinical evidence suggesting 
correlation between marker uptake and tum our behaviour, assumptions are 
inherent in the interpretation of imaging.
Despite these limitations, the non-invasive imaging technique associated w ith  
PET, the wide availability, large range of tracers and wealth of clinical experience 
have promoted PET as a popular tool to guide target volume definition.
I.4 .2 .I. Value of FDG as PET tracer In HNC
A large range of PET tracers is available for imaging specific biological tumour
characteristics that may be used as surrogates in the identification of 
radioresistant cell populations. Three main groups of tracers which have been 
investigated in the setting of HNSCC are presented in Table 1.3.
Table 1.3 Selection of PET tracers under evaluation in HNSCC.
Molecular uptake 
mechanism Tracer Isotope Availability
Glucose metabolism FDG lep Commercially available
Proliferation FLT 18p In-house production/cyclotron
FMISO 18p In-house production/cyclotron
Hypoxia FAZA 18p In-house production/cyclotron
Cu-ATSM 64CU In-house production/cyclotron
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FDG -  i^F-fluorodeoxyglucose; FLT -  i^F-fluoro-L-thymidine; FMISO -  i^F- 
fluoromisonidazole; FAZA -  i^F-fluoroazomycin arabinoside; CuATSM -  64Cu- 
diacetyl-bis(N'^I-methylthiosemicarbazone.
FDG-PET has been reported to be associated w ith  a sensitivity ranging between 
71% and 98%, and a specificity ranging between 82% and 100% in the setting of
HNC [43-46]. FDG-PET can be used to guide TNM staging in HNC at diagnosis and 
has been helpful in identifying the primary tumour in around 25% of cases 
in itia lly  suspected to present with a possible diagnosis o f metastatic squamous 
cell carcinoma of unknown prim ary [47, 48]. It is often used to assess the 
response to radiation or chemoradiation. Currently, a large UK multicentre 
randomised phase 111 tria l comparing PET-CT guided watch and wait policy 
versus planned neck dissection for the management of locally advanced (N2-3) 
nodal métastasés in HNSCC is well underway, w ith  a target sample size of 560 
patients [49].
FDG uptake as seen on PET has been shown to correlate w ith  histopathological 
tumour extent [42, 44]. Although proliferation and hypoxia tracers such as i^F- 
fluoro-L-thymidine (FLT) and Cu-diacetyl-bis(N(4)-methylthiosemicarbazone 
(CuATSM), respectively, are under evaluation, FDG, a marker of metabolism, 
remains by far the most widely used and available tracer. Practical advantages 
include a half-life of 110 minutes whilst caveats of use include difficulties in 
identification of false negative results for malignancy in locations of normal 
physiological and inflammatoiy uptake.
Clinical studies have reported correlation between pre-treatment FDG uptake on 
PET and sites of local recurrence following definitive treatment. Soto et al 
compared pre-treatment FDG-PET-defined biological target volume (PET-BTV) 
with the anatomical sites of loco-regional failure after radiotherapy for HNSCC 
[18]. At a median follow-up of 22 months, 9 out of 61 patients had developed 
locoregional failure, w ith  all failures occurring w ith in  the original gross target 
volume (GTV) (and w ith  8 out of the 9 failures occurring w ith in  the PET-BTV. 
Dirix et al performed a prospective study, comparing FDG PET w ith  FMISO PET
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and functional MRI [diffusion-weighted and contrast-enhanced] to evaluate the 
potential for to select an appropriate dose painting target in HNSCC. Disease 
recurred in 7 out of 15 patients, w ith  all recurrences being noted w ith in  the pre- 
Lreatment FDG-avid volume and 4 recurrences mapping to the pre-treatment 
FMISO-avid volume [50]. These results support the use of FDG as a marker to 
identify an appropriate dose- painting target volume.
1.4.2.2. FDG-PET-guided dose-painting with IIVIRT in HNSCC
Currently, the majority of w ork reporting clinical experience w ith  dose-painting
using IMRT to HNSCC relates to volumes identified by FDG-PET scanning. In 
2007, Madani et al reported the firs t clinical use of this technique to this tumour 
group. The authors reported a prospective phase 1 study in which FDG-PET was 
used to guide dose escalation of tumour sub-volumes w ith in  the prim ary tumour 
[6]. Forty-one patients were enrolled and treated in two cohorts of differing dose 
levels [D L l and DL2]. Both cohorts received a dose of 69.12Gy in 32 fractions to 
the high dose planning target volume (PTV). Twenty patients were treated in the 
D L l group and received a total dose escalation of the FDG-PET subvolume of 
72.52Gy in 32 fractions. Ten patients were treated in the DL2 group in which the 
FDG-PET subvolume received a total dose of 77.52Gy in 32 fractions. The 
reported late grade 3 or more dysphagia rate was 25% in DLl and 14% in DL2. 
These rates contrast w ith  an reported rate of enteral tube feed dependency -  
equivalent to grade 3 dysphagia -  of up to 6% at some centres [16, 51-54] but 
also up to 24.6% [55], using standard dose levels in sim ilar groups of patients. 
Interestingly, the m ajority - over half -  of the local relapses were found to occur 
w ith in  the FDG-avid region which was selected to receive dose-painting. This 
provides support for the theory that FDG-PET can be used to detect potentially 
treatment-resistance regions.
More recently, the same Belgian group reported firs t clinical results from a phase 
1 study of patients w ith  HNC which investigated the feasibility of adaptive IMRT 
using dose-painting by numbers [DPBN] [7]. Duprez et al performed a complex
study in which three separate IMRT plans were optimised for each patient. 
Again, patients were assigned to one of two dose level groups: D L l and DL2. 
Seven patients treated in D L l received median doses of 80.92Gy to the high dose
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clinical target volume (CTVl) and seven patients in DL2 received a total median 
dose of 85.92Gy to the gross tumour volume (GTV). These doses were equivalent 
to 91Gy (DLl) and 102Gy (DL2), in 2Gy fraction sizes. No grade 4 acute toxicity 
was observed. In terms of grade 3 acute toxicities of any type, six out of seven 
patients in D L l were affected, w ith  only six out of the fourteen patients in DL2 
reporting the same degree of toxicity. Severe dysphagia (grade 3) was more 
prevalent in DLl, leading to more patients requiring percutaneous gastrostomy 
(PEG): five patients in D L l compared w ith  three patients in DL2. The authors 
concluded that this study showed that adaptive DPBN to the FDG-avid 
subvolume is feasible. They also highlighted that there a significant volume effect 
was noted w ith  respect to acute toxicity: when the target for dose escalation was 
smaller (the GTV in DL2, versus the CTVl in D Ll), acute toxicity was less 
frequent.
1.4.2.3. FDG PET segmentation
Image segmentation is the process o f dividing up a digital image by assigning a
label to each pixel contained therein according to each pixel's value. The net 
result generates contours. This process -  often termed 'outlining' or 'delineation' 
of target volumes (TVs) or organs at risk (OARs) - is an im portant part of 
radiotherapy planning. Conventional TV or OAR delineation for three- 
dimensional conformai radiotherapy (3D-CRT) is performed on CT images by 
clinical oncologists, sometimes in collaboration w ith  radiology colleagues.
In contrast to imaging by CT, tumours tend not to have well-defined edges on 
PET imaging. The interpretation of FDG-PET is prone to large inter- and in tra ­
observer variab ility  and leads to questions asking what is the optimal method of 
image segmentation and whether it  is clinically relevant [56].
Visual interpretation by clinicians is probably the most w idely used method but 
is prone to significant inter- and intra-observer variab ility  [57]. Such factors are 
inevitably influenced by the training and experience of the clinician, which w ill 
vary between centres and w ill strongly influence an individual's philosophy for 
determining areas of uptake as true or false positive for cancer.
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Semi-automated segmentation methods tend to be based on absolute or relative 
thresholds of uptake which can be measured in units of the actual numerical 
value within a pixel (Becquerel (Bq)/m l or counts) or standardised uptake value 
(SUV) (Bodyweight per gram (bwg)/ml). As w ith  the clinician method, this 
method has the risk of further under- or over-estimating tumour extent but 
advantages include reproducibility and simplicity. PET scan reconstruction may 
result in bias of the pixel of highest -  or 'hottest' -  value. This effect can be 
smoothed by either averaging the uptake w ith in  a specified area around the 
hottest pixel or by normalising to a characteristic such as body weight or body 
glucose at time of scan. Examples of an absolute threshold include a specified 
percentage of maximal signal intensity (PMSl) or an arb itrary SUV such as 2.5, 
which has found some favour in the setting of lung cancer. The interpretation of 
imaging in lung cancer differs to HNC in that lung cancer tumours are frequently 
surrounded by tissues of relatively low density, such as the lungs themselves, in 
contrast to HNC, where tumours are often mucosally based and closely 
associated with tissues of sim ilar densities, such as muscle. The net result is that 
the difference between signal uptake in the tumour and the 'background' signal 
in the surrounding tissues may be less noticeable in the setting of HNC than for 
lung cancers. A relative threshold is based on some evaluable varying 
characteristic of the data acquired, which then influences the selection of an 
appropriate proportion of uptake. An example would be based on the source-to- 
background ratio (SBR) discussed by Daisne et al which has been validated 
against histopathological specimens [42, 58].
Fully automated segmentation algorithms are probably the most desirable 
delineation method, being free from observer bias and adaptive to 
heterogeneous patient and tumour characteristics. However, the accuracy of 
such complex algorithms is reliant on advanced modelling computations based 
on a certain amount of phantom and real patient data, and must be tested 
rigorously. Once developed and validated, the clinical relevance depends on the 
availability of the algorithms to clinical teams. Examples include a gradient 
based method [59], a volume-of-interest growing method [60], an iterative 
background-subtracted relative-threshold level method [61] and a fu lly  adaptive
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segmentation algorithm named 'Fuzzy Locally Adaptive Bayesian' (FLAB) [62, 
63].
The issue of optimal PET segmentation methodology is currently of great 
interest. Schinagl et al reported one of the largest comparisons of segmentation
tools for FDG-PET [64]. Four approaches to FDG-PET segmentation were 
compared to traditional CT-based GTV delineation (GTVCT): visual
interpretation, thresholding on the basis of an absolute SUV of 2.5, thresholding 
on the basis of two different proportions of maximum signal intensity (40% and 
50%) and thresholding on the basis of a source-to-background ratio (SBR). 
Seventy-seven datasets from patients w ith  HNC were analysed, comparing 
absolute volumes of GTVs and overlap volumes between GTVs. All overlap 
fractions were significantly different to each other, except for overlap fractions 
with GTVCT of GTV50% versus GTVSBR. These two volumes also had sim ilar 
absolute GTV volumes. However, the overlap of GTV50% and GTVSBR, relative to 
each other showed sim ilarity of less than 90% in one th ird  (26/77) of cases, 
demonstrating that numerical s im ilarity in average absolute volume does not 
necessarily equate geographical sim ilarity. The authors concluded that the 
choice of segmentation method has a strong effect on the contour produced. 
Application of an SUV threshold o f 2.5 was unsatisfactory and the SBR method 
seemed the best compromise as the threshold was adapted to the SBR of 
individual patients, free from inter- and intra-observer variab ility and had 
undergone histopathological testing [42].
Another group from the Memorial Sloan Kettering Cancer Center in New York 
reported their w ork evaluating different FDG-PET segmentation methods in 
patients w ith  HNC [65]. Twelve patients were included in the study. Four 
methods were compared: visual interpretation performed jo in tly  by a radiation 
oncologist and a nuclear medicine physician, fixed thresholding based on 50% of 
PMSl, fixed thresholding based on a SUV of 2.5 and also contours derived from an 
iterative segmentation algorithm. The contours were compared against the 
reference gross tumour volume (GTVref) which was defined on CT, rather than on 
PET. The authors reported that there was no statistically significant difference 
between both the GTVs delineated on CT by visual interpretation and by a fixed
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threshold SUV of 2.5, and the reference GTVref. The fixed threshold PMSl of 50% 
and the iterative algorithm method both produced significantly smaller volumes 
than the G T V r e f .
1.4.3. Three-dimensional (3D) image guidance using cone beam 
computed tomography (CBCT) in head and neck cancer
Intensity modulated radiotherapy (IMRT) is a technique of radiotherapy
planning in which deliberately inhomogeneous dose distributions are designed 
to deliver differing dose levels to target volumes (TVs) w ith  sparing of 
neighbouring organs at risk (OARs) [66]. Geometric treatment verification is an 
im portant process which enables detection and consequently, correction, of 
treatment delivery errors. The aim is to increase the accuracy of the delivery of 
planned dose distributions. Joint Royal College of Radiologists (RCR), the 
Institute of Physics and Engineering in Medicine (IPEM) and the Society and 
College of Radiographers guidance stipulates that 'each department should 
determine the verification protocols and planning margins required for their 
own practice [3].
1.4.3.1. Accuracy in radiotherapy for head and neck cancer
Head and neck anatomy consists of a complex arrangement of organs in which
tumours can lie in close proxim ity to critical OARs. The geometric accuracy of 
radiotherapy, and in particular, IMRT, delivery is an extremely im portant 
issue[67]. Errors may occur at any point in the treatment pathway and may 
result in unintentional overdosing to critical OARs, or underdosing of tumour 
volumes.
ICRU 50 and 62 guidelines [68, 69] define radiotherapy target volumes as 
follows:
• GTV (gross tumour volume) -  the gross palpable or visible or 
demonstrable extent and location of the tumour.
• GTV (clinical target volume) -  the volume which contains the GTV and 
any sub-clinical microscopic malignant disease that has to be eliminated 
to achieve the aim of therapy. The GTV is an anatomical concept, 
representing the volume of known or suspected tumour.
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• PTV (planning target volume) -  a geometrical concept defined to take 
into consideration the net effect of all possible geometrical variations and 
inaccuracies (patient movement, organ movement and set up errors). 
This is to ensure that the prescribed dose is actually absorbed in the CTV.
A CTV-PTV margin is applied to the CTV to form the PTV, taking into account the 
factors described above. This margin comprises two margins: the internal 
margin and the set-up margin. The internal margin accounts for patient-related 
factors such as variation in the size, shape and position of the CTV in relation to 
anatomical reference points [69]. Application of the internal margin to the CTV 
produces the internal target volume (ITV).
The set-up margin accounts for uncertainties in patient positioning and 
alignment of treatment beams during treatment planning and during treatment 
delivery. Set-up uncertainty depends on a range of factors including variation in 
patient positioning, mechanical uncertainties of the equipment, dosimetric 
uncertainties, transfer set-up errors between planning CT to the treatment unit 
and human factors.
1.4.3.1.1. Set-up error
Set-up errors have both systematic and random components. Verification
protocols are necessary to identify each component. Systematic errors should be 
identified and minimised using correction protocols. Random errors occur in a 
more unpredictable pattern and should be minimised by careful attention to 
immobilisation and patient preparation techniques [3].
Verification protocols enable to detection of set-up errors. Treatment images are 
compared against corresponding reference images taken at the simulation stage. 
The difference between the intended and actual treatment positions represent 
the set-up error.
1.4.3.1.1.1. Gross error
This is defined as an unacceptably large set-up error that m ight result in
underdosing of the CTV or overdosing of an OAR. The magnitude of the error 
exceeds the factors accounted for by the CTV-PTV margin and therefore gross
errors must be corrected before delivering treatment [3].
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1.4.3.1.1.2. Systematic error
This is defined as a deviation that occurs in the same direction and is of a sim ilar
magnitude for each fraction throughout the treatment course [3]. It may be used 
to describe individual or population systematic error. This type of error can be 
introduced and unintentionally bu ilt into a patient's treatment at any stage.
Head and neck immobilisation devices are routinely used in the treatment of 
HNC. Various methods are in use. Organ movement in general is small in the 
head and neck region, excepting the larynx, which moves during swallowing. 
The use of contouring protocols can reduce variation in target delineation and 
quality assurance [QA] protocols help to minimise planning errors.
1.4.3.1.1.3. Random error
The random component of any error is a deviation that can vary in direction and
magnitude for each delivered treatment fraction [3]. This can be used to refer to 
either individual or population error.
1.4.3.1.2. CTV to PTV margin estimation
A CTV to PTV margin recipe which takes into account the systematic and random
components of setup error has been proposed by Van Herk et al [70]. The recipe 
aims to provide a margin, which, when applied to the CTV, w ill provide for 95% 
of the intended dose to be delivered to at least 99% of the CTV:
CTV to PTV margin = 2.5Z + 0.7o
where E represents the systematic component of set-up error and o 
represents the random component of set-up error.
1.4.3.1.3. Verification strategies
Verification strategies can be either online or offline. Offline verification involves
measurement of set-up error based on imaging performed at one fraction but 
applying any necessary correction at subsequent treatment fractions. The 
advantage is that this approach is less resource heavy in terms of patient, linac 
occupancy and staff time, as image comparisons can be performed independent 
of patient treatment appointments. The disadvantage is that this approach 
cannot account for random set-up variation. Online verification involves 
assessment and correction of set-up error immediately p rio r to treatment
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delivery. This method w ill detect both random and systematic components of 
set-up error but may be costly in terms of practical use. The impact of 
verification strategy on the CTV to PTV margin is demonstrated below in figure
1.3.
Figure 1.3 The relationship between the CTV to PTV treatm ent margin 
and treatm ent verification strategy as described in RCR 'On target' 
document [3]:
Margin
B -  Off-line conecfion
C -  Online conecfion
A-NoconecScn
PTV
Extent of CTV
Systematic (treatment preparation) enors 
Random (treatment execution) errors
1.4.3.2. Technologies for image guidance in head and neck 
cancer
1.4.3.2.1. Two-dimensional (2D) imaging
Conventional image guidance involves generation of a two-dimensional (2D)
planar treatment image which is compared w ith  a 2D reference image generated 
from simulation imaging. The treatment image may be a portal film, or, more 
recently, an electronic portal image (EPI). Traditionally, either a radiographic 
film  or an electronic imaging panel would be exposed to the megavoltage [MV) 
treatment beam to generate the treatment image for comparison. The reference 
image most commonly has been a digitally reconstructed radiograph [DRR] 
which has been generated from the 3D planning CT dataset.
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The image quality of MV imaging is a well-known problem. This has led to the 
development of in-room kilovoltage [kV) x-ray source which can be mounted 
perpendicularly to the treatment beam axis and opposed w ith  flat panel 
detectors. The advantages include improved image quality, reduced patient dose 
and the potential for fluoroscopic imaging during treatment [5j.
1.4.3.2.2. Three-dimensional (3D) imaging
Cone beam computed tomography (CBCT) is a recent in-room imaging
technological advance. This technology provides the means for three- 
dimensional (3D) volumetric imaging which can be compared against the 
planning CT [5, 71, 72]. Conventional CT scanning involves directing a fine linear
x-ray beam at a row  of small silicon detectors arranged in a ring which encircles 
the patient. CBCT differs in that the x-ray beam is not linear, but has a cone 
shape. The attenuated x-ray beam is captured by a square flat-panel
arrangement of detectors. The beam and detector panel revolve around the 
patient. A 3D representation of the patient anatomy -  a CBCT dataset - is 
reconstructed once image acquisition has been completed. Volumetric imaging 
increases the amount of anatomical knowledge compared w ith  planar imaging.
Various groups have evaluated CBCT in delivering image-guided radiotherapy to 
patients w ith  head and neck cancer. Wang et al reported the ir experience using 
CBCT to guide treatment delivery to twenty-two patients w ith  nasopharyngeal 
carcinoma[73]. Their results supported the value of CBCT in increasing the 
accuracy of IMRT delivery for this tumour group and provided a basis for the 
shrinkage of planning margins by a reduction in both systematic and random 
components of set-up error. This outcome might have particular benefit to 
patients with this tumour subsite, as radiotherapy planning to nasopharyngeal 
tumours is frequently complex due to the close proxim ity to multiple neural 
structures such as the optic chiasm, optic nerves and spinal cord.
A British group from Manchester performed a larger prospective study 
evaluating CBCT image guidance in twenty-nine patients undergoing 
radiotherapy to tumours at ten different anatomical sites including the head and 
neck region, central nervous system, lung, breast and pelvis, amongst others 
[74]. McBain et al reported that 3D verification images w ith  soft tissue quality
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definition was possible at all anatomical sites although the soft tissue contrast 
was not as good as w ith  conventional CT imaging due to greater statistical noise. 
Overall, the image quality of the CBCT was deemed sufficient to visualise 
whether the tum our volume was contained w ith in  the planning target volume 
(PTV). The radiation doses involved appeared at acceptably low levels, ranging 
between O.OOSGy in the head region, to O.OSGy in the pelvis.
Li et al from the M.D. Anderson Cancer Center in Houston, Texas, compared 2D 
kV w ith  3D kV image verification using an onboard imaging (OBI) system 
(Trilogy; Varian Medical Systems, Palo Alto, CA) [75]. Twenty-one patients 
receiving radiotherapy for head and neck cancer underwent weekly imaging 
consisting of a pair of orthogonal kV planar EPIs before immediately proceeding 
to undergo CBCT imaging in the same session. Ninety-eight pairs of planar and 
CBCT image sets were obtained. The authors found that systematic and random 
components of set-up error were the same - <1.6mm -  for both imaging 
techniques. Statistically significant correlations were found between 2D and 3D- 
determined positional displacements, in all three directions of vertical, 
longitudinal and lateral.
1.5. Thesis aims
Recent advances in radiotherapy techniques have provided opportunities for 
radiation dose escalation. Dose-painting w ith  IMRT involves the delivery of 
escalated doses of radiation to tumour subvolumes w hilst m inim ising doses to 
the normal tissues. This approach may potentially lead to an improved 
therapeutic ratio, which may be associated w ith  better local control, and, in turn, 
survival rates. The identification of an appropriate tumour subvolume to receive 
dose-painting is an im portant issue that is not yet resolved. Treatment 
verification is a process in which the delivered treatment is compared to the 
intended treatment, enabling correction of set-up errors and the use of 
appropriate planning margins. W ith highly conformai radiotherapy treatments 
designed to deliver differing dose levels of radiation, the accuracy of treatment 
delivery is highlighted even further. Recent equipment advances include in-room 
volumetric imaging which may contribute to improving the accuracy of 
treatment delivery.
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The firs t part of this thesis aimed to test the hypothesis that dose-painting w ith  
IMRT to FDG-avid subvolumes in oropharyngeal tumours was feasible. A 
comparison of various FDG-PET segmentation techniques was performed to 
identify an optimal method for the delineation of the FDG-avid tumour 
subvolume.
In the second part of this thesis, a prospective clinical study was performed to 
test the hypothesis that CBCT can be used to improve the accuracy of IMRT 
delivery. Subsequent work evaluated how image guided IMRT using CBCT could 
be used to guide adaptive radiotherapy strategies.
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Chapter 2: FDG-PET image segmentation
Various groups have attempted to find the optimal FDG-PET segmentation 
technique in the setting of squamous cell carcinoma of the head and neck 
[HNSCC) [1-6]. To date, only one group has reported clinical correlation in this 
setting between a segmented FDG-PET volume and the 'true' volume examined 
in the corresponding histopathological specimen. The segmentation technique 
used by this group involved a semi-adaptive threshold method based on the 
source-to-background ratio [SBR) for each patient. Due to these shortcomings, 
currently, the most common approach to segmentation m irrors standard clinical 
radiological reporting of imaging, in other words, using clinician judgement and 
visual in terpretation to direct manual delineation of FDG-avid volumes. This 
method, however, is prone to inter- and intra-observer variability.
The w ork in this study compared manual delineation (the standard approach to 
tumour volume delineation in radiotherapy planning) against the SBR method 
(which has been compared to histopathological specimens). In addition, three 
other methods were evaluated -  two techniques based on a range of fixed 
thresholds of either maximum signal intensity or standardised uptake value 
(SUV), and a novel fuzzy locally adaptive Bayesian algorithm, FLAB [4].
2.1. Objectives of study
This study had the following aim:
• to compare five different approaches to FDG-PET segmentation using 
various measures of conformity
2.2. IVIethodology
2.2.1. Patients
For the purposes of this pre-clinical study, the anonymised FDG-PET/CT datasets 
of ten patients w ith  histologically proven squamous cell carcinoma (SCC) of the 
oropharyngeal region who had undergone co-registered FDG-PET/CT imaging at 
the Guildford Diagnostic Imaging centre, Guildford, were identified through 
retrospective review of the head and neck cancer patient database.
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2.2.2. FDG-PET/CT scanning procedure
Height, weight and baseline blood glucose measurements for each patient were
recorded. Approximately 400MBq of FDG was injected intravenously. Following 
a 55 minute period of complete rest, the patient was requested to void the ir 
bladder completely, after which the patient was positioned, using a head brace, 
on the standard concave PET/CT scanner [GE Discovery LS PET CT, GE 
Healthcare, General Electric Company) couch. All patients were scanned w ith  a 
comfortably neutral neck position and w ith  the ir arms positioned down by their 
sides. An in itia l scout view CT scan was performed and after appropriate 
evaluation, a CT scan of the whole body was performed, followed by the PET 
scanning protocol. The PET scanning protocol included the following mA 
modifications according to the patient's body mass index [BMl, weight in 
kg/(height in cm)^):
BMl < 24 80mA
B M I25-30 100mA
BMl > 30 120mA
The PET scan was acquired in 3.9mm axial slices, in a 128 x 128 matrix. (FOV = 
3.9 X 128 = 500.0mm). The PET pixel size was 3.9mm. A standard clinical 
PET/CT scan was acquired (single bed position, lOmin per bed, CT was 120kV, 
10mA). In-built software was used to co-register the acquired PET and CT 
datasets.
2.2.3. Radiology review of FDG-PET/CT images
The FDG-PET-CT scans were reviewed in itia lly  w ith  a consultant nuclear
medicine radiologist using a nuclear medicine imaging workstation (Xeleris, GE 
Healthcare, General Electric Company) to confirm that the prim ary tumour in the 
oropharyngeal region was FDG-avid. Windowing and image processing tools 
such as an automated standardised uptake value (SUV) calculation tool on the 
workstation were used at the nuclear medicine physician's discretion as per 
standard diagnostic radiology reporting practice.
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2.2.4. Image transfer into treatment planning system (TPS)
The co-registered FDG-PET/CT scans were imported directly into the Varian
Eclipse [Varian Medical Systems, Palo Alto, CA) treatment planning system 
(TPS), version 8.2, in digital imaging and communications in medicine (DICOM) 
format. The quality of registration was reviewed by an experienced consultant 
nuclear medicine physician to confirm satisfactory alignment to a standard that 
was visually consistent w ith  diagnostic radiology viewing standards. Image 
segmentation tools using the 'Contouring' w indow included reporting of point 
FDG uptake, quantified in Bq/ml.
2.2.5. Standard contouring procedure
The gross tum our volumes (GTV) for tumour and nodes were contoured on the
CT images, w ith  knowledge of diagnostic CT, MRl and PET imaging, as per 
standard practice. These were termed the GTV-CT(T) - prim ary tumour - and 
GTV-CT(N) - nodes. The composite GTV for both tumour and nodes was termed 
the GTV-CT. High dose and prophylactic dose clinical target volumes [CTVl and 
CTV2) were contoured according to departmental IMRT contouring protocol for 
the oropharyngeal region. The CTVl typically included the entire oropharynx, 
involved nodal levels and any other involved subsites.
2.2.6. Segmentation techniques
Regions of FDG uptake w ith in  the prim ary oropharyngeal tumour were
delineated for the purposes of this study. These regions, being delineated w ith in  
the prim ary gross tum our volume (GTV), were designated as biological GTV 
volumes, termed 'GTVb', followed by a suffix to denote the method applied to 
segment the image. Manual or semi-automated contouring generated by 
thresholding techniques were performed on each PET scan, after which each 
contour was transferred onto the co-registered CT scan by copying and pasting 
from the original PET scan.
Five FDG-PET image segmentation techniques were selected for application to 
the patient dataset and are described below:
1. Manual delineation
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2. Semi-automated segmentation based on a threshold of percentage of 
maximal signal intensity
3. Semi-automated segmentation based on a threshold of Standardised 
uptake value (SUV) of 2.5
4. Semi-automated segmentation based on a threshold of signal to 
background ratio
5. Fully automated voxels classifications algorithm based on fuzzy locally
adaptive Bayesian (FLAB)
2.2.6.1. IVIanual delineation
Manual delineation was performed jo in tly  and with simultaneous agreement
between a consultant nuclear medicine radiologist and the student. W indowing 
was adjusted manually to suit the nuclear medicine radiologist's usual practice 
for standard diagnostic w ork and varied between patient image sets. GTVb 
volumes were manually contoured on FDG-PET images. The volume was then 
transposed onto the co-registered CT image-set and reviewed to estimate the 
relationship to likely anatomical lim its and prim ary tumour, i f  visible, to guide 
whether the new contour was geographically consistent between FDG-PET and 
CT. The new contour was termed the GTVbM.
2.2.6 2. Semi-automated segmentation based on a threshold of 
percentage of maximal signal intensity (PIVISI)
Image processing tools on Eclipse version 8.2 included pixel statistics for FDG
signal intensity, reported in Bq/m l, point signal intensity reports for a chosen 
cursor point or pixel and maximum, mean and m inimum signal intensities w ith in  
either the entire volume or a chosen region of interest (ROl). Using these tools, it 
was possible to identify the pixel w ith  maximum signal intensity w ith in  the 
entire body region scanned, or w ith in  a region confined to the head and neck 
region only. A single pixel measured 3.9mm^ and therefore any single pixel 
uptake value may not be assumed to be tru ly  representative of the signal 
intensity detected w ith in  a region and thus potentially provide a confounding 
factor. In order to address this issue, values were recorded for not only the pixel 
w ith  the highest reported FDG uptake value ( P h o t t e s t )  but in addition, the 
surrounding 8 pixels, PsuRRl, PsuRR2, PsuRRS,..., to PsuRaS (Figure 2.1).
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Figure 2.1. Schematic two-dimensional diagram of the pixel matrix of the 
FDG-PET scan. The central red pixel, P h o t t e s t ,  is surrounded by 8 other 
pixels, P s u r r I  to P s u r r S ,  with varying FDG uptake values.
P surr I P surr2 P surr3
P surrS P h o t t e s t P surr4
P surr7 P surr6 P surrS
P h o t te s t ,  pixel w ith  highest FDG uptake value; P s u r r ,  one of the eight pixels 
surrounding P h o t te s t .
These 9 pixels represented a region of interest measuring 3 x 3.9mm = 11.7mm 
in each dimension, in total, constituting an area of size (11.7)2 = I36.9mm2, 
approximately l.Tcm^. The averaged signal intensity w ith in  this l.Tcm^ area was 
calculated by summing all nine pixel values and dividing by the total number of 
pixels (i.e., [ P s u r r I  +  P s u r r 1 2  +  P s u r r 3 ,  .. .  P s u r r S ]  /  9). This provided a 
representative value for the maximal signal intensity o f FDG detected on PET.
Thresholds of PMSl ranging between 36% and 73% have been reported to be 
associated w ith  generating FDG-PET volumes which fitted macroscopic 
pharyngolaryngeal squamous cell carcinoma tumour specimens adequately [7]. 
A range of PMSl thresholds between 20% and 73% were therefore selected for 
investigation. The calculated threshold value was then used to produce an 
isocontour using Eclipse contour processing tools. The resulting isocontour was 
called 'GTVbx..o/o', for example, the isocontour produced by applying a 20% of 
maximal signal intensity threshold was called the GTVb2o%.
2.2.6.3. Semi-automated segmentation based on a threshold of 
standardised uptake variable (SUV) of 2.5
Calculation of standardised uptake value (SUV) was performed manually, as no
automated SUV tool was available on the Eclipse treatment planning station. The 
formula for SUV used was as follows:
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SUV = [voxel value of detected activity (Bq/m l) x patient weight (kg)] /  
[activity injected at the beginning of the scan (Bq) x 1000]
Therefore, to calculate the value of the SUV 2.5 threshold, the follow ing was 
used:
Threshold voxel value of activity (Bq/m l) = [Threshold SUV x activity
injected at the beginning of the scan 
(Bq)] /  [patient weight (kg) x 1000]
= [2.5 X activity injected at the
beginning of the scan (Bq)] /  [patient 
weight (kg) X 1000]
The calculated value for the SUV 2.5 was then applied as a threshold using 
Eclipse contour processing tools. The resulting isocontour for SUV 2.5 was called 
GTVbsuv2.5.
2.2.6.4. Semi-automated segmentation based on a threshold of 
source-to-background ratio (SBR)
A semi-automated method for segmentation of the GTV based on a relationship
between source-to-background ratio (SBR) and a threshold level of FDG uptake 
reported by Daisne et al [1] and later validated against histological specimens [8] 
was selected for comparison. The parameters for this method vary according to 
institution and scanner and therefore, the necessary phantom w ork  was 
replicated in the PET scanner of the Guildford Diagnostic Imaging Centre in 
order to obtain these scanner-specific parameters.
The phantom w ork was performed jo in tly  between 2 medical physicists and the 
student. A National Electrical Manufacturers Association (NEMA) International 
Electrotechnical Commission (lEC) Body Phantom Set was used) (Figure 2.2).
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Figure 2.2. NEMA lEC Body Phantom
The NEMA phantom has a lung insert and a sphere insert. The sphere insert used 
for this study contained six spheres of various sizes. These six spheres were of 
inner diameter: 10mm, 13mm, 17mm, 22mm, 28mm and 37mm [Table 2.1). The 
distance from the sphere plane to the inside wall was 70mm. The volume of the 
empty cylinder was 9.81.
Table 2.1. Sphere dimensions in the NEMA lEC Body Phantom.
Sphere Diameter (mm) Volume (ml)
1 10 0.52
2 13 1.15
3 17 2.57
4 22 5.58
5 28 11.49
6 37 26.52
Total Volume: 
Background Volume:
47.84
9800
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5.8ml of FDG at reference activity 513.4MBq was prepared for this study. The 
phantom was firs t filled w ith  water, leaving an air bubble. 0.03ml of the 
reference quantity of FDG was removed. This FDG sample had an activity of 
2.5MBq and was mixed w ith  approximately 50ml of water in a 60ml syringe, 
w ith  a resulting solution of activity 0.05MBq/ml. This solution was used to fill 
the spheres. To produce a background signal, approximately 40MBq of FDG was 
added to the water in the background, followed by gentle agitation of the 
phantom to homogenise FDG w ith in  the larger volume of background water. 
Following this, the background volume was topped up w ith  water to remove the 
remaining air bubble. These steps produced a source [sphere)-to-background 
ratio [SBR] of 9.0 [see Figure 2.3].
Figure 2.3. Filling NEMA lEC Body Phantom with solutions of FDG to obtain 
required SBRs.
The phantom was placed on the PET scanner bed and a standard clinical PET/CT 
scan was acquired [single bed position, 10 minutes per bed position, CT scan at 
120kv and 10mA w ith  standard clinical reconstruction algorithm used) [Figure 
2.4).
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Figure 2.4. FDG-PET-CT scanning of NEMA lEC Body Phantom.
The phantom was then removed from the bed and taken back to the preparation 
room, where an additional quantity of FDG was added to the background, 
followed by agitation. This process was repeated, in order to produce varying 
SBRs ranging from 9.85 to 1.52 [Table 2.2). In total, 8 SBR were produced for 
scanning.
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Table 2.2. Summary of increasing quantities of FDG added to background 
(BG) in phantom to create decreasing SBR ranging from 9.85, down to 1.52.
Drawing up 
Measurement 
Time
Activity 
Drawn 
up for 
BG 
(MBq)
Residual
Measurement
Time
Residual 
Activity 
for BG 
(MBq)
Activity 
added to BG 
at
Acquisition 
Time (MBq)
SBR
(intended)
SBR
(actual)
09:10:00 47.350 09:14:00 0.056 73.571 10 9.85
09:47:30 10.770 09:49:00 0.050 21.130 8 7.65
10:16:00 11.740 10:18:00 0.009 27.682 6 5.92
10:31:00 8.675 10:35:00 0.034 22.413 5 5.01
10:45:00 12.320 10:49:00 0.005 34.898 4 4.03
10:59:00 19.640 11:04:00 0.110 60.447 3 3.02
11:16:30 34.760 11:19:00 0.087 119.868 2 2.01
11:35:00 29.870 11:36:30 0.127 115.562 1.5 1.52
SBR, source-to-background ratio
On completion of the phantom work, the scans were imported into the Eclipse 
TPS. A visual check of the CT images was performed to confirm whether any of 
the spheres contained air bubbles. Those spheres containing air bubbles were 
deemed unsuitable for volume estimation as the true volume of FDG solution in 
the sphere was unknown and therefore any measurements were at risk of 
inaccuracy. The next step was to determine the threshold value of activity 
required to obtain an isocontour of size which corresponded to each of the 6 
known true sphere volumes, for each scan acquired using each of the 8 SBRs. 
This was a tria l and error process, using the autothresholding tools available in 
Eclipse. For each sphere, an autothreshold was applied w ith in  a volume of 
interest which clearly contained the sphere under evaluation. This contour was 
then copied and pasted onto the co-registered CT image and a volume was 
measured. Volumes could not be reliably assessed on the PET images as PET 
images have poor spatial resolution compared to CT data and tend to 
overestimate volume sizes. The autothresholds corresponded to the lower lim it 
of the range applied in the Eclipse contouring tools. The upper lim it 
corresponded to the maximal signal intensity detected in the entire phantom.
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For close comparison w ith  the G T V p m s i ..% method which was based on a 
percentage of averaged maximal signal intensity, the procedure to identify the 
average signal intensity w ith in  a 1.4cm^ area surrounding the pixel of hottest 
intensity w ith in  the entire phantom scanned. The lower lim it threshold for 
isocontouring each sphere was then converted into a percentage of averaged 
maximal signal intensity [Table 2.3].
Some difficulties were presented by the automated post-processing tools applied 
by Eclipse. Eclipse automatically 'smoothed shapes into more rounded contours 
and occasionally sp lit thin volumes into two separate tiny rounded volumes. 
Some of these tiny volumes were too small to be copied from the PET images and 
pasted onto CT and therefore these volumes were excluded from the regression 
analysis.
Table 2.3. Actual and percentage activity thresholds required to 
autocontour each of the 6 spheres accurately.
Sphere
SBR 1 2 3 4 5 6
1.52 n/a n/a n/a n/a 65.7% 67.3%
2.01 n/a n/a n/a 57.4% 60.0% 61.7%
3.02 36.0% 38.5% 40.4% 42.8% 43.1% 45.2%
4.03 27.0% 36.7% 33.9% 35.9% 38.3% 41.4%
5.01 28.5% 32.5% 33.4% 36.8% 39.5% 42.6%
5.92 25.1% 29.8% 33.0% 34.0% 38.3% 40.2%
7.65 22.7% 31.2% 31.9% 34.4% 38.7% 41.1%
9.85 23.6% 28.5% 30.1% 34.9% 36.7% 39.3%
SBR, source-to-background ratio; n/a, not available.
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At lower SBR, it  was not possible to visualise the smaller spheres on PET and 
therefore the value 'not available, n /a ' was entered. Those values w ith  grey 
background in the table had artefactual inconsistencies and were discounted 
from the regression analysis.
The results from Table 2.3 were applied into the linear model: 
f[x ] =a + b*l/SB R  [Figure 5). 
to obtain the 'a' and 'b' parameters as follows:
a = 21.18 [95% confidence interval: 18.43, 23.93]
b = 50.54 [95% confidence interval: 40.75, 60.33]
Figure 2.5. Line of best fit showing relationship between SBR and threshold 
required to isocontour spheres of 6 different volumes.
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SBR, source-to-background ratio.
The 'goodness of fit', r^ was 0.7755 and the standard error was 588.7.
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The acquisition of 'a' and 'b' parameters now made it  possible to calculate 
thresholds of percentage of averaged maximal signal uptake [PMSl] according 
the SBR, providing the SBR had been measured from each individual patient's 
scans. Measurement of individual SBR in each patient was performed by 
choosing a region w ith in  the neck [ideally musculature] contralateral to the 
prim ary tum our volume and as far away from the plane of the tumours as 
possible. The average signal uptake in this region was sampled across a 
m inimum of 5 consecutive axial slices [Figure 2.6].
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Figure 2.6. SBR measurement for an example patient. The background area 
(white box on CT image, upper image) was marked as a region of interest 
on a minimum of 5 consecutive CT slices then copied over to the PET image, 
where the same volume of interest was applied (red box, lower image) and 
pixel statistics tools used to obtain a mean uptake in Bq/ml.
iiili
The resulting contours were termed ‘GTVbsBR.
2.2.6.5. Fully automated voxels classifications algorithm based 
on fuzzy locally adaptive Bayesian (FLAB) segmentation 
algorithm
A novel fuzzy locally adaptive Bayesian [FLAB segmentation for fu lly automated 
lesion volume delineation on PET was developed by Hatt et a l[4, 9], Brest, 
France. A research group collaboration was established between Guildford and 
Brest to compare the G T Y B flab  contours resulting from FLAB segmentation of
61
the FDG-PET images from the ten patients in the study w ith  the four other 
segmentation techniques described above. Segmentation of the anonymised 
FDG-PET/CT data of the 10 patients was performed in Brest and returned in 
both DICOM format and co-ordinates in text file format. Eclipse, however, was 
not able to process the contours, although images of the FLAB contour could be 
visualised. In view that the algorithm, however, was intended to obviate the need 
for clinician visual interpretation, custom-written code was developed to convert 
the co-ordinates of the text file format FLAB contours into a 3-dimensional 
volume which could be imported successfully into Eclipse and fused with the 
pre-existing contours for each patient. The resulting contours were termed 
'GTVbpLAB'.
2.2.7. Post processing of isocontours
Application of some of the lower thresholds of FDG uptake signal produced
extremely large volumes that were clearly inconsistent w ith  anatomical lim its 
seen on CT. For the practical purpose of potential clinical use, it  was decided that 
any volume contained outside of the pre-contoured high dose clinical target 
volume [CTVl] should not be included in the volume statistics. In addition, post­
processing tools available on Eclipse to remove volumes smaller than O.Scm^ 
were applied. Occasionally, volumes contoured on PET appeared to include both 
prim ary and nodal regions. Where an obvious plane of separation existed 
between prim ary and node, the PET volume was manually edited to consist of 
the prim ary site only. Where no clear plane of separation existed, the mass was 
not modified.
2.2.8. Conformity analysis methodology
2.2 .8 .1 . V o lum etric data
All volume dimensions were recorded from CT pixel data. The CT pixels were
smaller and of greater resolution than those of PET.
The GTVbM was selected as the reference volume against which all other 
segmented volumes were compared. The absolute volume of GTVbM was 
compared w ith  the absolute volumes of each of the four other GTVbE volumes: 
GTVbx. %, GTVbsuvz.s, GTVbsBR and GTVbpLAB, for all ten patients.
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Overlap [GTVbM fl GTVbE] and composite, or union [GTVbM U GTVbE] volumes 
were measured using Boolean tools [figure 2.7]. Absolute volumes of overlap 
and composite volumes of GTVbM and GTVbE were compared w ith  the absolute 
volumes of the reference GTVbM volume.
Figure 2.7 showing examples of recorded volumes.
GTVbM n GTVbE represents the common 
volume between the GTVbM and GTVbE.
GTVbM
GTVbE
GTVbM U GTVbE represents the total
volume encompassed by the GTVbM [red] 
and GTVbE [blue].
GTVbM, biological GTV produced by manual delineation; GTVbE, biological GTV 
produced by one of five different evaluated methods.
The overlap [GTVbM n GTVbE] volume informed on size and geographical 
conformity but less so for morphometric conformity. The ideal overlap volume 
would be equivalent to the GTVbM volume, indicating perfect agreement 
between the reference GTVbM volume and the evaluated GTVbE volume.
GTVbM U GTVbE represented the union, or composite volume. Again, as for 
GTVbM n GTVbE, this would ideally be equivalent in size to the reference 
volume, the GTVbM. If the value was sim ilar to the GTVbM, this informed on size 
but not geographical or morphometric sim ilarity and was therefore less useful 
than the GTVbM n GTVbE, or overlap, volume.
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2.2.8.2. Conformity Indices
Various tools in the literature have been used to describe conform ity in
delineation. In general, a conformity index equal to 1 indicates perfect agreement 
in the volumes compared. A conformity index greater than 1 indicates that the 
test volume (in this case, the GTVbE) is greater than the reference volume (in 
this case, the GTVbM), and vice versa.
2.2.8 2.1. Absolute volume index (AVI)
The most simplistic absolute volume index (AVI) is given by:
AVI (GTVbM, GTVbE) = Absolute volume of GTVbM /  absolute volume of GTVbE
The ideal AVI equals 1. However, the AVI does not describe any other aspects of 
conformity except size alone.
2.2.8.2 2. Jaccard Coefficient (JC)
This is defined as the intersection volume divided by the union volume:
)C = GTVbM n GTVbE volume /  GTVbM U GTVbE
If the GTVbM and GTVbE are identical in size, geographical location and shape, 
then this is a situation of perfect conformity and the value of the JC is 1. I f  the two 
volumes do not overlap, then the value of the JC is 0. However, the JC does not 
inform  well on morphometric -  shape -  conformity.
2.2.8 2.3. Overlap fraction (OF)
This is defined as the size of overlap region divided by the reference volume:
OF = GTVbM n GTVbE volume /  GTVbM
The OF indicates the proportion of the evaluated volume that share spatial 
conformity with the reference volume.
2.2.8 2.4. IVIean distance to conformity (IVIDC)
The MDC was proposed by Jena et al [10] and is defined as the mean distance of
that outlying points w ith in  the evaluation contour need to be moved in three 
dimensions in order to achieve perfect conformity with the reference contour. It 
also informs on the extent of under- and over-contouring.
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2.2.8.2.5. Shift in centre of mass (SCM)
The SCM was proposed by Jena et al [10] and is defined as the distance between
two centres of volumes. It is most useful for perfect spherical objects and less 
useful for irregularly shaped volumes.
Surrey Heuristics Engine for Radiobiology, Radiotherapy and Imaging (SHERRI) 
software was used to calculate Jaccard coefficients, MDC and SCM indices.
2.2.9. Statistical analyses
Student's two-tailed t-test was performed to evaluate the significance of the
differences in absolute volume of the evaluated volume and the reference 
volume. This was performed firs t w ith  the GTVbM as the reference volume and 
secondly when the GTVbE was compared w ith  the GTVbSBR as reference 
volume.
Wilcoxon signed rank test was used to identify the PMSl threshold that most 
closely reproduced the GTVbM contour.
The Bland-Altman method was used to assess the agreement between each pair 
of reference GTVbM contour and test GTVbE contour.
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2.3. Results
2.3 .1 . Patients
The anonymised FDG-PET/CT datasets of ten patients were used. All patients 
had histologically confirmed squamous cell carcinoma involving the oropharynx, 
w ith  the prim ary tumour being centred on the tonsil in five patients, and centred 
on either the base of tongue, or contiguous between the base of tongue and 
tonsil, in the remaining five patients. The prim ary tumour size measured up to 
4cm [T l-2 ) in four patients, w ith  the remaining six patients having larger, more 
extensive tumours (T4). Patient characteristics are described in table 2.4.
Table 2.4. Patient and tumour characteristics.
Sex
Male 5
Female 5
Median age (range) in years 53.5 (41-72)
Oropharyngeal tumour suhsite
Tonsil 5
Base of tongue 3
Tonsil/Base of tongue 2
T stage
T1 3
T2 1
T3 0
T4 6
Total 10
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2.3.2. Volumetric analysis
2.3.2.1. Reference GTVblVI volume compared with standard CT- 
delineated target volumes
The target volumes that were delineated on the CT scans comprised the GTV-CT,
GTV-CT[T), GTV-CT(N) and CTVl and are described in table 2.5.
Table 2.5. Median volumes for standard high dose target volumes and the 
ranges (in brackets) recorded for the 10 patients were analysed.
Median volume (range)
Target volume (cm^)
GTV-CT 35.85 (5.75-132.91)
GTV-CT(T) 19.91 (1.18-126.80)
GTV-CT(N) 5.80 (0.00-39.50)
CTVl 352.00 (153.38-507.24)
GTV, gross tumour volume; GTV-CT, standard GTV contoured on CT; GTV-CT(T), 
standard prim ary GTV contoured on CT; GTV-CT(N), standard nodal GTV 
contoured on CT; CTVl, high dose clinical target volume.
Absolute volume of the GTVbM was lO.TScm^ (median, range 1.95-81.18) (table 
2.6). In general, the GTVbM was significantly smaller than the standard CT- 
defined GTV-CT, w ith  a median reduction in volume of 20.80cm3 (range -0.49 to 
62.80,p = 0.006). The GTVbM was larger than the standard GTV-CT in only one 
patient and only by 0.49cm^. Similarly, the GTVbM was smaller than the GTV- 
CT(T) in all cases except in the same one patient (median reduction 7.12cm^, 
range -5.06 to 45.62cm^, p = 0.016). These differences are illustrated in Figure 
2.8.
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Figure 2.8. Variation in absolute volum e of GTVbM compared w ith
standard GTV-CT and GTV-CT(T) for each patient.
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GTVbM, biological GTV delineated manually; GTV-CT. standard GTV defined 
using CT; GTV-CT[T]; prim ary tumour GTV defined using CT.
2.3.2.2. Reference GTVbM volume compared with other GTVbE 
volumes
The five segmentation techniques produced, in total, twelve biological GTVb 
volumes: GTVbM, eight GTVbx..% volumes -  where 'x' ranged from 20% to 73%, 
GTVbsuv2.5, G TVb FLAB and GTVbssR. For simplicity, G TVbE -  where 'E ' represents 
any evaluated segmentation method used -  has been used to refer to the 
collective group of GTVb volumes under evaluation. Median absolute volumes 
produced by the five segmentation techniques are listed in table 2.6.
Table 2.6 Median (range) absolute volume (cm^) with standard deviations 
(s.d.) for the GTVbE, overlap (GTVbM n GTVbE} and composite (GTVbM U 
GTVbE) volumes.
Volume Median volume (range, s.d.) in cm^
GTVbE GTVbM n GTVbE GTVbM U GTVbE
GTVbM 10.78 
(1.95-81.18, 28.09)
GTVbzox 30.40 10.46 30.48
(11.94-165.10, 53.13) (1.94-80.01, 28.02) (13.32-165.64, 53.03)
GTVb3o% 12.45 9.49 13.18
(2.00-105.39, 36.49) (1.88-76.30, 27.53) (6.67-108.74, 36.68)
GTVb36% 8.73 8.24 11.20
(0.87-91.52, 32.48) (0.87-73.99, 27.08) (5.60-97.91, 33.27)
GTVb4o% 7.30 7.14 10.97
(0.69-83.91, 30.35) (0.69-71.99, 26.59) (3.72-93.04, 31.80)
GTVbso% 5.02 5.03 10.79
(0.00-68.43, 25.53) (0.00-64.45, 24.25) (1.96-86.43, 26.64)
GTVb6o% 3.33 3.33 10.78
(0.00-56.90, 21.52) (0.00-55.53, 21.10) (1.95-84.28, 28.90)
GTVbyo% 1.94 1.94 10.78
(0.00-46.05, 17.17) (0.00-45.63, 17.02) (1.95-82.97, 28.56)
GTVb73% 1.52 1.52 10.78
(0.00-42.25, 15.53) (0.00-41.97,15.46) (1.95-82.71, 28.45)
GTVbsuv2.5 27.84 10.08 27.60
(2.85-249.86, 76.02) (1.88-80.59, 28.39) (6.64-250.30, 75.56)
GTVbpLAB 7.82 6.09 11.01
(1.03-63.00, 23.82) (1.03-60.44, 22.88) (4.09-85.46, 29.20)
GTVbSBR 22.50 10.08 20.56
(6.07-124.69, 41.97) (1.94-77.97, 27.80) (8.12-126.21, 41.83)
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Key for table 2.6 (previous page):
GTVbM, biological GTV delineated manually; GTVbE, biological GTV defined 
using one of the five delineation methods under evaluation; GTVb2o%, biological 
GTV defined by a threshold of 20% of Maximal FDG Signal Intensity (PMSl), and
sim ilarly for other values of PMSl ranging between 30 and 73%; GTVbsuvz.s, 
biological GTV defined by a threshold of Standard Uptake Value (SUV) of 2.5; 
GTVbpLAB, biological volume defined by Fuzzy Locally Adaptive Bayesian (FLAB) 
algorithm; GTVLsbr, biological GTV defined by threshold of source-to- 
background ratio (SBR). The reference volume, GTVbM, is highlighted in grey.
For the group of GTVb PMSl volumes, the median absolute volume decreased 
from 30.40 cm  ^to 1.52 cm  ^as the PMSl threshold increased from 20% to 73%. 
The ideal overlap volume should be equivalent in size to the GTVbM volume. The 
median overlap (GTVbM n GTVbE) volume ranged from 1.52 cm^ (for GTVb73%) 
to 10.78 cm3 (GTVbM). Only the GTVb20%, GTVbsuvz.s and GTVbsBR median 
overlap volumes approached 10.78 cm^ (10.46 cm^, 10.08 cm^ and 10.08 cm^, 
respectively). The PMSl 20%, SUV Of 2.5 and SBR involved inherently lower 
thresholds and therefore produced larger volumes which often encompassed the 
GTVbM, w ith  the net result of sharing the most tissues in common w ith  the 
reference GTVbM volume.
For the composite (GTVbM U GTVbE) volumes, median absolute volume ranged 
from 10.78 cm^ (the median absolute volume for GTVbM) to 30.48 cm^ 
(GTVb20%). Those volumes w ith  higher thresholds, such as the PMSl thresholds 
between 50% and 73%, generated much smaller volumes which were 
geographically located w ith in  the GTVbM. This resulted in median composite 
volumes of around 10.78 cm^ (the median value for GTVbM), with sim ilar ranges, 
demonstrating that each of these volumes was enclosed by the GTVbM itself. 
Therefore although size conformity was small, geographical conformity was 
high.
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2.3.2.2.1. Comparison with GTVbx..%
The GTVbx..o/o volumes were generated by applying percentage thresholds
ranging between 20% and 73% of maximal FDG signal intensity (PMSl). As 
described in table 2.6, the volumes produced ranged from larger (PMSl 20%) to 
smaller (PMSl of 73%). Figures 2.9 (a-c) show the proportion of overlap (GTVbM 
n GTVbx.%) compared w ith  the region contoured by manual delineation alone 
and the PMSl method alone, for three selected thresholds of PSMl: 20%, 36% and 
50%. These three were selected to demonstrate the range in volume size; PMSl 
thresholds of 60% or greater frequently did not identify any region of FDG 
uptake.
Figure 2.9. Proportional variation between GTVbM only, GTVb% % only, 
where 'x..%' refers to the threshold of PMSl applied, generating (a) 
GTVb2o%, (b) GTVb36% and (c) GTVbso%, and overlap (GTVbM n GTVb% %) 
regions.
(a) Comparison between GTVbM, GTVbzo% and overlap for each patient.
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(b) Comparison between GTVbM, GTVbs6% and overlap for each patient.
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(c) Comparison between GTVbM, GTVbso% and overlap for each patient.
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The overlap region, shown in red, appears greatest for the PMSl threshold of 
36%, as shown in figure 2.9[b), suggesting better concordance w ith  the GTVbM 
than for the other two thresholds of PMSl [20% and 50%]. For the GTVb20% 
[figure 2.9[a]], the GTVb2o% [green bars) appeared larger than the overlap w ith  
GTVbM, indicating overcontouring, w hilst in contrast, the GTVb50% [shown in 
figure 2.9[c]] indicated undercontouring, w ith  the GTVbM only region [blue] 
appearing larger than both overlap and GTVb50% volumes.
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2.3.2.2.2. Comparison with GTVbSUV2.5, GTVbSBR and
GTVbFLAB
In general, the GTVbsuvz.s, GTVbsBR and GTVbpLAB all showed overlap regions w ith  
the GTVbM that appeared larger than the GTVbM only, or the evaluated GTVb 
only. For the GTVbsuvz.s (figure 2.10], the overlap region appeared the smallest 
out of these three methods, w ith  the GTVbsuvz.s only volume showing the largest 
proportional region compared w ith  small GTVbM only regions, suggesting 
overcontouring by the SUV2.5 threshold method.
The overlap regions for both GTVbsBR and G TVb FLAB regions appeared more 
consistent than the GTVbsuvz.s method (figures 2.11 and 2.12]. The G T V b M  was 
smaller than the GTVbsBR and larger than the G TVb FLAB methods, indicating 
overcontouring and undercontouring by these methods, respectively.
Figure 2.10. Comparison between GTVbM, GTVbsuvz.s and overlap for each 
patient
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Figure 2.11. Comparison between GTVbM, GTVbsBR and overlap for each 
patient.
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Figure 2.12. Comparison between GTVbM, GTVbpLAB and overlap for each 
patient.
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2 .3 .2 .2 .3 . Reference GTVbSBR volum e com pared w ith  o ther
GTVbE volum es
When GTVbM was set as the reference volume, the GTVb36%, GTVb40% and 
GTVbsuvz.s appeared sim ilar (Student's t-test, p = 0.602, p = 0.180 and p = 
0.098, respectively] (see table 2.7]. However, when the GTVbsBR was selected as 
the comparator, only the GTVbsuvz.s appeared to show no significant difference in 
terms of absolute volume (p = 0.217].
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Table 2.7. p values (Student's t-test results) for difference in absolute 
volume of GTVbE when compared to either GTVbM or GTVbSBR, as 
reference volume.
Volume Difference in absolute volume 
GTVbM
of GTVbE and: 
GTVbSBR
GTVbM p = 0.025
GTVb20% p = 0.007 p = 0.003
GTVb30% p = 0.076 p = 0.007
GTVb36% p = 0.602 p = 0.005
GTVb40% p = 0.180 p = 0.005
GTVb50% p = 0.000 p = 0.006
GTVb60% p = 0.002 p = 0.008
GTVb70% p = 0.006 p = 0.010
GTVb73% p = 0.007 p = 0.011
GTVbSUV2.5 p = 0.098 p = 0.217
GTVbFLAB p = 0.012 p = 0.013
GTVbSBR p = 0.025
2.3.3. Other analyses
Wilcoxon signed rank and Bland-Altman agreement tests were performed to
compare absolute volumes of GTVbM and GTVbE. Results are shown below in 
table 2.8.
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Table 2.8. Wilcoxon signed-ranks test 2 -tailed p values and Bland-Altman 
agreement results from comparisons between absolute volumes of GTVbM 
and GTVbE.
GTVbE Wilcoxon rank Bland-Altman
2- Median
tailed difference 95%  Limits of
p value (cm^) Bias agreement
G T V b z o % &002 -ZT030 28.931 -22.767 to 80.629
G T V b 3 o % &084 -4.870 5.857 -12.283 to 23.997
GTVb36% 0.770 -0.320 0.893 -9.351 to 11.137
G T V b 4 0 % 0.232 1.580 -T535 -8.074 to 5.004
G T V b s o % &002 &470 -6.459 -13.383 to 0.465
G T V b e o % &002 8.705 -9.695 -23.550 to 4.160
G T V b 7 o % 0.002 10.685 -12.847 -34.887 to 9.193
G T V b ? 3 % 0.002 11.135 -13,927 -39T^8to 11.214
G T V b s u v z s &020 -13.720 30.998 -7& 081to l3& 077
G TV bF LA B 0.010 5.205 -&648 -16.898 to 5.602
GTVbsBR 0.010 -9.435 12.832 -l& 815to42A 79
For the Wilcoxon test results, only the GTVb36% and GTVb4o% volumes were
sim ilar to the GTVbM volume (p = 0.770 and 0.232, respectively).
The Bland-Altman method gives an indication of whether the two methods agree
and also informs on the level of bias -  that is to say, how much the contour is 
different to the reference contour. A bias value of 'zero' indicates perfect 
agreement. From our results, it  can be seen that the GTVb36% has the smallest 
bias.
76
Figure 2.13. Bland-Altman difference plot for agreement between absolute 
GTVbM and GTVb36% (the volume which had the smallest bias for 
agreement).
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Figure 2.14. Bland-Altman difference plot for agreement between absolute 
GTVbM and GTVbSUV2.5 (the volume which was the most biased compared 
with the reference volume).
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2.3.4. Conformity indices anaiysis
Conformity indices included:
• Absolute volume index (AVI)
• Jaccard coefficient QC)
• Overlap fraction [OF)
'Perfect' conformity w ith  the reference volume, the GTVbM, would be indicated 
by a value of for each of the above indices. Results are shown in table 2.9.
With respect to AVI, the GTVb36% had a median value of 1 [95% Cl, 0.54 -  1.56). 
The GTVbsuv2.5 and GTVbsBR were greater than 1 [1.67 and 1.52, with large 95%  
Cls, respectively), showing overcontouring relative to the GTVbM. AVI for the 
GTVbFLAB had a median value of 0.72, w ith  a 95% Cl of 0.39 -  1.15, showing a 
moderate degree of undercontouring in general.
The GTVb36% also had the largest )C compared to the rest of the group of GTVbE
volumes [median JC 0.64, 95% Cl 0.39 -  0.74). The FLAB and SBR techniques had 
sim ilar median JC's [0.47 and 0.53, respectively). The SUV2.5 showed low 
conformity w ith  a median value of 0.38 [95% Cl 0.26 -  0.59).
In terms of OF of GTVbM, as expected, those techniques involving low threshold 
values showed the greatest overlap w ith  the reference volume and therefore 
showed the values closest to 1. These were the GTVb2o% and GTVb3o% [median 
OF 0.99 and 0.92, respectively), GTVbsuvz.s [median OF 0.98) and GTVbsBR [OF 
0.94).
78
Table 2.9. Median (range) values and 95%  confidence intervals (95%  CI) 
for the absolute volume index, Jaccard coefficient and the overlap fraction 
of GTVbM.
Volume Absolute volume 
index
Jaccard coefficient Overlap fraction of 
GTVbM
Median
(range)
95% Cl Median
(range)
95% Cl Median
(range)
95% Cl
GTVbM 1 1 1
GTVb2o% 2.38 0.86-7.23 0.38 0.24-0.52 0.99 0.89-1.01
(1.54-16.16) (0.06-0.64) (0.78-1.00)
GTVb3o% 1.25 0.56-2.51 0.61 0.41-0.73 0.92 0.64-0.99
(0.29-5.17) (0.19-0.82) (0.29-0.98)
GTVb36% 1.00 0.54-1.56 0.64 0.39-0.74 0.79 0.52-0.92
(0.12-2.77) (0.12-0.83) (0.12-0.96)
GTVb4o% 0.88 0.49-1.16 0.59 0.36-0.73 0.72 0.44-0.85
(0.10-1.71) (0.10-0.85) (0.10-0.94)
GTVbso% 0.48 0.24-0.67 0.47 0.24-0.63 0.48 0.24-0.66
(0.00-0.88) (0.00-0.82) (0.00-0.85)
GTVb6o% 0.32 0.12-0.52 0.32 0.12-0.50 0.32 0.12-0.51
(0.00-0.74) (0.00-0.72) (0.00-0.73)
GTVb7o% 0.18 0.05-0.38 0.18 0.05-0.37 0.18 0.05-0.37
(0.00-0.57) (0.00-0.55) (0.00-0.56)
GTVb?3% 0.15 0.04-0.33 0.15 0.04-0.33 0.15 0.04-0.33
(0.00-0.52) (0.00-0.51) (0.00-0.52)
GTVbsuvz 5 1.67 0.91-4.77 0.38 0.26-0.59 0.98 0.69-1.03
(0.46-8.91) (0.11-0.76) (0.39-1.00)
GTVbpLAB 0.72 0.39-1.15 0.47 0.32-0.63 0.66 0.40-0.74
(0.15-1.74) (0.15-0.80) (0.15-0.84)
GTVbSBR 1.52 0 .21 -4 .84 0.53 0.37 - 0.66 0.94 0.76 -1.00
(0.64-11.54) (0.09-0.76) (0.48-1.00)
2.3.4.I. SHERRI (Surrey Heuristics Engine for Radiobiology, 
Radiotherapy and Imaging) software analysis
SHERRI (Surrey Heuristics Engine for Radiobiology, Radiotherapy and Imaging)
software was used to measure:
•  Jaccard coefficients
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•  Mean distance to conformity (MDC)
• Shift in centre o f mass (SCM)
2.3 .4 .I.I. Jaccard coefficient
Jaccard coefficients (JCs) calculated by SHERRI were sim ilar to calculated values
using known volume data from the Eclipse TPS w ith  the GTVbM used as the 
reference volume [table 2.10). Small differences were expected due to the 
differing way in which three-dimensional volumes are read and analysed from 
DICOM files by differing software.
SHERRI was then employed to evaluate JCs for the situation where the reference 
volume was set as the GTVbsBR. Use of the GTVBsBR as the reference produced
different JCs compared to when the GTVbM was set as the reference volume. The 
highest conformity results by JC were for the GTVb20% and GTVb30% (0.69 and 
0.67, respectively). The next highest JC was for the GTVbSUV2.5 and all other 
segmented volume compared poorly w ith  the GTVbsBR, all w ith  JCs of less than 
0.50.
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Table 2.10. Median Jaccard Coefficient (JC) values calculated manually from  
Boolean volumes measured on Eclipse treatm ent planning station, and 
calculated by SHERRI software, comparing against GTVbM and GTVbsBRas 
reference volumes.
Volume
Eclipse
JC
Ref vol = 
GTVbM
Ref vol = 
GTVbM
SHERRI JC 
Ref vol =
95%  Cl
GTVbsBR
95%  Cl
GTVbM n/a 0.59 0.38 - 0.68
GTVb20% 0.38 0.39 0.24-0.52 0.69 0.48 - 0.76
GTVb30% 0.61 0.68 0.43 - 0.76 0.67 0.55 - 0.78
GTVb36% 0.64 0.74 0.42 - 0.79 0.49 0.37 - 0.65
GTVb40% 0.59 0.67 0.40 - 0.77 0.42 0.28-0.58
GTVb50% 0.47 0.54 0.44 - 0.73 0.36 0.19 - 0.52
GTVb60% 0.32 0.39 0.21 - 0.62 0.25 0.16 - 0.42
GTVb70% 0.18 0.25 0.11 - 0.47 0.16 0.10 - 0.32
GTVb73% 0.15 0.21 0.10 - 0.42 0.13 0.07 - 0.28
GTVbsuvz. 5 0.38 0.40 0.27 - 0.62 0.54 0.45 - 0.72
GTVbFLAB 0.47 0.51 0.35 - 0.70 0.33 0.25-0.51
GTVbsBR 0.53 0.59 0.38 - 0.68 n/a
Ref vol, reference volume
2.3.4.I.2. IVIean distance to conformity (IVIDC) and shift in 
centre of mass (SCIVI) analysis
Mean distance to conformity (MDC), details of over- and under-contouring and
values for the shift in the centre of mass (SCM) were obtained using SHERRI
software. Both the GTVbM and the GTVbsBR were compared as reference 
volumes. The results are shown in tables 2.11 and 2.12, respectively.
Using GTVbM as the reference volume, the greatest amount of over-contouring 
(MDC(O)) was produced by the GTVb20%, GTVb30%, GTVbsuvz.s and GTVbsBR. 
The amount of under-contouring was low for all techniques. Similarly, the largest
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shifts in centre of mass were for the GTVb20%, GTVb30%, GTVbsuvz.s and 
GTVbsBR, w ith  the smallest shifts being required when comparing the GTVb50%, 
GTVb60% and GTVbFLAB volumes.
Table 2.11 Median values for mean distance to conformity (MDC), quantity 
of over-contouring (MDC(O)), under-contouring (MDC(U)) and shift in 
centre of mass (SCM) using GTVbM as reference volume.
Volume MDC MDC(O) MDC(U) SCM
GTVb20% 3510.94 3511.39 0.01 12.58
GTVb30% 1241.99 1240.96 0.09 5.13
GTVb36% 45.46 42.90 0.84 2.55
GTVb40% 15.46 12.48 1.21 2.50
GTVb50% 2.63 0.01 2.15 1.31
GTVb60% 3.33 0.00 2.61 1.85
GTVb70% 55.13 0.00 3.36 2.41
GTVb73% 36.60 0.00 3.79 2.03
GTVbsuvz 5 1421.27 1420.15 0.02 8.02
GTVbFLAB 3.03 0.03 2.21 2.09
GTVbsBR 1778.19 1778.19 0.03 7.18
In contrast, when the GTVbsBR was set as the reference volume, the majority of 
techniques were found to under-contour the GTVbsBR, with only the GTVb20%, 
GTVb30% and GTVbsuvz.s having small under-contouring errors. The SCM 
showed a smaller median range than for GTVbM as reference volume ((3.22 -  
8.34) versus (1.31 -  12.58), respectively).
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Table 2.12 showing median values for mean distance to conformity (MDC), 
quantity of over-contouring (MDC(O)), under-contouring (MDC(U)) and 
shift in centre of mass (SCM) using GTVbsBRas reference volume.
Volume MDC MDC(O) MDC(U) SCM
GTVb20% 610.38 610.31 0.00 4.96
GTVb30% 32.09 0.00 2.76 3.41
GTVb36% 424.96 0.00 424.96 4.41
GTVb40% 475.47 0.00 475.47 4.54
GTVb50% 938.37 0.00 938.37 7.34
GTVb60% 973.65 0.00 427.51 7.68
GTVb70% 968.72 0.00 450.94 8.12
GTVb73% 1003.70 0.00 496.66 8.34
GTVbsuvz.s 476.40 264.45 0.89 3.22
GTVbFLAB 381.84 0.00 381.84 6.94
GTVbsBR 1778.19 0.03 1778.19 7.18
2.4. Discussion
In this study, five techniques for segmentation of FDG-PET scans were used to 
identify the metabolically active, FDG-avid subvolume (GTVb) in ten patients 
w ith  histologically confirmed squamous cell carcinoma of the oropharyngeal 
region. The results were intended to inform the design of a pre-clinical planning 
study evaluating dose-painting w ith  IMRT to the GTVb volume, which in turn 
might influence the segmentation technique used in a future phase 1 clinical 
study to investigate dose-painting IMRT to the GTVb. Data relating to absolute 
volume, overlap, conformity indices such as the Jaccard coefficient and 
morphometric conformity tools such as the mean distance to conformity [MDC) 
which informs on under- and over-contouring, were used to guide the 
comparison.
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2 .4 .1 . M anual delineation
The GTV has been defined internationally as the 'gross demonstrable extent and
location of the tumour' [11-13]. Currently, visual interpretation of available
imaging which may commonly include diagnostic CT, magnetic resonance 
imaging (MRl) and FDG-PET/CT is used to guide the standard manual approach 
to delineating the GTV on a radiotherapy planning CT scan. The manually 
delineated GTVbM was selected to be used as the reference volume to reflect 
standard practice w ith  respect to contouring the standard GTV. Visual 
interpretation by clinicians is widely available, familiar and a simple approach to 
defining the GTVb and other radiotherapy planning volumes. The problem w ith  
this method is that it  is prone to inter- and intra-observer variation in 
interpretation. The work in this study aimed to investigate whether a simple 
semi-automated segmentation method could approximate the manually defined 
GTVbM.
Various groups have demonstrated that the incorporation of FDG-PET/CT data, 
interpreted visually and defined by manual delineation -  in this study, termed 
the GTVbM - has resulted in modification of the volume delineated on CT alone 
(GTV-CT) [14, 15]. The results from the segmentation study performed by this 
student showed that in nine out of the ten patients, the GTVbM was significantly 
smaller than the prim ary tumour GTV-CT[T) [p = 0.016]. In the remaining 
patient, the GTVbM was only smaller than the GTV-CT by 0.49cm^.
Ciernik et al performed manual delineation of the GTV using co-registered FDG-
PET/CT images from twelve patients w ith  head and neck cancer (HNC) [14]. Two 
independent oncologists were involved w ith  the delineation procedure. The 
group reported that delineation variab ility  of the GTV reduced w ith  the addition 
of information from FDG-PET and that the size of the GTV was reduced by a 
m inimum of 25% in one th ird  of the patient sample.
In 2007, a Dutch research group reported a comparison of five FDG-PET/CT
segmentation techniques for target volume delineation in HNC [15]. Schinagl et 
al reported a larger study including seventy-eight patients w ith  HNSCC. Standard 
GTV-CT was contoured. The five segmentation techniques included manual 
delineation and application of three fixed thresholds including SUV of 2.5 and
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PMSIs [percentage of maximal signal intensities) o f 40% and 50%. The group 
also generated contours using the source-to-background ratio [SBR) technique. 
In general, all volumes based on FDG-PET [mean absolute volumes ranging 
between lO.Scm^ and Zl.Scm^) were smaller than the GTV-CT [mean absolute 
volume, 22.7cm3).
2.4.2. Fixed threshold based on percentage of maximal signal 
intensity (PMSI)
Advantages of the PMSl method include the removal of inter- and intra-observer 
variability, speed and sim plicity of use and the fact that few software tools 
outside of the standard range of treatment planning station contouring tools are 
required. Providing the PET scanner has undergone quality assurance [QA) 
procedures to national guidelines [16], no additional PET phantom background 
work is required. This approach therefore does not add pressure to either 
financial [fo r example, extra costs of making or ordering FDG tracer for phantom 
work) or staff [physics or clinical) resources, both of which are im portant 
realities in the current economic climate which may restrict the development 
and implementation of newer techniques.
The chief disadvantage of the PMSI approach is the reliance on a single threshold 
percentage value. No single threshold can be optimal for all tumours of 
heterogeneous shape and size. Recorded absolute pixel or point values of FDG 
uptake w ill vary according to a very large number of factors. These factors can be 
divided into biological -  for example, baseline blood glucose levels, tracer uptake 
period, patient movement during image acquisition, and technical and physical 
factors including differing PET scanner characteristics and differing image 
acquisition and reconstruction parameters [16, 17]. These issues highlight the 
importance of adhering to a nationally or even internationally agreed minimum 
set of quality standards.
PMSl thresholds of FDG uptake used to delineate the FDG-avid subvolume seen 
on PET in the setting of HNC in the literature have ranged from 36% to 73%. A 
Belgian group has reported a number of studies investigating the potential 
applications of FDG-PET/CT in head and neck oncology. Daisne et al compared 
CT, MRl and FDG-PET/CT against histopathological specimens from nine
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patients w ith  pharyngolaryngeal squamous cell carcinoma tumours [8]. The 
group also reported a sub-analysis of the ir study [7]. Nine patients underwent 
total laryngectomy surgery. The researchers were able to measure macroscopic 
tumour contours -  deemed 'the gold standard', which were subsequently 
compared w ith  the corresponding FDG-PET images. It was found that varying 
thresholds of FDG uptake of between 36% and 73% were required to produce an 
adequate 'fit ' to the macroscopic contour. This range -  36-73% is wide and 
suggests that thresholds based on a fixed percentage of maximal signal intensity 
(PMSI] may be unreliable. The findings prompted the authors to develop a 
segmentation method based on the source-to-background ratio (SBR) [1]. Both 
this reported range of thresholds of PMSl and the SBR techniques were 
evaluated in the w ork performed in this chapter.
Another group from Atlanta, Paulino et al, performed FDG-PET delineation based 
on a threshold of 50% of the maximum signal uptake [18], generating the 
equivalent of the GTVb5o% volume evaluated in this student's study. Forty 
patients w ith  head and neck squamous cell carcinoma (HNSCC) underwent FDG- 
PET/CT in the radiotherapy treatment position, in addition to standard 
radiotherapy planning CT scanning. The GTVbso% was compared to the standard 
GTV-CT and was found to be smaller than the GTV-CT in the m ajority of cases - 
75% of the forty patients. For the remainder of the patients, the GTVb50% was 
found to be the same size in 8% and larger than the GTV-CT in 18% of cases. 
Intensity modulated radiotherapy (IMRT) plans were optimised for standard 
(non-PET-defined) CT delineated radiotherapy target volumes (TVs) and organs 
at risk (OARs) only. Interestingly, on retrospective dosimetric review of the 
IMRT plans, it  was found that approximately one quarter (24%) o f the forty 
patients would have received less than 95% of the prescribed dose to the 
GTVbso%.
Schinagl et al included an evaluation of the GTVb4o% and GTVbso% in their
investigation of various segmentation methods [15]. These volumes were found 
to be smaller than the standard GTV-CT volumes. The group concluded that the 
use of fixed thresholds for image segmentation was debatable and that w hilst 
phantom-based experiments using symmetrical volumes w ith  homogenous
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activity might generate reasonable results, that the same results might not be 
expected of biological tumours which may show heterogeneous distributions of 
FDG uptake and have complex non-spherical shapes.
The w ork reported in this chapter shows the impact of using a range of fixed 
thresholds of PMSl. The PMSl threshold of 20% resulted in overcontouring of the 
reference GTVbM, w hilst the PMSl of 73% were often associated w ith  a threshold 
value of FDG uptake that was too high to generate any clinically meaningful, or 
even measurable, GTVb73% volume.
This student’s results found that the threshold of 36% appeared comparable 
w ith  the manually contoured GTVbM, for the ten patients. As described above, 
Daisne et al reported that a large range of thresholds between 36% and 73% 
were required to 're tro -fit' the macroscopic GTV contour to FDG signal intensity 
on PET images. The interpretation of this finding in the context of our own 
findings requires consideration of several issues. Different scanners and 
different reconstruction algorithms were used and may affect the PET images 
and the measured FDG uptake values. In contrast to Daisne et al, in our study, 
our reference volume was the manually delineated GTVbM, rather than the 'gold 
standard' histopathological delineated specimen, which has been demonstrated 
to have a smaller volume than those defined on CT, MRl or PET imaging. 
Therefore it  is not surprising that we found that the GTVb36% compared sim ilarly 
w ith  the GTVbM volume, since application of a lower threshold w ill generate 
larger contours and therefore be more comparable w ith  a manually delineated 
GTVb. The tumour subsite also accounts for some of the differences noted. Our 
work was based on oropharyngeal tumours only, in contrast to the Daisne group, 
who analysed post-laryngectomy specimens. The oropharynx has several organs 
which are known to have greater physiological uptake than other tissues, namely 
the tonsils and base of tongue, in contrast to the larynx. This may lead to false- 
positive visual in terpretation for cancer.
2.4.3. Fixed threshold of standardised uptake variable (SUV) 2.5
Results showed that using a fixed SUV of 2.5 resulted in a large amount of
overcontouring of the GTVb w ith  respect to the GTVbM (the median increase in 
volume by GTVbsuvz.s was 13.720cm3, Wilcoxon rank two-tailed p value of
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0.020). This volume was also associated w ith  the largest bias of all the methods 
(30.998) and w ith  wide 95% lim its of Bland-Altman agreement (-73.081 to 
135.077). The MDC(O) confirmed a large amount o f overcontouring.
Two patients were exceptions to this trend: patients 1 and 2 both had GTVbM 
volumes that were much larger than the corresponding GTVbSUV2.5 volumes. In 
other words, for these two patients, the SUV2.5 method undercontoured the 
GTVbM. On closer examination of the results, both patients had relatively small 
prim ary tumours compared w ith  the remainder of patients, w ith  GTVbM 
volumes of 6.24cm^ and 6.99cm^. For the ten patients, the median GTVbM 
volume measured 10.78cm^, w ith  a range of 1.95-81.18cm^. The corresponding 
GTVbSUV2.5 volumes for patients 1 and 2 were 2.85cm^ and 3.24cm^, 
respectively, w ith  median and range for the GTVbSUV2.5 for the ten patients of 
27.52cm^ and 2.85-249.86cm^. Both of patients 1 and 2 had small tonsillar 
prim ary tumours. The tonsillar region commonly displays 'physiological uptake' 
of FDG even when normal, making detection of tumour edge in a small tonsillar 
mass or deposit from background FDG uptake in the uninvolved part of the 
tonsillar region challenging. Our results suggest that in the case of small tonsillar 
tumours, the contrast between abnormal and physiological areas of FDG uptake 
in this region may be less and also that clinicians may overcontour the GTVbM in 
an effort to err on the side of caution and avoid 'missing' the tumour. Future 
work could include an assessment of maximum and average FDG uptake within 
the tumour delineated manually and also the average FDG uptake w ith in  the 
surrounding l-2cm  of tissue. This may inform  us as to how visual in terpretation 
is affected in the case of tumours of small and large size, w ith  differing contrast 
in FDG uptake.
An SUV of 2.5 has some popularity in FDG-PET imaging for lung cancer. The 
discrepancy w ith  GTVbM either suggests that a higher threshold of SUV would 
seem appropriate for HNSCC, or that the nuclear medicine physician and clinical 
oncologist responsible for delineating the GTVbM were conservative w ith  their 
approach. Higher values of SUV w ith  respect to dichotomising FDG uptake in 
HNSCC have been reported in the literature and could be explored in the future.
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2.4.4. Semi-adaptive thresholding based on the source-to-
background ratio (SBR)
One of the chief strengths of the SBR method is that i t  is semi-adaptive, rather
than being a fixed and relatively arb itrary threshold of uptake and is not prone to 
inter- or intra-observer variability. With this technique, the threshold selected to 
generate an isocontour depends on the measured SBR of each individual patient 
concerned. It is also the only technique that has undergone histopathological 
validation [8]. Various criticisms of this technique include the requirement that 
each centre using this technique would need to perform phantom w ork to 
calculate individual scanner-specific variables. This w ork was described in 
section 2.2.6.4 and was costly in terms of both staff [physicist] and financial [cost 
o f FDG tracer for phantom work and scanner time to perform the study] 
resources. Another lim ita tion is that perfectly spherical phantoms were used 
whereas tumours have non-geometric shapes and usually have inhomogeneous 
FDG uptake, and the fact that low SBRs are unreliable in estimating tumour 
volumes due to the inherently low contrast between tissues.
Schinagl et al reported that the mean absolute volume of the GTVbsBR was 
11.2cm3, compared w ith  21.5cm3 for their equivalent of the manually delineated 
GTVbM volume. The student found that the GTVbsBR overestimated the GTVbM -  
median absolute volume 22.50cm^ versus lO.TBcm^, respectively. The absolute 
volume of the overlap region between GTVbsBR and GTVbM, however, measured 
a median of lO.OBcm ,^ sim ilar to the volume of the GTVbM. SHERRI conformity 
indices were less favourable, showing overcontouring (MDC) compared w ith  
other techniques and a larger SCM (table 2.11).
SHERRI software provided a way to compare different reference volumes against 
the other evaluated methods (see table 2.10). As described, the GTVbM was 
selected to be the standard reference volume. The GTVbsô# was found to have a 
Jaccard coefficient (JC) closest to ‘V -  a value of 0.74. The JC for the comparison 
of GTVbM and GTVbsBR was 0.59. In view of published w ork which validated the 
GTVbsBR against surgical specimens, the student also compared the evaluated 
volumes against the GTVbsBR. When the GTVbsBR was set as the reference volume, 
the JC for GTVb36% was 0.49, w ith  a sim ilar JC for GTVbsuvz.s (0.54). This suggests
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that the GTVbs6% might be considered a reasonable fixed threshold for 
segmentation use, should the background w ork for the SBR technique not be 
feasible w ith in  a centre.
2.4.5. Fuzzy locally adaptive Bayesian algorithm (FLAB)
W hilst the SBR method was semi-adaptive to individual patients in contrast to
fixed thresholds based on PMSl or SUV, it  essentially remains a binary method of 
image segmentation. The only fu lly  adaptive observer-independent method 
evaluated in this study was the use of a fuzzy locally adaptive Bayesian [FLAB) 
algorithm [4, 9]. This algorithm was developed by a French research group in 
Brest, to address the heterogeneous nature of tumours.
The GTVbpLAB was smaller than the reference GTVbM [median 7.82cm^, range 
1.03-63.0) versus 10.78cm^ [range 1.95-81.18), respectively. The Wilcoxon rank 
p value was consistent w ith  a statistically significant difference [median 
difference, 5.21cm^, p = 0.010) but the Bland-Altman suggested good agreement, 
w ith  a bias value of -5.648, relatively close to 1 (table 2.8). The JC for the 
comparison between GTVb FLAB and GTVbM was unremarkable at 0.47.
The experience of the student with the FLAB algorithm was that w hilst the tool 
was fully automated, thus removing operator variability, overall, the GTVb FLAB 
did not closely approximate the GTVbM. Since the GTVbFLAB had not been 
developed w ith  in collaboration w ith  the two observers (the student and a 
consultant nuclear medicine physician in the same institution) involved w ith  
visual interpretation and manual contouring of the GTVbM in this study, this is 
not surprising. Furthermore, the FLAB algorithm was developed on other patient 
and other tum our datasets. However, valuable experience was gained in image 
processing skills. The Eclipse TPS has commercial in -bu ilt software to protect the 
TPS and pre-existing data. It was therefore not a straightforward issue to 
introduce the externally-generated GTVbFLAB contours into the TPS and fused 
w ith  the diagnostic planning CT.
Through a special collaboration w ith  the software developers of a Visualisation 
and Organisation of Data for Cancer Analysis (VODCA) software [19], it  was 
possible to translate the co-ordinates of the GTVbFLAB structure into a DICOM
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format compatible w ith  Eclipse. This experience highlights the potential and 
significant challenges to developing adaptive and automatic FDG-PET 
segmentation algorithms for universal use, particularly w ith  the potential 
application to clinical phase 1 studies.
2.4.6. Other approaches to FDG-PET segmentation
A number of other FDG-PET segmentation techniques have been proposed in the
literature, including a gradient-based method [2], a 'watershed' segmentation 
method [20], a novel iterative approach based on background-subtracted relative- 
threshold [5] and another iterative approach in which a volume is 'grown' from a 
single identified 'seed point' within the visualised tum our [6].
Moule et al recently reported work in which commercial software in-built into the 
TPS provided means to segment FDG-PET by application of thresholds of either SUV 
Cut Off (SUVCO) or by a percentage of the maximum SUV detected within the lesion 
of interest (SUVmax) [21]. The SUVCO approach was equivalent to the SUV2.5 
approach employed in the student's work to generate the GTVbsuvz.s- In the work of 
Moule et al, SUV cut o ff thresholds o f between 2.5 and 4.0 were used. These tools 
were applied to evaluate temporal changes in FDG uptake during radical 
radiotherapy in eight patients w ith locally advanced HNSCC. The authors concluded 
that the simple SUVCO method was less susceptible to tum our and background FDG 
uptake changes during treatment.
2.5. Conclusions
The purpose of this study was to evaluate various methods of FDG-PET image 
segmentation. Ideal properties of this method would include ease of use and 
independence from both operator and scanner variability. The results of this 
study were intended to contribute to the design of a phase 1 clinical study 
investigating dose-painting intensity modulated radiotherapy (IMRT) to 
oropharyngeal squamous cell carcinomas (SCC).
Our results suggest that in this centre, application of a fixed percentage of 
maximal signal intensity of 36% could approximate the manual contour agreed 
by the pair of nuclear medicine physician and clinical oncologist. These results 
were supported by the Wilcoxon signed rank test and the smallest bias as tested
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by the Bland-Altman method. Furthermore, the Jaccard Coefficient was the 
closest to conform ity (one) for the GTVb36% when compared to the GTVbM, 
w ith  a median overlap fraction of 0.79, which seems a reasonable value.
Limitations of this study include the lack of radiotherapy specific immobilisation, 
the unavoidable variation in PET imaging between centres and the sample size. 
As a consequence of the imaging datasets of both FDG-PET/CT and standard 
radiotherapy planning CT being performed in different positions, the decision 
was taken to perform the entire analysis on the co-registered FDG-PET/CT 
datasets, which were not performed in the treatment position and w ith  no 
intravenous CT contrast used, unlike standard practice. Future w ork should 
include analysis of FDG PET scans performed in the treatment position, on a flat 
couch w ith  radiotherapy-specific head and neck immobilisation, using a 
standard radiotherapy planning CT scan protocol. Ideally a larger sample of 
image sets would be shared between a number of centres and at least one 
clinician pair per centre would submit GTVbM contours for comparison.
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Chapter 3: FDG-PET guided dose-painting with IMRT to oropharyngeal 
tumours -  a pre-clinical study
A phase I clinical study was designed to evaluate the feasibility o f dose-painting a 
subvolume w ith in  the gross tum our volume (GTV) identified by FDG-PET 
imaging in oropharyngeal tumours. The intention was to examine the safety, 
to lerab ility  and practical issues associated w ith  this approach. Pre-clinical work 
was performed to act as a baseline for this phase I study. Several issues were 
explored; FDG-PET segmentation methodology was one such issue and was 
discussed in Chapter 2.
This chapter reports a pre-clinical study, which investigated the feasibility of
dose-painting w ith  intensity modulated radiotherapy (IMRT) to an FDG-avid 
subvolume -  the biological gross target volume (GTVb) - w ith in  oropharyngeal 
tumours. Anonymised FDG-PET/CT datasets for ten patients w ith  confirmed 
squamous cell carcinoma (SCC) of the oropharynx were identified. Four IMRT 
plans were created for each patient w ith  a different dose level of escalation 
prescribed to the GTVb, increasing in 5% increments of dose relative to the dose 
prescribed to the high dose planning target volume (PTVl). A ll plans were 
required to comply w ith  standard organs at risk (OARs) dose constraints, as per 
departmental protocol. A comparison of the estimated radiobiological effects in 
terms of tumour control probability (TCP) and normal tissue complication 
probability (NTCP) was performed using BioSuite [1], a radiobiological software 
package. Finally, an evaluation of the impact of using the different delineation 
methods described in Chapter 2 was also performed.
3.1. Objective of study
To perform a pre-clinical study to test the hypothesis that dose painting w ith
IMRT to FDG-avid volumes in oropharyngeal tumours is feasible.
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3.2. Methodology
3.2.1. Patients
The anonymised datasets of ten patients w ith  histologically proven squamous 
cell carcinoma of the oropharyngeal region and who had undergone co­
registered FDG-PET-CT imaging at the Guildford Diagnostic Imaging centre on 
the site of the Royal Surrey County Hospital in Guildford, were identified 
retrospectively from Clinical Oncology Head and Neck Cancer patient databases. 
These were the same ten patients described in Chapter 2.
3.2.2. Contouring procedure
Delineation of standard target volumes -  prim ary and nodal GTVs, high dose
CTVl, prophylactic dose CTV2 and organs at risk [OARs) - was performed 
according to departmental contouring protocol, using knowledge of diagnostic 
CT, MRl and FDG-PET-CT imaging, as per standard. This protocol is compliant
w ith  ICRU 50, 62 and 83 guidelines [2-4]. Contouring for one of the ten patients 
is shown in figure 3.1.
3.2.2.1. Primary gross tumour volume identified on CT (GTV-T)
GTV-T was defined as the visible tum our in the prim ary oropharyngeal
tumour region, as seen on the CT component of the co-registered PET-CT 
scans. The GTV-T was delineated w ith  knowledge of the maximum 
information available from diagnostic CT (contrast enhanced, i f  available), 
FDG-PET-CT and MRl i f  available as it  is done in clinical practice. When no 
clear plane of separation existed between prim ary tumour and nodal 
extent, for example, a tonsillar tumour that had extended to become 
contiguous w ith  retropharyngeal nodes, the entire contiguous volume 
was delineated as GTV-T, w ith  any more obvious nodal extensions edited 
out and included in the GTV-N volume.
3.2.2.2. Nodal gross tumour volume identified on CT (GTV-N)
GTV-N was defined as the visible tum our in the nodal regions, as seen on
the CT component of the co-registered PET-CT scans. The GTV-N was 
delineated w ith  knowledge of the maximum information available from 
diagnostic CT (contrast enhanced, i f  available), FDG-PET-CT and MRl if  
available.
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3 .2 .2 3 . Biological gross tu m o u r volum es (GTVb):
Five GTVb volumes were contoured for each patient:
i. GTVbM
ii. GTVbs6%
iii. GTVbsuvz.s
iv. GTVbsBR
V. GTVbpLAB
These five volumes corresponded to the same volumes evaluated in
Chapter 2. The volume generated by applying a threshold percentage of 
maximal signal intensity (PMSl) of 36% - the GTVb36%- was selected for 
reporting based on results presented in Chapter 2.
3.2 2.4. High dose clinical target volume (CTVl)
This was defined as the clinical target volume to be treated to a radical
dose. It included the prim ary tumour and involved nodes (GTV-T and 
GTV-N) and high risk areas. In general, the GTV-T was grown w ith  a 10- 
15mm margin and lim ited w ith in  visible anatomical barriers to guide 
appropriate delineation of the CTVl, similarly, a margin of 10mm was 
added to the GTV-N to account for the risk of extracapsular spread. The 
standard CTVl in oropharyngeal tumours encompassed the entire 
oropharynx. The 'adjacent but not directly involved' regions were 
included in the CTVl. Any neighbouring structures involved by tumour 
(for example, parotid gland, medial pterygoid muscle and parapharyngeal 
space) were also included. Where no obvious anatomical barriers existed 
(for example, the base of tongue), a geometric margin was used, as 
specified above. In the case of node-negative disease, the retropharyngeal 
nodes at the level of the oropharynx (ipsilateral in well lateralised T l /2  
tumours, bilateral in all others) and ipsilateral level 2a nodes were 
included in this volume. All involved nodal levels were included in CTVl. 
Finally, i f  level 2 nodes were involved, the ipsilateral jugular fossa and 
retrostyloid space extending cranially up to the base of skull were 
included.
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3.2.2.5. Prophylactic dose clinical target volume (CTV2)
This was defined as the clinical target volume to be treated to a
prophylactic, or elective dose. The CTV2 included un-involved levels Ib-V 
bilaterally and supraclavicular fossa (SCF] nodes bilaterally. Delineation 
of nodal volumes lb to V and retropharyngeal nodal regions was 
performed according to the Consensus guidelines [5, 6].
3.2.2.6. Planning target volumes (PTVl and PTV2)
A 3mm margin was applied in all directions to each of the CTVl and CTV2,
to produce the PTVl and PTV2, respectively. This margin reflected the 
setup accuracy reported for the local centre. Both PTVl and PTV2 were 
edited to ensure that they did not come w ith in  5mm of the patient's skin. 
PTV2 was edited such that the overlap w ith  PTVl was removed.
3.2.2.7. Organs at risk (OARs)
The following OARs were delineated in all patients: spinal cord, brain
stem, parotid glands bilaterally, mandible, oral cavity, whole tongue, base 
of tongue and submandibular glands bilaterally. The base of tongue was 
defined as the posterior th ird  of the whole tongue [as seen on sagittal 
view). The larynx was defined as consisting of the vocal cords, arytenoids 
including laryngeal musculature and excluding the thyro id cartilage, as 
described by Eisbruch [7]. In addition, the superior, middle and in ferior 
pharyngeal constrictor muscles were delineated using methods described 
by Bhide et al [8].
3.2 2.8. Other volumes
3mm and 5mm margins were applied to both spinal cord and brain stem
to create planning organ at risk volumes (PRVs).
An untreated tissue volume was created by subtracting the PTVl and 
PTV2 from the patient contour; this was performed to aid estimation of 
integral dose for the purpose of IMRT plan review and appraisal.
Finally, pseudostructures, or planning avoidance volumes, were created 
in the m idline and posterior neck, to reduce deposition of dose in these 
regions.
100
Figure 3.1. Example showing target volume and organs at risk contours on 
planning CT scan.
t  ‘  > Transversal • titRT ptannmo 8 - Unapprovao - MrxW Vtew - WRT
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3.2.3. IMRT planning
IMRT planning was performed w ith  Eclipse version 8.2 [Varian Medical Systems,
Palo Alto, CA) treatment planning system [TPS]. A five to seven static split-beam 
arrangement was used, w ith  a simultaneous integrated boost [SIB] technique [9].
Once optimisation was completed, the leaf motion calculator was run w ith  
dynamic m ulti-leaf collimator [MLC] delivery. A pencil beam algorithm was used 
for dose calculation. The prescribed dose was normalised to the median volume 
[50%] of the PTVl.
This process was repeated iteratively until the optimal balance between 
achieving dose objectives for PTVl, PTV2 and GTVbM were met, w ith in  the dose 
constraints set for the OARs. ICRU 50 and 62 [2, 3] guidelines were followed, 
w ith  the aim to cover the PTV w ith  95% of the prescribed dose and the 
prescribed dose was normalised to 100% at the isocentre. As for the PTVl and 
PTV2, no more than 5% of the GTVbM was allowed to receive more than 105% of 
the prescribed dose. Similarly, no more than 2% of the GTVbM was allowed to
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receive more than 107% of the prescribed dose to the GTVbM. The PTVl was 
edited to exclude the GTVbM, thus creating a 'shell' volume. This guided the 
treatment planning system in creating steep dose gradients between the PTVl 
and GTVbM volumes.
3.2.4. Dose prescription and fractionation
Four plans were created for each patient, each w ith  a different dose level (DL) of
escalation prescribed to the GTVbM volume (table 3.1]. Volume objectives for the 
GTVbM differed to those for the PTVl and PTV2 in that the target dose to 100% 
o f the GTVbM was 100% of the prescribed dose.
The DLl of 65Gy in 30 fractions over six weeks was selected as it reflects
standard SIB-IMRT dose prescription in our centre. This has a calculated 
biologically effective dose (BEDio] of approximately 70Gy in 35 fractions over 
seven weeks. The following EQD2 formulae [10] were used to calculate the 
equivalent dose in 2Gy per fraction and to take into account the shortening of 
overall treatment time to six weeks:
.  EQD2 = D (d+(a/p]/2  + (a/|3]]
.  and EQD2,T = EQD2,t - (T-t] x Dpmiif
where the EQD2 represents the equivalent dose in 2Gy fractions, D and d 
represent the total dose and dose per fraction, respectively, T and t  represent 
reference and change in overall treatment time, respectively and is a
proliferation factor (0.74Gy d'^] [11]. Values of a /p  of lOGy and 3Gy were 
selected to represent a/p  for tumour and late-responding tissues, respectively.
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Table 3.1. Dose prescription to target volumes.
Target
volume
Prescription dose 
and fractionation
d EQD2,T Volume
objective
Dose required
PTVl 65.00Gy in 30F 2.17Gy 71Gy 99% >90% (58.50 Gy]
95% >95% (61.75 Gy]
50% 100% (65.00 Gy]
5% <105% (68.25 Gy]
2% <107% (69.55 Gy]
PTV2 54.00Gy in 30F 1.80Gy 50Gy 99% >90% (48.60 Gy]
95% >95% (51.30 Gy]
50% 100% (54.00 Gy]
GTVbM
DLl 65.00 Gy in 30F 2.17Gy 71Gy 100% 100% (65.00 Gy]
(100%)
DL2 68.25 Gy in 30F 2.28Gy 75Gy 100% 100% (68.25 Gy]
(105%)
DL3 71.50 Gy in 30F 2.38Gy 79Gy 100% 100% (71.50 Gy]
[110%]
DL4 74.75 Gy in 30F 2.49Gy 83Gy 100% 100% (74.75 Gy]
(115%]
d, dose per fraction; F, fraction; EQD2,T = equivalent dose in 2Gy fractions, w ith  
changes in overall treatment time [T] taken into account; DL, dose level.
One aim of this study was to evaluate the radiobiological impact of different 
methods of FDG-PET segmentation. Of all five biological GTVb volumes delineated 
for each patient, only the GTVbM was specified in the IMRT planning dose 
prescription, as shown above in table 3.1. The remaining four GTVb volumes -  
GTVbs6%, GTVbsuvz.s, GTVbpLAB and GTVbsBR -  were delineated during the 
contouring procedure but were not specified in the dose prescription. The dose 
coverage of these four volumes was deliberately not reviewed at the time of IMRT 
plan review and approval but was reviewed retrospectively once a plan had been
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approved as meeting ICRU requirements satisfactorily w ith  respect to the PTVl, 
PTV2, GTVbM dose objectives and OAR constraints.
W ith respect to OARs, only the spinal cord and brain stem were absolute 
requirements for plan approval although the plans were optimised as much as 
possible with respect to the contralateral parotid gland, mandible and larynx. OAR 
constraints are shown in table 3.2. The pharyngeal constrictor muscles and tongue
were not specified in the IMRT planning prescription.
Table 3.2. Dose constraints to organs at risk.
OAR volumes Dose constraint
Spinal cord Max < 45 Gy
Spinal cord + 3mm lcm3 < 48 Gy
Spinal cord + 5mm Icm^ < 50 Gy
Brain stem Max < 50 Gy
Brain stem + 3mm lcm3 < 55 Gy
Brain stem + 5mm Icm^ < 55 Gy
Left parotid Mean < 24 Gy
Right parotid Mean < 24 Gy
Mandible (excluding PTVl) Max < 70 Gy
Larynx Mean < 40 Gy
3.2.5. IMRT plan evaluation
The following tools were used to compare treatment plans:
1. Dose statistics
2. Dose volume histograms [DVHs]
3. Isodose distributions in three dimensions [axial, sagittal and coronal)
4. Estimated tum our control probability (TCP)
5. Estimated normal tissue complication probability (NTCP)
Dose statistics were recorded for the various objectives listed in Table 3.1. Doses
for PTVl were reported as for the 'PTVlshell', in other words. Boolean operators 
were used to subtract the GTVbM from the PTVl volume, to avoid conflict with
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reporting doses to the PTVl. DVHs and isodose distributions were reviewed on 
screen following review of clinically acceptable dose statistics. Finally, DVHs for 
each structure were exported in text file format.
3.2.6. Radiobiological modelling
BioSuite, a radiobiological software package, was used to generate estimates of
tumour control probability [TCP) and normal tissue complication probability 
(NTCP) for each structure. BioSuite is an updated version of Bioplan, an earlier 
version of a radiobiological software package developed by the same research 
group[12]. BioSuite uses a Poisson TCP model developed by Webb et al [13]. For 
NTCP modelling, the Lyman - Kutcher- B urman model was used. A literature 
search was performed to obtain the parameters required for TCP and NTCP 
modelling.
3.2.6.1. TCP parameters
A literature search was performed to identify suitable parameters for squamous
cell carcinoma and the results are summarised below in table 3.3 [14]. Alpha 
values in the literature range between 0.2 and G.SGyi.
Table 3.3. Radiobiological parameters for tumour control probability used
in this study.
Parameter
alpha 0.27 Gy-i
alpha spread 0.11
alpha/beta lOGy
Clonogen density 10  ^cm-3
Repopulation parameters such as the repopulation constant or delay before 
repopulation value were not incorporated into the estimated TCP values. Specific 
values for these parameters are not w idely agreed in the literature and the 
rationale was made that providing TCP values were all generated using the same 
parameters as listed above in table 3.3, using the same radiobiological software
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package, that comparing these TCP values against each other would be a valid 
approach.
3.Z.6.2. NTCP parameters
A literature search was performed to identify parameters for dysphagia. Feng et
al reported an endpoint of aspiration -  grade 3 dysphagia -  when the entire 
length of the pharyngeal constrictor (PC) muscles received either a mean dose of 
66Gy, a V50 of 80%, a V60 of 70%, or a V65 of 50% [15]. Levendag reported that 
a mean dose of 55Gy to the superior and middle pharyngeal constrictor muscles 
(SPG and MPC) predicted for grade 3 dysphagia [16]. Therefore, dose statistics 
for the mean dose, V50, V60 and V65 were recorded for the PCs and also 
specifically for the SPC and MPCs.
No specific NTCP parameters for acute mucositis of the oral/pharyngeal region, 
or late dysphagia relating specifically to the tongue, were available. Therefore, a
literature search was performed to evaluate potential surrogate parameters. 
Parameters for grade 2-3 acute oesophagitis in the setting of radiotherapy for 
non-small cell lung cancer (NSCLC) were used as a surrogate for acute mucositis 
[17] w ith  updated data for acute oesophagitis from the QUANTEC reports taken 
into account [18]. For late toxicity, parameters for grade 3-4 (stricture or 
perforation) oesophageal toxicity were used [19, 20].
Table 3.4. Radiobiological parameters for normal tissue complication 
probability used in this study.
Parameter Toxicity
Acute mucositis Late dysphagia
m (slope) 0.32 0.06
TD50 51Gy 72Gy
n (volume effect) 0.44 0.06
alpha/beta lOGy 3Gy
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3.3. Results
3.3.1. Standard planning target volume dosimetry
Four individual plans were generated for each patient. The target dose objectives
for the PTVl and PTV2 were 65Gy in 30 fractions and 54Gy in 30 fractions, 
respectively. Median values satisfied the required plan objectives and are shown 
in table 3.5 below.
Table 3.5. Planning target volume (PTV) dose statistics for all ten patients 
(median (range) in Gy). Four individual plans were generated per patient, 
each with a different dose level (DL) prescribed to the GTVbM: D L l -  
65.00Gy, DL2 - 68.25Gy, DL3 -  71.50Gy and DL4 -  74.75Gy.
(i) Doses (Gy) received by PTVl:
Volume
objective
Dose
required
(%,Gy)
DLl DL2 DL3 DL4
99% 90%, 59.55 59.30 59.50 59.60
58.50Gy (58.9-61.1) (58.7-60.9) (58.2-60.8) (58.6-60.8)
95% 95%, 61.80 61.70 61.80 61.90
61.75Gy (61.3-62.8) (61.1-62.8) (60.9-62.8) (61.0-62.7)
50% 100%, 65.10 65.00 65.00 65.00
65.00Gy (65.0-65.3) (64.8-65.8) (64.7-65.4) (64.7-66.9)
5% <105%, 66.80 67.90 69.00 70.10
68.2 5Gy (66.4-68.4) (67.1-69.0) (67.7-70.4) (67.9-72.3)
2% <107%, 67.15 68.50 70.70 72.50
69.55Gy (66.7-69.1) (67.7-69.7) (68.9-71.4) (68.9-74.4)
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(ii) Doses (Gy) received by PTV2:
Volume
objective
Dose 
required 
(%, Gy)
DLl DL2 DL3 DL4
99% 90%, 49.80 50.30 50.30 50.30
48.60Gy (48.1-52.1) (49.3-52.2) (48.9-52.2) (48.9-52.0)
95% 95%, 51.80 52.30 52.20 52.30
51.30Gy (51.1-53.2) (51.2-53.4) (50.8-53.3) (50.7-53.1)
50% 100%, 54.80 55.00 54.90 54.90
54.00Gy (54.2-56.8) (54.2-55.9) (54.0-55.8) (53.9-56.3)
The GTVbM for one patient was very large (greater than 70cm^) and it  was not 
feasible to deliver the intended dose to the entire volume of the PTVl, resulting 
in some small areas of underdosage.
Dose volume histograms (DVHs) were reviewed. An example of a combination 
DVH summarising the DVHs of D L l to DL4 is shown below in figure 3.2.
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3 3 .1 .1 . Global m axim um  dose
ICRU 50 and 62 [2, 3] guidelines state that hotspots should be minimised. In all
IMRT plans, the global dose maximum was located w ith in  the GTVbM or the 
PTVl. In all cases, the global dose maximum represented less than 107% of the 
prescribed dose to the GTVbM, as shown in table 3.6 below:
Table 3.6. Global maximum dose statistics:
Dose statistic D L l DL2 DL3 DL4
Global max dose 106.6% 107.9% 113.1% 118.6%
(%  dose relative to dose 
prescribed at D L l (100% ))
(105.3-
106.6)
(107.1-
110.1)
(112.5-
115.0)
(118.3-
119.1)
Median Global max dose
(relative to dose prescribed 
at each dose level)
106.6% 102.8% 102.8% 103.1%
3 3.2. GTVbM dosimetry
The GTVbM was the only biological gross target volume (GTVb) which was
specified in the IMRT prescription for planning and dose escalation.
Doses received by the GTVbM at each dose level are shown in table 3.7:
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Table 3.7. Doses (Gy) received by GTVbM. A different dose level (D L l to 
DL4) was prescribed to the GTVbM in each plan.
Volume
constraint
Dose
required
D L l
65.00Gy
DL2
68.25Gy
DL3
71.50Gy
DL4
74.75Gy
99% 90% 65.10 68.10 71.20 73.80
(63.3-65.7) (66.4-70.1) (69.8-71.6) (72.0-74.9)
95% 95% 65.20 68.60 71.70 74.60
(64.5-66.0) (67.4-70.4) (70.7-71.9) (72.9-75.1)
50% 100% 66.30 69.30 72.60 75.70
(65.6-67.1) (68.9-71.2) (71.9-73.7) (75.4-77.0)
5% <105% 67.00 70.10 73.30 76.60
(66.4-68.8) (69.3-71.7) (72.6-74.8) (75.9-79.2)
2% <107% 67.40 70.30 73.40 76.70
(66.5-69.0) (69.3-71.8) (72.8-75.1) (76.0-79.5)
min 64.60 67.30 70.50 72.60
(54.7-65.2) (58.1-69.6) (61.1-71.0) (64.1-74.3)
max 67.80 70.40 73.60 77.10
(66.7-69.6) (69.5-72.4) (73.1-75.9) (76.4-80.1)
V100% 98.9% 98.9% 96.8% 93.2%
(85.3-100.0) (90.0-100.0) (78.4-99.5) (70.2-99.7)
I l l
3.3.2.1. Dosimetry for other biological volumes
As described in Section 3.2.4, only the GTVbM was specified in the IMRT
planning prescription. The other four GTVb volumes which had been contoured - 
the GTVs6%, GTVbsuv2.5, GTVbpLAB and GTVbsBR -  were not specified and, after 
contouring, were only reviewed again once an IMRT plan had been approved for 
each dose level, having satisfied target volume dose objectives and OAR dose 
constraints.
Dose statistics consisting of the D99, D95 and V100% for all five GTVb volumes 
are presented below in tables 3.8(i] to 3.8[iii). Dose statistics for the GTVbM are 
highlighted in pale grey.
Table 3.8(1) GTVb dose statistics for the 'D99' - the dose received by 99%  of 
the volume.
Median (range) D99 values (Gy)
Volume D L l DL2 DL3 DL4
65.00Gy 68.25Gy 71.50Gy 74.75Gy
GTVbM 65.10 68.1 70.8 72.7
(63.3-65.7) (66.4-69.2) (69.8-71.4) (72-73.8)
GTVbs6% 64.00 64.80 64.50 64.30
(63.8-65.6] (63.4-68.9) (62.7-73) (63.1-75.2)
GTVbsuvz 5 63.90 64.60 64.40 64.00
(63.3-65.5) (63.5-67.3) (62.8-71.7) (62.7-73.5)
GTVb f l a b 64.60 68.70 71.70 74.60
(64.3-65.5) (64.9-68.8) (65-72.7) (64.9-75.2)
GTVbsBR 64.10 64.60 64.00 63.80
(62.8-65.4) (63.1-69.0) (62.2-70.7) (62.9-73.9)
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Table 3.8(ii) GTVb dose statistics for the 'D95' - the dose received by 95%  
of the volume.
Median (range) D95 values (Gy)
Volume D L l DL2 DL3 DL4
65.00Gy 68.25Gy 71.50Gy 74.75Gy
GTVbM 65.30 68.60 71.40 74.00
(64.5-66) (67.4-69.4) (70.7-71.7) (72.9-74.5)
GTVbs6% 64.80 66.90 69.90 72.40
(64.4-65.7] (63.9-69.3) (63.2-73.1) (63.5-75.4)
GTVbsuvz.s 64.70 66.30 68.40 70.20
(64.3-65.7) (64.1-68.9) (63.3-72.6) (63.4-74.7)
GTVb FLA B 65.50 68.90 72.10 75.00
(64.7-65.7) (66.8-69.2) (67.2-72.9) (67-75.6)
GTVbsBR 64.70 65.50 65.70 65.70
(63.6-65.7) (63.9-69.8) (63.6-71.6) (63.6-74.7)
Table 3.8(iii) GTVb dose statistics for the 'VlOO' - the proportion of the 
volume receiving 100%  of the prescribed dose to the GTVbM.
Median (range) VlOO values in %
Volume D L l DL2 DL3 DL4
65.00Gy 68.25Gy 71.50Gy 74.75Gy
GTVbM 99.5% 99.2% 93.9% 81.8%
(85.3-100) (92.4-100) (78.4-98.5) (70.2-91.1)
GTVb36% 92.5% 98.6% 79.9% 80.8%
(85.6-100) (58.9-100) (39.3-100) (34.7-100)
GTVbsuvz 5 89.6% 96.8% 70.9% 72.2%
(83.4-100) (46.5-98) (24.9-99.2) (20.6-94.7)
GTVbpLAB 98.8% 100.0% 99.3% 98.4%
(88.4-100) (69.4-100) (44.8-100) (38.1-99.7)
GTVbsBR 91.3% 74.8% 68.6% 65.6%
(78.4-100.0) (26.2-99.8) (11.2-96.4) (9.1-94.5)
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3.3.3. OAR dosimetry
Maximum dose constraints for spinal cord and brain stem were achieved in all
IMRT plans. W ith respect to non-critical OARs, the median doses to contralateral 
parotid glands and the mandible satisfied standard dose constraints (mean dose 
24Gy and maximum dose 70Gy, respectively). Results are shown in table 3.9(i).
Table 3.9(1) Doses received by organs at risk (Gy).
Structure D L l DL2 DL3 DL4
65.00Gy 68.25Gy 71.50Gy 74.75Gy
Spinal cord 44.2 44.4 44.3 44.2
maximum dose
(43.2-44.9) (43.2-44.8) (43.6-44.5) (42.8-44.7)
Spinal cord+3mm 44.7 45.3 45.0 44.9
(lcm 3)
(43.3-45.2) (43.3-46.1) (43.3-46.1) (43.0-46.3)
Spinal cord+5mm 47.7 48.6 48.0 48.0
(lcm 3)
(46.7-48.9) (45.9-49.6) (45.8-49.2) (46.1-49.5)
Brain stem 47.5 47.7 47.9 47.3
maximum dose
(43.3-49.8) (43.7-49.6) (43.1-49.1) (43.0-48.8)
Brain stem+3mm 47.6 47.6 48.0 47.5
(lcm 3)
(41.6-52.2) (41.6-52.3) (41.6-49.8) (41.1-50.3)
Brain stem+5mm 51.5 51.4 51.4 51.8
(lcm 3)
(45.6-56.5) (45.4-56.8) (45.3-53.5) (45.7-54.2)
Contralateral 23.6 23.1 24.5 23.9
parotid mean
dose* (21.1-27.3) (20.9-28.1) (21.7-27.0) (21.8-26.8)
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Mandible 67.7 68.9 69.7 69.4
maximum dose
(66.9-70.1) (66.9-71.6) (67.3-75.0) (67.7-79.6)
*The CTVl in four patients included bilateral level II neck nodal levels and 
therefore parotid sparing was not feasible. These patients have not been 
included in the statistics reported for contralateral mean parotid dose.
Regarding organs involved in swallovinng, the pharyngeal constrictor muscles
(PCs) were not specified in the IMRT optimisation process and all IMRT plans 
exceeded the PC V50, V60 and V65 of 80%, 70% and 50%, respectively. Dose 
statistics for these structures are shown in table 3.9(ii):
Table 3.9(ii) Doses received by organs involved in swallowing.
Structure D L l
65.00Gy
DL2
68.25Gy
DL3
71.50Gy
DL4
74.75Gy
PCs V50 89.1% 89.4% 89.1% 89.7%
(69.2-100) (71.4-100) (70.8-100) (67.8-100)
PCs V60 73.8% 73.8% 74.0% 74.1%
(57.3-99.7) (56.1-99.8) (59.3-99.6) (55.2-99.5)
PCs V65 50.9% 57.6% 55.9% 55.8%
(33.8-67.4) (41.3-64.7) (47.1-65.4) (48.7-61.8)
PCs mean dose 61.7 61.8 62.2 62.7
(49.3-65.0) (49.7-65.0) (50.2-65.3) (49.9-65.4)
SPC+MPC mean 65.7 66.1 66.4 66.4
dose
(65.2-65.9) (65.4-66.4) (65.7-67.1) (65.8-67.8)
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IPC mean dose 50.8 50.7 50.5 51.2
(29.8-64.4) (30.2-64.1) (30.2-64.0) (28.9-64.1)
BoT mean dose 66.1 66.8 67.3 67.9
(65.6-66.8) (66.6-68.1) (67.0-69.9) (67.3-72.4)
W T mean dose 61.7 62.5 61.9 62.3
(60.6-66.1) (61.9-67.5) (61.7-68.8) (62.0-70.9)
UV mean dose 12.3 12.5 12.8 13.2
(3.7-22.1) (11.5-14.4) (11.2-14.5) (11.3-21.7)
Pharyngeal constrictors (PCs), superior pharyngeal constrictor (SPC), middle 
pharyngeal constrictor (MPC), in ferio r pharyngeal constrictor (IPC), base of 
tongue (BoT), whole tongue (WT), untreated volume (UV).
3,3.4. Radiobiological evaluation
Biosuite 8 was used to estimate tumour control probability (TCP) and normal
tissue complication probability (NTCP) values for the GTVbs and selected OARs.
3 3.4.1. Tumour control probability (TCP)
TCP values for the five biological volumes are shown in table 3.10 and figure 3.3.
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Table 3.10. Estim ated TCP values fo r each GTVb.
Median (range) TCP values (% )
Volume D L l DL2 DL3 DL4
65.00Gy 68.25Gy 71.50Gy 74.75Gy
GTVbM 61.7 66.8 69.7 73.0
[51.9-69.6} [57.7-73.2} [62.5-75.9} [67.0-78.4}
GTVbs6% 62.6 66.2 67.8 69.5
[51.3-72.2} [56.9-75.8} [60.9-78.9} [63.6-81.0}
GTVbsuvz.s 57.1 61.8 64.0 65.3
[45.8-67.2} [47.6-70.8} [48.2-73.8} [48.9-75.4}
GTVbpLAB 63.3 66.6 69.5 72.5
[53.1-71.5} [58.3-75.3} [62.5-78.5} [66.4-80.6}
GTVbsBR 58.5 63.0 64.2 66.0
[49.8-65.0} [54.3-68.4} [57.0-70.2} [58.7-71.4}
The results show that TCP increased w ith  increasing dose for each GTVb volume. 
This increase in TCP was statistically significant [Student's two-tailed t-test p 
values all less than 0.005%} and varied according to the segmentation method 
used to generate the GTVb.
Figure 3.3. Variation in estimated TCP for the GTVbM, according to dose 
level.
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The effect of differing FDG-PET segmentation method on the estimated TCP is 
shown in figure 3.4. In general, the lowest TCPs tended to be associated w ith  the 
GTVbsuvz.s and GTVbsBR volumes.
Figure 3.4. Variation in estimated TCP for each biological GTVb volume, at 
four dose levels.
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0GTVbSUV2.5 
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^GTVbSBR
Student's paired t-test was then applied to compare the differences in estimated 
TCP between segmentation modality, as shown in table 3.11. It can be seen that 
only the GTVb36% and GTYbpLAB volumes were associated w ith  estimated TCPs 
where the differences compared w ith  those for the GTVbM were not statistically 
significant. This was the case at all four dose levels except for the GTVb FLAB at 
DLl.
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Table 3.11. Mean estimated TCP for each volume and significance of 
difference compared with TCP for the reference GTVbM volume using 
Student's paired t-test. P values of greater than 0.05 are highlighted in bold 
text.
DLl DL2 DL3 DL4
GTVbM 60.9% 65.5% 69.3% 72.6%
GTVbs 6% 
GTVbsuV2.5 
GTVbsBR 
GTVbpLAB
61.7%, p=0.52
57.6%, p=0.05 
58.2%, p=0.04 
63.1%, p=0.05
65.7%, p=0.92  
60.9%, p=0.03 
61.7%, p=0.02 
67.3%, p=0.15
68.3%, p=0.56  
62.9%, p=0.02 
63.9%, p=0.01 
70.3%, p=0.45
70.6%, p=0.30  
64.4%, p=0.01 
65.4%, p=0.00 
72.9%, p=0.86
3.3.4.Z. Normal tissue complication probability (NTCP)
Estimated NTCP values for early [acute mucositis) and late toxicities [late
dysphagia] for the base of tongue and whole tongue are presented in table 3.12. 
NTCP increased w ith  increasing dose prescribed to the GTVbM. Student's 2- 
tailed t-test was used to compare the effect of increasing dose level on estimated 
TCP compared w ith  the reference of D L l and show that all increases in NTCP 
were statistically significant.
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Table 3.12. Estimated NTCP values for acute mucositis and late dysphagia 
for the base of tongue and whole tongue.
Median (range) NTCP values for acute mucositis
D L l DL2 DL3 DL4
Base of tongue
83.4%
(83.0-85.2)
86.5%
(83.2-90.1)
87.0%
(83.9-93.8)
89.3%
(84.4-96.0)
Comparison with  
D Ll
NA p=0.001 p=0.002 p=0.001
Whole tongue
77.4%
(70.4-84.0)
79.7%
(71.5-89.0)
78.9%
(73.3-92.2)
80.4%
(72.6-94.6)
Comparison with  
D Ll
NA p=0.017 p=0.014 p=0.007
Median (range) NTCP values for late dysphagia
D L l DL2 DL3 DL4
Base of tongue
20.6%
(19.4-34.2)
44.1%
(23.4-75.4)
61.0%
(31.7-97.4)
90.0%
(41.3-99.8)
Comparison with  
D Ll
NA p=0.001 p=0.000 p=0.000
Whole tongue
16.0%
(10.9-24.8)
34.0%
(12.2-70.4)
36.1%
(17.2-95.5)
63.0%
(21.2-99.7)
Comparison with
D Ll NA p=0.008 p=0.003 p=0.000
3.4. Discussion
This study tested the hypothesis that incorporation of functional characteristics 
of a tumour based on FDG-PET imaging into radiotherapy planning (RTP) was 
feasible. The aim was to deliver an increased dose to the GTVb and to model 
whether this strategy might lead to therapeutic benefit to the patient in terms of 
increased tumour control whilst maintaining isotoxicity to critical OARs and 
evaluating compromises in dose to non-critical OARs.
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This w ork demonstrates that it  is technically feasible to plan dose escalated SIB- 
IMRT to FDG-avid subvolumes. Critical OAR dose constraints for spinal cord and 
brain stem were not exceeded in any of the IMRT plans. In addition, where 
parotid-sparing IMRT was indicated, mean parotid doses were 24.5Gy or lower 
at all dose levels.
PTVl dosimetry was reported w ith  respect to the 'PTVl-shell' -  that is to say, 
doses were reported for the entire PTV from which the GTVbM subvolume had 
been subtracted for planning and reporting purposes. IMRT planning techniques 
achieved steep dose gradients in the area immediately surrounding the GTVbM 
w ith in  the PTVl volume. W ith respect to satisfying ICRU 50, 62 and 83 
recommendations, standard objectives for PTVl and PTV2 were met at dose 
levels (DL) 1 and 2 (100% and 105%, respectively). For plans at DL3 (110%) and 
DL4 (115%), however, there was greater dose gradient spill from the GTVbM 
into the surrounding PTVl and the standard maximum dose constraint of 107% 
of the prescribed dose was exceeded. This suggests that standard dose 
constraints for the PTVl do not apply when dose-escalating a subvolume to a 
dose greater than that prescribed to the PTVl. In clinical practice, a sim ilar 
situation happens w ith  the PTV2, which commonly abuts or may indeed 
surround, part of the PTVl. Review of the dosimetry in all three dimensions 
(axial, coronal and sagittal) and application of clinical judgement as to the likely 
relevance of the high dose regions, should be performed.
As shown in table 3.5, the median dose to the D5% which would as standard be 
lim ited at 105% of the PTVl dose was 69Gy, equivalent to 106% relative to the 
dose prescribed to the PTVl, and 70.1 Gy, equivalent to 108%, at DL3 and DL4, 
respectively. Similarly, for the D2%, which serves as a measure of maximum 
dose and is normally lim ited at a maximum of 107%, the median dose at DL3 was 
70.7Gy (109%) and 72.5Gy (112%) at DL4.
In this study, the global point dose maximum was located w ith in  the GTVbM or 
PTVl in all plans. The value of the global point dose should not exceed 107% and 
i f  possible, should be lower. As shown in table 3.6, the median global dose 
maximum was exceeded at DL2 to DL4. However, when these doses were
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reported relative to the dose prescribed to the dose-escalated GTVbM, all values 
translated to between 102.8 and 103.1%. These results are reassuring and 
suggest that a smaller dose maximum objective might be more appropriate for 
the dose-escalated subvolume -  for example, a global point dose maximum of 
105% for the GTVbM, rather than 107%, as for the PTVl. This may help to 
further sharpen the dose gradient between GTVbM and PTVl and may reduce 
the area w ith in  the PTVl receiving doses greater than 107%.
Table 3.9 showed that the median values for mean dose to the untreated volume 
(UV) ranged from 12.3Gy at D L l to 13.2Gy at DL4. Statistical [Student’s t-test] 
testing was performed and statistical significance was not reached (p > 0.05), at 
all dose levels. These results suggest that dose escalation of up to 115% of the 
PTVl dose can be delivered to a smaller subvolume w ith in  the PTVl w ithout 
adverse effect on integral dose which in turn is associated with late secondary 
malignancy [21].
Early and late mucosal and pharyngeal toxicities are im portant in the radical 
treatment of HNSCC as they are frequently severe, may adversely affect the 
patient's ability to complete a treatment course w ith in  the planned time frame 
and may lead to serious detriment to nutritional status, amongst other common 
problems. Published clinical studies suggest rates of acute grade 3 mucositis of 
between approximately 40 to 80% [22-27] associated treatment w ith  SIB-IMRT. 
Our pre-clinical data appears consistent w ith  these figures (see table 3.11) and 
would be expected to increase w ith  increasing dose to the GTVbM. One argument 
is that whilst unpleasant and of potential risk to the patient, acute mucositis is 
temporary and can be managed w ith  appropriate analgesia, tube feeding and 
specialist support from a multidisciplinary team including dietitians and 
swallowing therapists. There is also evidence to suggest that the severity o f acute 
mucositis does not correlate w ith  late toxicity [28].
Late toxicity is arguably a more serious issue, particularly since organ 
preservation is a key aim of radical non-surgical treatment strategies. Available 
clinical data at total prescription doses approximating 70Gy in 35 fractions 
suggests late grade 3 mucositis rates of between approximately 0 and 33% [25-
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27, 29]. Again, our data at D L l (biologically equivalent approximately to 70Gy in 
35 fractions) appears consistent w ith  these figures. The ability of IMRT 
techniques to facilitate highly conformai dose distributions has led various 
groups to explore whether IMRT can be used to reduce late pharyngeal toxicity 
w ithout compromising doses to target volumes [8, 15, 16, 30, 31]. Clinical 
evaluation, however, w ill not be straightforward. A key obstacle is the difficulty 
in obtaining robust and objective data to compare dysphagia rates. 
Videofluoroscopy and nasendoscopy are more robust but resource-intensive and 
frequent examinations may not be popular w ith  patients. Various metrics have 
been developed, including RTOG assessments which are evaluated by the 
clinician and the MD Anderson dysphagia inventory (MDADl) and EORTC quality 
of life questionnaires (QLQ) C30 and H&N35 which are self-assessed by patients 
but their subjective nature makes comparison more challenging. Another 
im portant issue is that the process of swallowing is highly complex and involves 
a series of organs and anatomical subsites, commencing in the oral cavity and 
proceeding to the thoracic inlet.
Levendag et al [16] reported a significant correlation between mean dose to the 
superior and middle pharyngeal constrictor (PC) muscles and severe (grade 3 
and 4) late dysphagia in the setting of oropharyngeal squamous cell carcinoma 
(SCC). It was reported that the probability of severe dysphagia increased by 19% 
w ith  every additional lOGy in dose after 55Gy. Reviewing our data for whole 
tongue late toxicity (table 3.11), the estimated NTCP rates are comparable, for 
example, at DL3, taking into account the hypofractionation and acceleration of 
treatment, which translate approximately to an increase of 10Gy. It can be seen 
that the estimated NTCP for late dysphagia for the whole tongue organ would 
rise to 36.1% at DL3 compared with 16% at DLl. As this study was intended to 
form  the basis for a phase 1 clinical study, it  would be im portant to consider the 
estimated increase in late dysphagia when balancing w ith  potential gains in TCP.
Ultimately, the question is whether swallowing structures, in particular, the 
pharyngeal constrictor muscles should have specification of dose constraints. 
This question has been debated by various groups [8, 31, 32]. Feng et al [15] 
reported a prospective study of 36 patients undergoing chemo-lMRT for
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oropharyngeal or nasopharyngeal cancer. They noted that grade 3 dysphagia 
(aspiration) occurred w ith  mean PC doses exceeding 60Gy, PC V65 of greater 
than 50% and grade 4 toxicity (stricture) for PC V70 of greater than 50%. In our 
department, the standard contouring protocol for oropharyngeal tumours 
includes the entire length of oropharyngeal mucosa w ith in  the CTVl, cranially 
from the left of hard and soft palate and caudally to the inferior aspect of the 
hyoid bone. Sparing of these structures for this tum our subsite therefore would 
probably not be feasible w ithout compromised dose coverage of the PTVl; this 
in turn might lead to geographical miss of microscopic disease.
Radiobiological modelling showed that estimated TCP increased with increase of
dose escalation to the GTVbM, ranging from 61.7% at DLl, to 73.0% at DL4. 
These changes are summarised in table 3.13;
Table 3.13. Absolute changes in TCP associated w ith the GTVbM and NTCP 
for all four dose levels.
D L l DL2 DL3 DL4
TCP(GTVbM)
Absolute change in TCP 
relative to D L l
61.7%
NA
66.8%
+5.1%
69.7%
+8%
73.0%
+11.3%
NTCP late dysphagia (BoT)
Absolute change in TCP 
relative to D L l
20.6%
NA
44.1%
+23.5%
61.0%
+40.4%
90.0%
+69.4%
NTCP late dysphagia (W T) 
Absolute change in TCP
relative to D L l
16.0%
NA
34.0%
+18%
36.1%
+20.1%
63.0%
+47%
Base of tongue, BoT; whole tongue, WT.
Comparisons of estimated TCP values must be considered alongside of 
compromises in terms of the effects of dose escalation on NTCP values. Both the 
base of tongue and the whole tongue were contoured in order to model potential 
changes in NTCP. There were very large increases in estimated NTCP for the
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base of tongue. In this study, all anonymised datasets originated from patients 
w ith  oropharyngeal tumours, w ith  half of the patients having prim ary tumours 
FDG uptake located in the base of tongue, w ith  the remaining half located in the 
tonsillar region. The base of tongue was defined as the posterior one th ird  of the 
whole tongue structure. The base of tongue was therefore a relatively small 
structure and therefore dose escalation to a primary located either in the base of 
tongue itself, or nearby, in the tonsillar region, would be expected to result in a 
large increase in dose to a large proportion of the organ. It can also be argued 
that a tumour in the base of tongue may invade, surround or efface this organ 
and a lack of adequate treatment might result in a serious loss of function, not to 
mention a potential failure of treatment, in a site which is not usually amenable 
to surgical salvage. With these considerations, it seems reasonable to select 
NTCP of late dysphagia to be based on modelled dosimetry for the whole tongue 
organ. It can be seen that at DL3, for an absolute increase in TCP of 8%, that 
NTCP of late dysphagia would be estimated to increase by 20.1%, compared with 
an absolute increase in TCP of 11.3% in exchange for increased NTCP of 47% at 
DL4. In conclusion, it  would seem that selecting DL3 might be a reasonable 
compromise between potential gain in TCP versus detriment in estimated NTCP.
The selection of DL3 as a reasonable regimen for dose escalation to the GTVbM 
seems feasible when compared w ith  reported clinical phase 1 studies. Lauve et al 
reported a phase 1 study involving twenty patients w ith  locally advanced HNSCC 
[25]. SIB-IMRT was used to escalate dose to the entire gross target volume 
(GTV), which comprised both prim ary and nodal involved sites. The purpose of 
the study was to determine the maximum tolerated dose [MTD] to GTV that 
elicited dose lim iting toxicity (DLT). DLT was defined as any grade 4 toxicity 
presenting w ith in  90 days of radiotherapy, in no more than 33.3% of the 
patients. The CTVl was formed from a concentric 1cm margin around the GTV 
and an expansion of the GTV by 0.3cm in all directions formed the PTVl. The 
median primary-only GTV volume was 28.4 cm^ and the median combined 
primary-plus-nodes GTV was 37.7cm^. Three dose levels to the GTV were used: 
DLl - 68.1Gy; DL2 - 70.8Gy and DL3 - 73.8Gy. At least 98% of the GTV was 
required to be covered by the nominal dose level. A t least 60Gy was delivered to
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95% of the CTVl and 54Gy was delivered to at least 90% of the CTV2. 
Concomitant chemotherapy was not used. Treatment was delivered in a total of 
th ir ty  daily fractions over a total period of 40 day. DL2, 70.8Gy in th ir ty  fractions 
of 2.36Gy -  associated with a normalised total dose (NTD) of 79.3Gy - was 
defined as the MTD deliverable to the GTV. Early toxicity and locoregional 
control rates were comparable w ith  other accelerated regimens. A t DL2, there 
were two cases of grade 4 late mucositis and one case of grade 3 late dysphagia, 
out of a total of twelve patients at this dose level. W hilst concomitant 
chemotherapy was not used, i t  should be noted that the median GTV was at 
37.7cm3 much larger than the GTVbM volume (median 10.8cm^) selected for 
dose-painting in our study. This suggests that toxicity might potentially be less, 
due to a smaller target being nominated for dose escalation. Overall, this data is 
reassuring for our selection of 71.5Gy in thirty fractions as a selected dose level 
for investigation in a future planned phase 1 study.
Clinical data for dose-escalated chemotherapy-1 MRT was reported earlier this 
year by a UK group who presented results from a phase 1/11 tria l involving 60 
patients [33]. Miah et al investigated the feasibility and potential improvements 
in locoregional control and organ preservation associated w ith  induction 
chemotherapy followed by dose-escalated IMRT delivered w ith  concomitant 
cisplatin chemotherapy in the setting of laryngo-hypopharyngeal cancers. Two 
dose levels (DL) were planned: D Ll (29 patients), 63Gy in 28 fractions to PTVl 
and 51.8Gy in 28 fractions to PTV2; DL2 (31 patients), 67.2Gy in 28 fractions to 
PTVl and 56Gy in 28 fractions to PTV2. The dose delivered at D L l was 
equivalent to 70Gy in 2Gy fractions and the 2Gy equivalent dose at DL2 was 
76Gy. Acute toxicity was common, w ith  acute grade 3 dysphagia reported as 
59% at D L l and 87% at DL2, w ith  acute grade 3 mucositis of 45% at both DL 
which persisted for longer in DL2. There were no dose lim iting toxicities (DLT) 
and no treatment breaks required. The rate of late toxicity was recorded at one 
year following completion of treatment and was low: grade 2 was the worst 
toxicity for mucositis, at a rate of 43% at D L l and 30% for DL2. W ith respect to 
late dysphagia, one patient (5%) at D L l and one patient (4%) at DL2 reported 
grade 3 symptoms and one patient in DL4 developed grade 4 late dysphagia. A t 2
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years of followup, the local control rate was 70.8% at D L l and 85.9% at DL2. 
Overall survival was similar at between 72.4 and 74.2%. The group concluded 
that dose escalation was feasible and has the potential to improve locoregional 
control rates without increasing long-term toxicities.
To date, only one group has published clinical data for dose escalation to the 
FDG-avid tumour subvolume in HNSCC [34]. Madani et al performed a phase 1 
clinical study designed to assess the feasibility o f PET-guided dose escalation and 
to determine the MTD in HNC. Two dose levels were used: D L l at a total dose of 
72.5Gy or DL2 at 77.5Gy delivered in 32 fractions to the FDGPET-positive 
subvolume, termed the GTVpET. The GTVpET was generated by automatic 
segmentation of the FDGPET images using the source-to-background ratio (SBR) 
technique. A 0.3cm concentric margin was applied to form the PTV fet, which had 
an average volume of 41.61cm^ at D L l and 53.68cm^ at DL2. For DL2, the PTV pet 
was modified to lim it the volume receiving 77.5Gy to a lOcm^ subvolume, with 
any remaining PTVpET receiving 72.5Gy. The high dose PTV received doses 
between 62 and 69Gy and the prophylactic dose PTV received a dose of 56Gy, all 
delivered in 32 fractions. Two separate IMRT plans, constituting phase 1 and 
phase 11, were planned for each patient. A total of 23 patients were treated at 
DLl, w ith  18 at DL2. Most patients had tumours w ith  stage T3N2. Concomitant 
cisplatin chemotherapy [lOOm g/m^/q2Idays) was delivered to nine patients in 
D L l and fourteen patients in DL2. Two cases of DLT (grade 4 dermatitis and 
grade 4 dysphagia) occurred at DLl, w ith  one treatment-related death (sepsis 
and renal failure) at DL2. The MTD was not reached, as the study was terminated 
at the point of treatment-related death. One-year local control was 85% and 87% 
at D L l and DL2, respectively. There were nine locoregional recurrences, of 
whom the site of relapse in four patients was located w ith in  the original GTVpet. 
This data supports the ability  of FDGPET in identifying relapse-prone regions 
and more im portantly provides additional valuable reassurance regarding the 
anticipated to lerab ility  of dose escalation using cisplatin-lMRT to the FDG-avid 
subvolume, at biologically equivalent doses greater than our selection of 71.5Gy 
in th irty  fractions delivered w ith  concomitant cisplatin. Furthermore, our single
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plan approach compares favourably in being less resource-intensive and 
potentially less prone to error.
More recently, the same group from Belgium reported firs t clinical experience in 
adaptive dose painting by numbers (DPBN) for HNC [35]. This phase 1 study 
involved a complicated three phase IMRT plan approach to delivering one out of 
two possible dose levels: D L l -  80.9Gy delivered to the high dose GTV or DL2 -  
85.9Gy delivered to the GTV, w ith  adaptive re-planning being performed using a 
second FDG-PET/CT scan after the eighth fraction. Seven patients were 
randomised to DLl and fourteen patients to DL2. No grade 4 toxicity was 
observed. All but one patient in D L l developed any type of grade 3 acute toxicity, 
with six of fourteen patients in DL2 developing grade 3 toxicity. The adaptive 
planning strategy resulted in shrinkage of the GTV by 41% and shrinkage of the 
high dose GTV by 18%. As a result, further dose escalation at DL2 resulted in less 
severe toxicity than that observed at DLl. This novel study provides further 
reassurance regarding the feasibility -  for acute toxicity - of dose escalation at 
doses far greater than the dose level selected for our own phase 1 study [71.5Gy 
in 30 fractions). The aspects of adaptive planning strategy, incorporation of 
FDGPET into adaptive planning, and dose-painting-by-numbers approach 
combine to make this novel study technically and practically challenging. Late 
toxicity and treatment efficacy data is awaited.
In our study, a planning margin was not applied to the GTVbM dose escalated 
volume. The rationale for this decision was that an increase in size would be 
likely to adversely affect target coverage of both GTVbM and PTVl, in terms of 
potential underdosage and overdosage, respectively and might also lead to 
increased toxicity. Two strategies were adopted to take this practice into 
consideration. First of all, for the clinical phase 1 study, daily online matching 
using cone beam computed tomography (CBCT) image guidance was planned, 
w ith  an action level of 1mm being applied. A clinical study to evaluate the 
potential benefits of using CBCT in the delivery of radical radiotherapy to HNSCC 
was performed by our group and is discussed in Chapter 4. Secondly, the dose 
objective for the GTVbM was stipulated such that the entire volume should 
ideally receive the fu ll prescribed dose. Table 3.7 showed that the median
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V100% ranged between 96.8 and 98.9% for D L l to DL3, but dropped to 93.2% at 
DL4. This was mostly due to skewing o f the data as one patient had a large 
GTVbM volume, resulting in technical challenges in planning adequate dose 
coverage to this volume.
The question of whether a lim it should be placed on the volume to be dose- 
painted is interesting. As discussed earlier, Madani and Duprez et al reported 
clinical experience of dose-painting to target volumes identified by FDG-PET. In 
both studies, the size of the boost volume was lim ited -  either by applying the 
highest dose level to a lOcm^ region and then dose escalating the remainder of 
the FDG-avid volume (average size of 53.68cm^) to a lower, but s till escalated, 
dose [34], or by applying DPBN at one level of dose escalation to the entire CTVl, 
and restricting the DPBN at the higher dose level by applying this only to the GTV 
[35]. Miah et al prescribed dose escalation equivalent to 76Gy in 2Gy fractions 
w ith  concomitant cisplatin chemotherapy to the entire PTVl (prim ary site and 
involved nodal levels) with acceptable toxicity as detailed above. W hilst data 
regarding the size of the PTVl was not specified, it  is reasonable to assume that 
the PTVl in the ir study was far larger than the median size of 10.78cm3 (range:
1.95-81.18cm3) size of the GTVbM in our study. All three studies were of phase 
1/11 design, w ith  small patient numbers but appear reassuring. Future work 
planned by our group includes an evaluation of the effect of increasing the boost 
volume size on estimated TCP and NTCP and may guide appropriate setting of 
planning lim its to the size of the GTVb.
Radiobiological modelling also provides additional perspective to the issue of so- 
called optimal segmentation method of the GTVb, for which an international 
consensus is lacking. Radiobiological modelling can help to evaluate whether the 
method of delineation affects the estimated TCP. Estimated TCP values were 
generated for each of the segmented GTVb volumes, at each dose level. As might 
be expected, our results (see table 3.10) show that TCP can be influenced by 
segmentation method. TCP estimates for the GTVb36% and GTVbpLAB were not 
significantly different to those for the reference GTVbM, at all dose levels (except 
for GTVbpLAB at DLl, p=0.05). This suggests that semi-automated FDG-PET 
segmentation using the 36% PMSl threshold technique might be a reasonable
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approach to consider in the design of a future phase I clinical study at this 
institution.
The work reported earlier in Chapter 2 showed that GTVb segmentation 
technique affects volumetric, spatial and morphometric conformity between
GTVb volumes. Median absolute volumes for the five GTVb volumes evaluated in 
Chapter 2 are summarised below in table 3.14.
Table 3.14. Median volume data for the segmented GTVb volumes and 
statistical comparison with the reference GTVbM (grey) volume.
Absolute volume 
Median (range) (cm^)
Significance level 
(Student’s t-test)
GTVbM 10.78 (1.95-81.18) NA
G T V b 3 6 % 8.73 (0.87-91.52) p = 0.602
G T V b s u v z s 27.52 (2.85-249.86) p = 0.098
GTVbpLAB 7.82 (1.03-63.00) p = 0.012
G T V b s B R 22.50 (6.07-124.69) p = 0.025
As shown, the magnitude of absolute volume for the GTVbsuvz.s and GTVbsBR
volumes appeared larger than for the GTVbM. Student's two-tailed t-test was 
applied to compare differences in absolute volume and show that the GTVb FLAB 
and GTVbsBR were significantly different (p < 0.05) and approached statistical 
significance for the GTVbsuvz.s.
In view that only the GTVbM was specified for dose escalation during the 
planning process, it  is logical that estimated TCP would be lower for volumes 
larger than the GTVbM, such as the GTVbsuvz.s and GTVbsBR, since dose coverage 
by the escalated dose level would be reduced.
3.5. Conclusion
FDG-PET guided dose-painting w ith  IMRT to oropharyngeal squamous cell 
carcinomas is feasible and has the potential to improve tumour control w ith  
acceptable acute and late toxicity. A dose level of 71.5Gy in 30 fractions delivered
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over a six week period is a reasonable choice for further evaluation in the setting 
of a future clinical phase 1 study.
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Chapter 4: Image-guided intensity modulated radiotherapy (IG-IMRT) 
using cone beam computed tomography (CBCT) in patients with head 
and neck cancer (HNC) -  a clinical study
A prospective p ilo t study was designed to evaluate the potential of image guided 
intensity modulated radiotherapy (IG-IMRT] using cone beam computed 
tomography (CBCT) to improve local tumour control and reduce side effects in 
patients w ith  head and neck cancer (HNC). The hypothesis was that CBCT could 
be used to improve the accuracy of radiation delivery, thereby ensuring the 
lower doses to neighbouring normal tissues achieved w ith  intensity modulated 
radiotherapy (IMRT) planning techniques would be delivered reliably during 
treatment. The results would provide quantification of the patient benefits and 
serve as the basis for the translation of these new technologies into clinical 
practice through the design of optimal verification protocols for patients w ith  
HNC having radical radiotherapy at this department.
4.1. Objectives of study
To perform a clinical study to test the hypothesis that CBCT can be used to 
improve the accuracy of IMRT delivery and lead to improved local tumour 
control w ith  reduced side effects in patients w ith  HNC.
4.2. Methodology
4.2.1. Patients
This study received Research Ethics Committee approval. Patient recruitment 
was carried out during the period of June 2009 to July 2010, at St Luke's Cancer 
Centre, Royal Surrey County Hospital, Guildford, UK. Eligible patients were 
prospectively identified through the weekly Head and Neck Multidisciplinary 
Meeting (MDM). After informed consent, twenty patients w ith  histologically 
confirmed squamous cell carcinoma of the head and neck (HNSCC) who were to 
be treated w ith  IMRT were entered into the study. IMRT was delivered w ith  a 
Varian linear accelerator w ith  integrated On-Board Imager (OBI) (Varian Medical 
Systems, Palo Alto, CA).
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4.2.2. Radiotherapy procedure
4.2.2.1. Immobilisation
All patients were immobilised in neutral neck position using a five 
fixation point, custom made thermoplastic shell which fitted over the 
head and upper shoulders. The neck was supported on a rest mounted on 
a carbon fibre board. No mouth bite was used.
4.2.2.2. Planning
A planning computed tomography (CT] scan was performed to image the 
head and neck region in 1.5mm contiguous slices whilst the patient was 
immobilised in the treatment position. CT contrast was used in all cases. 
The image datasets were reconstructed into 3mm contiguous slices then 
transferred to a Prosoma® contouring workstation, where target volume 
(TV) and organs at risk (OAR) volume delineation were performed by the 
clinical oncologist as per institutional protocol. On completion of TV and 
OAR delineation, the datasets were imported into the treatment planning 
system (TPS) (Eclipse version 8.0, Varian Medical Systems, Palo Alto).
4.2.2.3. Target volume delineation
4.2.2.3.1. Gross target volume (GTV)
The GTV was defined to encompass all macroscopic disease at the 
prim ary site (GTV-T) and involved nodes (GTV-N), as demonstrated on 
clinical examination, flexible nasendoscopy, examination under 
anaesthetic and computed tomography (CT), magnetic resonance imaging 
(MRl), w ith  additional imaging by fluoro-deoxyglucose positron emission 
tomography (FDG-PET), when indicated.
4.2.2.3.2. High dose clinical target volume (CTVl)
This was defined as the clinical target volume to be treated to a radical 
dose. It included the prim ary tumour and involved nodes (GTV-T and 
GTV-N) and high risk areas. In general, the GTV-T was grown with a 10- 
15mm margin and lim ited w ith in  visible anatomical barriers to guide 
appropriate delineation of the CTVl. Similarly, a margin of 10mm was
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added to the GTV-N to account for the risk of extracapsular spread. The 
standard CTVl in oropharyngeal tumours encompassed the entire 
oropharynx. The 'adjacent but not directly involved' regions were 
included in the CTVl. Any neighbouring structures involved by tumour 
(for example, parotid gland, medial pterygoid muscle and parapharyngeal 
space] were also included. Where no obvious anatomical barriers existed 
(for example, the base of tongue], a geometric margin was used, as 
specified above. In the case of node-negative disease, the retropharyngeal 
nodes at the level of the oropharynx (ipsilateral in well lateralised T l/2  
tumours, bilateral in all others] and ipsilateral level 2a nodes were 
included in this volume. All involved nodal levels were included in CTVl. 
Finally, i f  level 2 nodes were involved, the ipsilateral jugular fossa and 
retrostyloid space extending cranially up to the base of skull were 
included.
4.2.2.3.3. Prophylactic dose clinical target volume (CTV2)
This was defined as the clinical target volume to be treated to a 
prophylactic, or elective dose. The CTV2 included un-involved levels Ib-V 
bilaterally and supraclavicular fossa (SCF] nodes bilaterally. Delineation 
of nodal volumes lb to V and retropharyngeal nodal regions was 
performed according to the Consensus guidelines [1, 2].
4.2.2.3.4. Planning target volumes (PTVl and PTV2)
A 3mm margin was applied in all directions to each of the CTVl and CTV2, 
to produce the PTVl and PTV2, respectively. This margin reflected the 
setup accuracy reported for the local centre. Both PTVl and PTV2 were 
edited to ensure that they did not come w ith in  5mm of the patient's skin. 
The PTV2 was edited such that the overlap w ith  PTVl was removed from 
the PTV2.
4.2.2.3.5. Organs at risk (OARs)
The following OARs were delineated in all patients: spinal cord, brain 
stem, left and right parotid glands, mandible and bilateral submandibular 
glands.
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3mm and 5mm margins were applied to both spinal cord and brain stem 
to create planning organ at risk volumes (PRVs].
Finally, pseudostructures, or planning avoidance volumes, were created 
in the m idline and posterior neck, to reduce deposition of dose in these 
regions.
4.Z.2.4. IMRT planning
IMRT planning was performed by the radiotherapy planning team at St Luke's
Cancer Centre, Royal Surrey County Hospital, using an Eclipse version 8.2 
[Varian Medical Systems, Palo Alto, CA] treatment planning system. A 5 to 7 
static split-beam arrangement was used, w ith  a simultaneous integrated boost 
(SIB] technique.
Once optimisation was completed, the leaf motion calculator was run w ith  
dynamic m ulti-leaf collimator (MLC] delivery. A pencil beam algorithm was used 
for dose calculation. The prescribed dose was normalised to the median volume 
(50%] of the PTVl.
This process was repeated iteratively until the optimal balance between 
achieving dose objectives for PTVl and PTV2 were met, w ith in  the dose 
constraints set for the OARs. ICRU 50 and 62 [3, 4] guidelines were followed, 
w ith  the aim to cover the PTV w ith  95% of the prescribed dose and to normalise 
the prescribed dose to 100% at the isocentre. No more than 5% of the PTVl or 
PTV2 was allowed to receive more than 105% of the prescribed dose, sim ilarly 
no more than 2% of the PTVl or PTV2 was allowed to receive more than 107% 
of the prescribed dose.
4.2.2.5. Dose prescription and fractionation
Two different dose levels were prescribed: the high dose PTVl was treated to a 
biologically equivalent dose of 70Gy in th irty-five  fractions using either a prescription 
of 65Gy in th ir ty  fractions in the case of the m ajority (nineteen] of patients, w ith  55Gy 
in twenty fractions prescribed to the high dose PTV for one patient. The elective dose 
PTV2 was treated to a biologically equivalent dose of 50Gy in twenty-five fractions 
using a prescription of 54Gy in th ir ty  fractions, using a simultaneous integrated boost
139
(SIB) technique.
W ith respect to OARs, only the spinal cord and brain stem were absolute requirements 
for plan approval although the plans were optimised as much as possible w ith  respect 
to the contralateral parotid gland, mandible and larynx. Dose constraints for target
volumes and OARs are summarised below in Table 4.1.
Table 4.1. Target volume dose objectives and dose constraints for organs at risk.
Target volumes Prescribed doses
PTVl 65Gy in 30 fractions or 55Gy 
in 20 fractions
PTV2 54Gy in 30 fractions
OAR volumes Dose constraint 
(in 2 Gy fractions)
Spinal cord Max < 45Gy
Spinal cord + 3mm Icc < 48Gy
Spinal cord + 5mm Icc < 50Gy
Brain stem Max < 50Gy
Brain stem + 3mm Icc < 55Gy
Brain stem + 5mm Icc < 55Gy
Left parotid Mean < 24Gy
Right parotid Mean < 24Gy
Mandible (excluding PTVl) Max < 70Gy
Larynx Mean <40Gy
4.2.3. Image guidance
All patients were treated on the same dedicated research linear accelerator 
(linac) fitted w ith  an On-Board Imager (OBI) system. The OBI system comprised 
a kilovoltage (kV) source and an opposing silicon flat-panel detector mounted 
perpendicularly to the treatment beam axis. The flat-panel detector enabled the 
generation of either orthogonal 2-dimensional (2D) electronic portal images
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(EPIs) or 3-dimensional (3D) cone beam computed tomography scans (CBCTs). 
In CBCT acquisition mode, the gantry rotated during continuous acquisition of 
kV projection images, from which a 3D CBCT was reconstructed. The following 
parameters were used for acquisition of the CBCT scan: kVp, lOOkV; nominal 
milliamperes per frame, 20mA; nominal milliseconds, 20mS and total rotation 
angle, 200°.
4.2.3.1. Electronic Portal Imaging
The standard verification protocol at this institution involved weekly offline 
review of megavoltage (MV) EPIs. The OBI system enables kV EPl and therefore
orthogonal kV EPIs were performed on a weekly basis to provide a reference 
comparator against CBCT. Positional displacement data recorded following 
verification using these image sets were termed kV EPl weekly.
4.2.3.2. Cone Beam Computed Tomography
A 'critical match region' was identified at the plan approval stage to provide 
guidance to the treating therapy radiographer team in the event of uncertainty 
as to which region to prioritise for optimal anatomical match quality. CBCT 
datasets were acquired on a daily basis and an online verification protocol was 
followed. CBCT images were obtained immediately following standard 
positioning practice by the therapy radiographers. The images were compared 
against the planning CT scan, w ith  matching performed to bony anatomy. A two 
stage approach was followed in obtaining a satisfactory anatomical match: 
initially, automatic matching software available on the treating linac was used, 
followed by manual adjustment of the match, taking into account the 'critical 
match region' but also reviewing the quality of match throughout the imaged 
volume. A region of interest was deliberately not selected to enable matching 
across the entire anatomical volume that had been imaged. A minimum action 
level of 1mm was used, for corrections in all three directions of vertical 
(anterior-posterior), longitudinal (superior-inferior) and lateral (right-left) 
directions. Floor rotation was assessed and corrected w ith  a minimum action 
level of 1 degree. Positional displacement data recorded following verification 
using these image sets were labelled as follows:
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• CBCTdaily, auto “  referring to review of automatic matching of daily CBCT 
images
•  CBCTdaiiy -  referring to review of manual matching of daily CBCT images
•  CBCTweekiy -  referring to review of manual matching of CBCT images
acquired immediately following the corresponding kV EPl image pair, 
during the same treatment session
• kV EPlweekiy -  referring to review of manual matching of weekly kV EPl 
linages
4.2.4. Clinical evaluation
4.2.4.1. Baseline assessment
The clinical presentations for all patients were discussed at a specialist head and 
neck cancer m ultidisciplinary meeting (MDM) at which clinical examination 
findings, diagnostic imaging and histologies were reviewed, before agreement 
regarding the TNM (tumour-node-metastasis) stage and appropriate treatment 
approach were reached. Once a patient had consented to study participation, the 
in itia l clinical evaluation comprised recording a medical history and performing 
a complete physical examination, including fu ll head and neck examination.
4.2.4.2. On-treatment assessment
Documentation of weight was performed on a weekly basis during treatment.
4 .2 .5 . Endpoints
The study was designed to record the following outcomes:
4 .2 .5 .1 . Prim ary outcom e
• To quantify the magnitude of treatment delivery errors using a daily 
on-line correction protocol w ith  CBCT in patients receiving IMRT to 
head and neck region.
4 .2 .5 .2 . Secondary outcom es
• To assess the suitability of the CTV to PTV margin size and to evaluate 
possible margin reductions.
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• To identify factors that impact on accuracy of delivery such as weight
loss and changes in shape/volume/size.
•  To assess rotational displacements.
• To quantify dosimetric changes and variations in TCP and NTCP w ith
this correction protocol and to model alternative protocols.
• To develop a local institutional verification protocol that combines
improvements in the therapeutic ratio w ith  the best use of resources.
• To characterise acute and late toxicity profile in this group of patients.
• To determine the feasibility of using daily CBCT for verification
purposes: patient tolerability, staff time, identify potential problems of 
use.
• To assess the impact on treatment times and Linac occupancy.
• To assess suitability of CBCT for re-planning purposes.
• To assess tim ing and rate of change in tumour volume and model
different adaptive radiotherapy [ART] strategies.
4.2 .6 . Statistical analysis
Daily acquisition o f CBCT images and weekly kV EPl images enabled an 
evaluation of different verification strategies.
Four imaging strategies comprising verification using CBCTdaiiy, auto, CBCTdaiiy, 
CBCTweekiy and kV EPlweekiy image datasets were compared to evaluate the
optimal modality and imaging frequency for this department. Measurements of 
correlation and agreement were calculated using Excel and Analyse-it software. 
The Pearson product-moment correlation coefficient, r, is a measure of the 
correlation, or the strength of a linear relationship between two variables. A high 
correlation between imaging strategies would be expected as kV EPl and CBCT 
have been developed for the same purpose of treatment verification. Strong 
correlation, however, does not necessarily imply good agreement between 
methods. A Bland-Altman plot assesses agreement between two methods by 
plotting the difference between the methods against the mean measurement 
recorded by both methods. Bias is the average difference between methods. A 
bias of zero indicates excellent agreement. The null hypothesis is that the bias is 
equal to zero and the p-value is the probability of rejecting the null hypothesis.
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Limits of agreement report the agreement between methods, w ith  large lim its of 
agreement indicating poor agreement between methods.
4.3. Results
4.3.1. Patients
Twenty patients with a median age of 59.5 years (range 39-72 years] w ith  
histologically confirmed squamous cell carcinoma [SCC] to be treated w ith  
radical IMRT were recruited for study participation and treated between June 
2009 and August 2010. Data was collected prospectively. Patient characteristics 
are as shown in table 4.2.
Table 4.2. Patient characteristics.
Patient
no.
Gender
Age
(years)
Primary
site
TNM Histology
Concomitant
platinum
chemotherapy
1 Male 69 Scalp T2N2b SCC No
2 Female 63 OPX T2N2b SCC Yes
3 Female 39 UKP T0N2b SCC No
4 Male 54 UKP T0N2b SCC Yes
5 Male 60 LNX T2N1 SCC Yes
6 Male 59 UKP T0N2b SCC Yes
7 Male 61 OPX T4bNl SCC Yes
8 Male 59 OPX T2N2b SCC Yes
9 Male 65 OPX T3N0 SCC Yes
10 Male 54 OPX T2N2C SCC Yes
11 Male 62 OPX TlN2b SCC Yes
12 Male 58 OPX T2N2b SCC Yes
13 Male 72 OPX T4aN2c SCC Yes
14 Male 52 OPX TlN2b SCC Yes
15 Male 62 OPX T4N1 SCC Yes
16 Male 52 HPX T4N2b SCC Yes
17 Male 70 OPX T4N2b SCC Yes
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18 Female 44 OPX T4N1 SCC Yes
19 Female 47 OPX T4N2b SCC Yes
20 Male 66 OPX T4aN2b SCC Yes
OPX, oropharynx; UKP, unknown primary; LNX, larynx; HPX, hypopharynx; SCC, 
squamous cell carcinoma
In total, 116 kV EPl and 514 CBCT images were obtained and analysed for setup 
error. The mean [standard deviation, s.d.) numbers of image sets per patient 
were 5.8 [1.0] for kV EPl and 27.0 [3.0] for CBCT.
4.3.2. Frequency of magnitude of displacement
Displacements in the vertical, longitudinal and lateral directions were recorded 
following verification comparing daily CBCT [CBCTdaiiy], weekly kV EPl [kV 
EPlweekiy] and Weekly CBCT [CBCTweekiy] [date matched to the weekly kV EPl 
acquisitions] w ith  simulation-derived reference image sets. The mean magnitude 
o f displacement ranged 1.61 -  1.72mm, 1.53 -  1.70mm and 1.16 -  1.35mm, in the 
vertical, longitudinal and lateral directions, respectively, for all three image 
verification strategies, as shown in Table 4.3.
Table 4.3 showing the mean and standard deviation of the magnitude of 
displacements in mm, in all three directions using three differing image 
sets.
Vertical Longitudinal Lateral
Mean Mean Mean
[s.d.] Range [s.d.] Range [s.d.] Range
CBCTdaiiy 1.61 0.00- 1.53 0.00- 1.35 0.00-
[1 .45 ] 7.00 [1 .34 ] iLOO [1 .06 ] 5.00
CBCTweekiy 1.72 0.00- 1.58 0.00- 1.32 0.00-
[1 .49 ] 7.00 [1 .31 ] 5.00 [0 .97 ] 3.00
KV EPlweekiy 1.66 0.00- 1.70 0.00- 1.16 0.00-
[1 .46 ] 6.00 [1 .34 ] 6.00 [1 .18 ] 6.00
s.d., standard deviation
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In the vertical direction, the frequency of displacements measuring between 0 
and 3mm ranged between 86.2 and 89.7% for the three verification image sets 
(CBCTdaiiy, kV EPlweekiy and CBCTweekiy). Similarly, the frequency of displacements 
between 0 and 3mm in the longitudinal direction ranged between 87.9 and 
91.2%. Displacements in the lateral direction rarely exceeded 3mm, w ith  
between 96.5 and 100% recorded at 0 -  3mm. The variation in the frequency of 
magnitude of displacement in all three directions according to imaging strategy 
is demonstrated in Figures 4.1(a), 4.1(b) and 4.1(c). The most common 
magnitude of displacement in all three directions was 1mm, for all imaging 
strategies.
Figure 4.1. The frequency of magnitude of displacement in mm recorded 
using CBCTdaiiy, CBCTweekiy and kV EPlweekiy image sets: (a) vertical direction; 
(b) longitudinal direction; (c) lateral direction.
(a) Vertical
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(b ) Longitudinal
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(c) Lateral
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4.3.3. Systematic and random components of setup error
4.3.3.1. Individual setup error
Individual systematic [Table 4.4] and random [Table 4.5] components 
of setup error in each direction for the twenty patients are shown 
below.
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4.3.3.1.1. Systematic setup error
Table 4.4. Individual systematic setup errors measured in mm as detected 
by various image verification techniques: (a) vertical direction; (b) 
longitudinal direction; (c) lateral direction.
(a) Vertical
Patient CBCTdaiiy, auto CBCTdaiiy CBCTweekiy kV EPlweekiy
1 0.80 -0 .17 1.00 (100
2 -0 .15 -2 .56 -2 .50 -2 .5 0
3 (155 0.93 1.33 2 .00
4 -0 .50 -1 .35 -0 .8 0 -1 .8 0
5 0.85 (127 -0 .25 (100
6 -0 .18 (154 1.00 1.00
7 0.82 (121 (183 (150
8 0.00 -1 .1 7 -1 .1 4 -1 .29
9 -2 .0 9 -1 .73 -1 .5 0 -1 .75
10 1.40 1.15 1.67 (117
11 (111 (125 (117 (117
12 0.00 -1 .0 4 -0 .71 -0 .57
13 0 .68 (132 -0 .5 0 1.00
14 0.04 -0.11 0 .40 -0 .20
15 -0 .5 4 -1 .13 -0 .5 0 -0 .75
16 -0 .85 -2 .7 6 -2 .8 6 -3 .43
17 1.65 -112 3.33 2 .00
18 0 .0 4 (100 0.00 (140
19 1.37 2.52 3117 2.83
20 0 .66 (172 1.20 1.00
Population
error 0 .8 4 1 .4 9 1 .6 8 1 .6 3
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(b ) Longitudinal
Patient CBCTdaiiy, auto CBCTdaiiy CBCTweekiy kV EPlweekiy
1 -0.33 -0.39 -0.75 -0.75
2 L l l 0.74 0.67 0.50
3 2.03 2.21 2.17 1.67
4 0.88 -0.04 0.80 0.80
5 -1.58 -2.42 -3.75 -5.00
6 (150 -0.93 0.17 0.00
7 1.46 2.61 3.33 3.50
8 -1.21 -0.66 -0.57 -0.86
9 1.41 1.36 1.13 0.50
10 -0.50 -0.30 -0.17 0.50
11 -1.29 -1.61 -1.17 -1.83
12 -0.81 -0.59 -0.57 -0.29
13 (145 (123 0.17 0.33
14 -0.74 -0.93 -0.20 -0.20
15 1.21 1.21 0.00 -0.63
16 -0.74 -2.24 -2.71 -3.29
17 -0.31 -0.23 0.00 -0.67
18 -0.52 -1.15 -1.80 -2.40
19 (178 1.19 1.33 1.50
20 -0.55 -0.52 -0.60 -0.75
Population
error 1.08 1.37 1.54 1.76
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(c) Lateral
Patient CBCTdaily, auto CBCTdally CBCTweekly kV EPlweekly
1 (113 0.17 -0.25 -&,25
2 (115 0.22 100 -&83
3 -0.38 -0.04 017 &17
4 1.69 181 120 &60
5 -2.04 -2.23 -ZOO -1.50
6 -1.21 -0.86 -&83 (117
7 &75 -1.04 -167 -167
8 -0.07 -0.55 -0.71 -2.29
9 1.55 1.27 0.75 -0.50
10 -0.50 -0.10 &83 aoo
11 1.36 164 2.33 167
12 1.00 100 129 &86
13 &64 0.55 0.67 -&67
14 0.70 100 160 &80
15 0J3 -0.38 013 (100
16 &48 1.24 100 (143
17 1.62 Z42 Z17 2.00
18 1.15 144 160 (180
19 &78 -&04 -0.50 -117
20 0.31 &17 0.40 0.25
Population
error Œ95 1.13 1.14 1.10
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4 .3 3 .1 .2 . Random setup error
Table 4.5. Individual random setup errors measured in mm as detected by 
various image verification techniques: (a) vertical direction; (b) 
longitudinal direction; (c) lateral direction.
(a) Vertical
Patient CBCTdaily, auto CBCTdaily CBCTweekly kV EPlweekly
1 034 120 1.15 032
2 032 236 138 0.84
3 037 109 133 039
4 107 Z19 130 2.05
5 101 104 0.96 0.82
6 034 2.19 3J3 238
7 038 2.17 2.64 134
8 146 131 135 130
9 172 237 231 3.20
10 &75 118 133 1.17
11 &74 135 035 (175
12 032 170 130 137
13 &78 136 236 137
14 035 1.15 1.14 1.10
15 107 133 135 115
16 033 159 131 137
17 033 175 Z16 2.90
18 032 114 031 132
19 038 148 147 147
20 037 116 134 L32
Population
error 0.93 1.64 1 7 4 1.69
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(b) Longitudinal
Patient CBCTdaily, auto CBCTdally CBCTweekly kV EPlweekly
1 (172 038 &96 139
2 (170 036 032 034
3 (157 034 038 032
4 1.11 139 164 110
5 lAO 142 030 032
6 133 Z46 132 137
7 036 139 131 035
8 3J3 330 215 2.61
9 171 138 233 135
10 039 033 035 105
11 030 117 117 147
12 032 030 039 111
13 036 138 130 103
14 036 033 0.84 0.84
15 038 118 130 033
16 106 139 2.06 138
17 139 133 210 237
18 034 110 130 035
19 035 132 137 138
20 037 037 114 134
Population
error 1.20 1.55 1.52 1.39
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(c) Lateral
Patient CBCT daily, auto CBCTdaily CBCTweekly k V  EPlweekly
1 032 039 030 139
2 032 1.09 110 038
3 0.49 032 113 038
4 0.84 127 130 134
5 032 036 032 038
6 133 212 132 147
7 037 135 032 242
8 214 231 139 229
9 182 134 138 207
10 036 102 113 &63
11 036 033 &82 032
12 036 107 0.76 107
13 133 147 163 103
14 037 124 114 0.45
15 034 106 146 132
16 039 113 0.82 &98
17 030 106 0.98 167
18 036 030 035 0.45
19 034 122 0.84 113
20 100 100 0.89 015
Population
error 1.08 1 .2 9 1.19 1.37
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43.3 .2 . Population setup error 
Population systematic and random components of setup error as detected by
various verification strategies are summarised in Table 4.6. Systematic errors 
were small in general, ranging 0.84 - 1.76mm, w ith  a sim ilar range of random 
errors [0.93 -  1.74mm).
Table 4.6. Population setup error in mm using CBCTdaily, auto, CBCTdaily, 
CBCTweekly and kV EPlweekly Verification in all three directions, for all twenty 
patients.
Vertical 
Systematic Random
Longitudinal 
Systematic Random
Lateral 
Systematic Random
C B C T d a lly ,a u to 0 3 4 0 3 3 1.08 1.20 0 3 5 1.08
C B C T d a ily 1.49 1 3 4 1 3 7 1.55 1 3 3 1.29
C B C T w e e k ly 1.68 1 3 4 1 3 4 1.52 1 3 4 1.19
kV E P lw e e k ly 1 3 3 1 3 9 1 3 6 1.39 1 3 0 1.37
43.4. Comparison between imaging strategies
Pearson's product-moment correlation coefficient, r, and Bland-Altman plots 
were calculated to provide measures of correlation and agreement between the 
four imaging strategies: CBCTdaily, auto, CBCTdaily, CBCTweekly and kV EPlweekly for 
systematic and random components of setup error.
4.3.4.1. Systematic error
For systematic error, there was a strong correlation between all imaging 
strategies in all three directions ( r  statistic 0.76 -  0.98, p<0.0001) (Table 4.7).
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4 .3 .4 .I.I. Correlation
Table 4.7. Correlation between imaging strategies in: (a) vertical; (b) 
longitudinal; (c) lateral directions for systematic error.
(a) Vertical
CBCTdaily, auto CBCTdaily vs CBCTdaily VS CBCTweekly VS
Comparison VS CBCTdaily CBCTweekly kV EPlweekly k V  EPlweekly
n 20 20 20 20
r  statistic 030 036 034 031
9 5 %  Cl 036%) 032 0.90 to 0.99 0 3 5 to 0 3 8 0.77 to 0.96
t statistic 539 14.95 11.48 9.07
DF 18 18 18 18
2-tailed p <03001 <0.0001 <0.0001 <0.0001
(b )  Longitudinal
CBCTdaily, auto CBCTdaily VS CBCTdaily VS CBCTweekly VS
Comparison VS CBCTdaily CBCTweekly kV EPlweekly k V  EPlweekly
n 20 20 20 20
r  statistic 0.89 032 0.87 0.98
95% bC I & 7 3to 035 0.81 to 037 0.69 to 0.95 0.94 to 0.99
t statistic 832 1039 7.45 19.35
DF 18 18 18 18
2-tailed p <03001 <0.0001 <0.0001 <0.0001
(c) Lateral
CBCTdaily, auto CBCTdaily VS CBCTdaily vs CBCTweekly VS
Comparison VS CBCTdaily CBCTweekly kV EPlweekly k V  EPlweekly
n 20 20 20 20
r  statistic 036 032 0.76 0.82
95% oC I 0 3 6 to 0 3 4 0.79 to 0.97 0.47 to 0.90 0.59 to 0.93
t statistic 731 934 4.92 6.08
DF 18 18 18 18
2-tailed p <03001 <0.0001 0.0001 <0.0001
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4.3.4.I.2. Agreement
Bland-Altman plots were calculated and the results are shown in Table 4.8. 
Overall, for systematic error, the average discrepancy (the bias) between 
imaging strategies was small at approximately up to 0.5mm of discrepancy, 
ranging -0.331 to 0.266mm in the vertical direction, -0.241 to -0.004mm in the 
longitudinal direction and -0.515 to 0.072mm in the lateral direction, for all 
strategies.
Table 4.8. Bias and 95%  limits of agreement in mm measured by Bland- 
Altman plots comparing imaging strategies in: (a) vertical; (b) longitudinal; 
(c) lateral directions for systematic error.
(a) Vertical
CBCTdaily, auto CBCTdaily VS CBCTdaily VS CBCTweekly VS
Comparison VS CBCTdaily CBCTweekly k V  EPlweekly k V  EPlweekly
n 20 20 20 20
Bias -0331 0366 0338 -0.228
95% bC I -0.772 to 0.058 to -0.215 to -0.550 to
0310 0.473 0391 0395
P 03322 0.0149 0.7576 0.1558
95%  Limits 
of
agreement
-2.178 to 
1315
-0.604 to 
1335
-1.023 to 
1399
-1.578 to 
1333
( b )  Longitudinal
CBCT daily, auto CBCTdaily VS CBCTdaily vs CBCTweekly VS
Comparison VS CBCTdaily CBCTweekly kV EPlweekly kV EPlweekly
n 20 20 20 20
Bias -0386 -0.004 -0.245 -0.241
95% oC I -0.486 to -0.295 to -0.685 to -0.450 to -
0334 0387 0394 0.032
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p 03101 0.9765 03575 03258
95% Limits 
of
agreement
-1.442 to  
1370
-1.221 to 
1313
-2.086 to 
1396
-1.115 to 
0333
(c) Lateral
CBCTdaily, auto CBCTdaily vs CBCTdaily vs CBCTweekly VS
Comparison VS CBCTdaily CBCTweekly kV EPlweekly k V  EPlweekly
n 20 20 20 20
Bias -0.025 0.072 -0.442 -0.515
95%bCI -0396m -0.150 to -0.802 to - -0.835 to -
0346 0.295 0.083 0394
P 0.8462 0.5043 03186 03033
95%  Limits
of
agreement
-1360 to 
1330
-0.860 to 
1305
-1.948 to  
1.064
-1358 to 
0.828
The smallest bias (the average discrepancy) between methods was 0.038 
(p=0.7576) for CBCTdaily vs kV EPIweeWy in the vertical direction (Fig. 4.2), and for 
CBCTdaily vs CBCTweekly, 3.004 (p=0.9765) and 0.072 (p=0.5043), in the 
longitudinal (Fig. 4.3) and lateral directions (Fig. 4.4), respectively. These results 
indicate very good agreement between these imaging strategies.
The largest bias results were noted in the lateral direction, measuring -0.442mm 
(p=0.0186) for the CBCTdaily vs kV EPIweeWy comparison (Fig. 4.5), and -0.515mm 
(p=0.0033) for the CBCTweekly vs kV EPlweekly comparison (Fig. 4.6). These results 
infer that use of kV EPlweekly images recorded differing systematic error of the 
magnitude of approximately 0.4 - 0.5mm in the lateral direction when compared 
with either CBCTdaily or CBCTweekly images.
157
Figure 4.2. (a) Scatter plot; (b) Bland-Altm an difference p lot and (c)
histogram of differences between systematic e rro r measured by CBCTdaily
and kV EPIweeUy in the vertical direction.
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(c) Histogram of differences (in  m m )
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Figure 4.3. (a) Scatter plot; (b) Bland-Altman difference plot and (c) 
histogram of differences between systematic error measured by CBCTdaily 
and CBCTweekly in the longitudinal direction.
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Figure 4.4. (a) Scatter plot; (b) Bland-Altm an difference plot and (c)
histogram of differences between systematic e rro r measured by CBCTdaily
and CBCTweekly in the lateral direction.
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(c) Histogram  of differences (in  m m )
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Figure 4.5. (a) Scatter plot; (b) Bland-Altman difference plot and (c) 
histogram of differences between systematic error measured by CBCTdaily 
and kV EPlweeWy in the lateral direction.
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Figure 4.6. (a) Scatter plot; (b) Bland-Altm an difference plot and (c)
histogram of differences between systematic e rro r measured by CBCTweeWy
and kV EPlweekly in the la tera l direction.
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(c) Histogram of differences (in  m m )
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4.3.4.2. Random error
43.4 .2 .1 . Correlation
Correlation between random error measurements was less strong than for 
systematic error, ranging between 0.34 to 0.88, for all method comparisons, in all 
three directions (Table 4.9).
Table 4.9. Correlation between imaging strategies in: (a) vertical; (b) 
longitudinal; (c) lateral directions for random error.
(a) Vertical
Comparison
CBCT daily, auto 
VS CBCTdaily
CBCTdaily VS 
CBCTweekly
CBCTdaily VS 
kV EPlweekly
CBCTweekly VS 
kV EPlweekly
n 20 20 20 20
r  statistic 0.41 0.71 0.59 0.71
95%  Cl -0.04 to 0.72 0.39 to 0.88 0.19 to 0.82 0.39 to 0.88
t  statistic 1.93 4.25 3.07 4.29
DF 18 18 18 18
2-tailed p 0.0699 0.0005 0.0067 0.0004
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(b) Longitudinal
CBCTdaily, auto CBCTdaily VS CBCTdaily VS CBCTweekly VS
Comparison VS CBCTdally CBCTweekly k V  EPlweekly k V  EPlweekly
n 20 20 20 20
r  statistic 0.88 &72 033 0.63
9 5 %  Cl 0.71 to 0.95 & 4 1 to 0 3 8 0 3 5 m 0 3 4 0.25 to 0.84
t statistic 733 442 &40 3.40
DF 18 18 18 18
2-tailed p <03001 0.0003 0.0032 0.0032
(c) Lateral
CBCTdaily, auto CBCTdaily VS CBCTdaily VS CBCTweekly VS
Comparison VS CBCTdaily CBCTweekly k V  EPlweekly kV EPlweekly
n 20 20 20 20
r  statistic 0.85 071 0.68 034
9 5 %  Cl 0.65 to 0.94 0 3 8 to 0 3 7 0.34 to 0.86 -0.12 to 0.68
t statistic 6.74 422 334 135
DF 18 18 18 18
2-tailed p <0.0001 0.0005 0.0010 0.1395
43.4.2.2. Agreement
In contrast to a weaker correlation in random error recorded by various imaging 
strategies, in general, agreement between methods w ith  respect to random 
error, was very strong, ranging between -0.141 and 0.091mm for all 
comparisons except CBCTdaily,auto vs CBCTdaily, with p values exceeding 0.05 in all 
cases. Only the comparison between CBCTdaily, auto and CBCTdaily had statistically 
significant [p<0.0001 or 0.0002) larger differences in random error, ranging 
between 0.232 and 0.683mm (Table 4.10), in all three directions (Fig. 4.7-4.9).
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Table 4.10. Bias and 95%  limits of agreement in mm measured by Bland- 
Altman plots comparing imaging strategies in: (a) vertical; (b) longitudinal; 
(c) lateral directions for random error.
(a) Vertical direction
CBCTdaily, auto CBCTdaily VS CBCTdaily VS CBCTweekly VS
Comparison VS CBCTdaily CBCTweekly kV EPlweekly k V  EPlweekly
n 20 20 20 20
Bias 0.683 -0.014 -0090 -0.076
95%  Cl 0 4 9 3 m -0.234 to -0.346 to -0.313 to
0.874 0206 0167 0.162
P <00001 0.8964 0.4733 0.5132
95%  Limits 
of
agreement
-0.115 to 
1481
-0.935 to 
0907
-1.162 to 
0.983
-1.071 to 
0.920
(b )  Longitudinal direction
CBCTdaily, auto VS CBCTdaily VS CBCTdaily VS CBCTweekly VS
Comparison CBCTdaily CBCTweekly k V  EPlweekly k V  EPlweekly
n 20 20 20 20
Bias 0.348 -0019 -0141 -0122
95%  Cl 0203 to -0231 to -0394 to -0.340 to
0.492 0.194 0112 0096
P <00001 0.8566 02573 02550
95%  Limits 
of
agreement
-0.257 to 
0.952
-0.909 to 
0.871
-1.199 to 
0.917
-1.036 to 
0791
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(c) Lateral direction
CBCTdaily, auto CBCTdaily VS CBCTdaily VS CBCTweekly VS
Comparison VS CBCTdaily CBCTweekly kV EPlweekly kV EPlweekly
n 20 20 20 20
Bias 0.232 -0.125 -0.034 0.091
95% Cl 0.124 to -0.265 to -0.248 to -0.195 to
0.340 0.015 0.179 0.376
P 0.0002 0.0768 0.7389 0.5138
95%  Limits 
of
agreement
-0.220 to 
0.684
-0.712 to 
0.462
-0.928 to 
0.859
-1.105 to 
1.287
Figure 4.7. (a) Scatter plot; (b) Bland-Altman difference plot and (c) 
histogram of differences between systematic error measured by CBCTdaily, 
auto and CBCTdaily in the vertical direction.
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Figure 4.8. (a) Scatter plot; (b) Bland-Altm an difference plot and (c)
histogram of differences between systematic e rro r m easured by CBCTdaily.
auto and CBCTdally in the longitudinal direction.
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(c) Histogram of differences (in  m m )
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Figure 4.9. (a) Scatter plot; (b) Bland-Altman difference plot and (c) 
histogram of differences between systematic error measured by CBCTdaily, 
auto and CBCTdaily in the lateral direction.
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4.3.5. Estimated CTV to  PTV margins
Van Herk et a l[5] proposed a CTV to PTV margin recipe which aims to achieve a 
m inimum dose of 95% to the CTV for 90% of patients:
Van Herk margin recipe: 2.5^+ 0.7a
where Y. represents population systematic error and a represents random error. 
Neither margin recipe accounts for delineation error. Systematic error and 
random error components from CBCTdaily, auto, CBCTdaily, CBCTweekly and kV
EPlweekly Verification (Table 4.6) were entered into the Van Herk PTV margin 
recipe to calculate PTV margins (Table 4.11). The calculated PTV margins ranged 
between 3 and 5mm, in all three directions, for all imaging strategies.
Table 4.11. Planning target volume (PTV) margins in mm calculated using 
setup error recorded by various imaging strategies.
Vertical Longitudinal Lateral
CBCT daily, auto 275 253 214
CBCTdally 4.87 4.52 273
CBCTweekly &42 4.91 268
kV EPlweekly 5.27 237 272
4.3.6. Impact on linear accelerator (linac) time
In order to evaluate the impact of providing an online IGRT service, the total 
patient time in the treatment room was recorded, from the time the patient was 
called from the waiting-room, to the time that the patient exited the treatment 
room. The average room-time was 21 minutes per patient (Fig. 10). This data 
included timings from the very firs t patient in the pilot, when the technology was 
completely new to the treatment team. The IGRT room-time of 21 minutes 
marked a 1 minute increase in time over the standard treatment time slot of 20 
minutes allocated to patients receiving radical radiotherapy to the head and 
neck. Fig. 4.10 shows a trend towards a reduction in the room-time required as 
well as a narrowing of the error bars.
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Figure 4.10. Average tim e (in  m inutes) in trea tm ent room, per fraction.
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4.4. Discussion
This prospective study tested the hypothesis that CBCT could be used to improve 
the accuracy of radiation delivery, which in turn would increase the potential for 
highly conformai radiotherapy planning techniques such as IMRT to minimise 
normal tissue toxicity in the clinical setting. In addition, the results would 
provide a rationale for the optimal integration of this technology into radical 
radiotherapy treatment for patients w ith  HNC in this department.
Standard treatment verification in this department consists of comparing two- 
dimensional (2D) megavoltage (MV) EPIs w ith  20 reference digitally 
reconstructed radiographs (DRRs) generated from simulation CT data. The 
research linac used in this study was fitted with an On-Board Imager (OBI) 
system. This system comprises a kV source mounted perpendicularly to the 
treatment beam axis and provides functionality to generate either 20 kV EPIs or 
30 CBCTs. The setup data results from this study enable comparison between 20 
and 30 kV imaging and also comparison between daily and weekly imaging
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protocols. In turn, the data provides a basis for review of CTV-PTV planning 
margins.
4.4.1. Setup error
The setup error analysis showed that both systematic and random components 
of setup error were small for all four reported verification methods: CBCTdaiiy.auto, 
CBCTdaiiy, CBCTweekiy and kV EPIweekiy [Table 4.6). All patients in this study were
treated w ith  online matching which has the potential implication of increased 
costs in terms of both linac and staffing time in addition to potentially increased 
distress to patients in tolerating closely fitting  immobilisation devices for a 
prolonged treatment time. In order to minimise online matching review time, a 
two stage process of matching was employed: firstly, by application of the Varian 
OBI automated comparison tools to a 'critical match' region of interest (RGI) -  
with these results recorded as CBCTdaiiy,auto displacement data, and secondly, 
radiographer review of the automated comparison match and adjustment taking 
into account the full length of the treatment volumes which may not have 
necessarily been included w ith in  the ROl.
CBCTdaiiy, auto displacement datasets were recorded and were found to be 
statistically different to CBCTdaiiy displacement datasets in both vertical 
[p<0.0001) and longitudinal [p<0.0001] directions but not in the lateral 
direction (p=0.493). These findings were expected since the second stage in 
image review would usually involve some adjustment of the match in the vertical 
and longitudinal directions, taking into account the full length of the treatment 
volume whilst in general prioritising areas including the high dose PTV and 
spinal cord which were more likely already to have a good quality of automatic 
matching in the lateral direction.
The remaining three verification strategies -  CBCTdaiiy, CBCTweeWy and kV
EPIweekiy all required radiographer judgement before approval of a match and 
employment of appropriate positional shifts. Systematic and random 
components of setup error for these three techniques were small. Systematic 
errors in the vertical, longitudinal and lateral directions were 1.49 -  1.68mm, 
1.37 -  1.76mm and 1.10-1.14mm, respectively, for all strategies. Random errors
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in the vertical, longitudinal and lateral directions were 1.64 -  1.74mm, 1.39 -  
1.55mm and 1.19 -  1.37mm, respectively, for all strategies. The magnitude of
these setup errors appears comparable w ith  published data from other centres 
[Table 4.12).
Table 4.12. Reported magnitude [in mm) of systematic and random setup 
error in the literature.
Author N ni Imaging Systematic Random
modality Vert Long Lat Vert Long Lat
Gupta et 25 93 EPI 0.96 1.20 0.98 1.94 2.48 1.97
al. [6]
Li et al.[7J 21 98 CBCT 1.60 1.50 1.30 1.60 1.60 1.20
Li et al. [7] 21 98 EPI 0.50- 0.60- 0.60- 1.20- 1.20- 0.70-
1.10 1.00 1.20 1.60 1.50 1.20
Pehlivan 20 567 EPI 0.93 1.20 0.89 1.78 2.26 1.93
et al. [8]
Wang et 22 505 CBCT 1.20 1.30 1.10 1.10 1.30 1.10
al.[9]
Velec et 11 338 CBCT 1.00 1.50 0.80 1.60 1.50 1.50
al.[10]
Den et 28 -8 5 0 CBCT 1.41 1.06 1.13 1.93 2.00 1.50
al. [11]
N, number of patients; ni, number of image pairs; vert. vertical; long,
longitudinal; lat, lateral.
For systematic error, the correlation between CBCTdaiiy, CBCTweekiy and kV 
EPIweekiy was Very strong [r statistic 0.76 -  0.96, p < 0.0001 in all cases) [Table
4.8). This result was expected, since both kV EPl and CBCT have been developed 
specifically for the same purpose of verification and both involved prioritisation 
of a 'critical match' ROl which was based on vertebral levels deemed to lie in 
regions of high clinical significance in terms of radiotherapy plan dosimetry. kV 
EPls image bony anatomy, and hence, vertebral bodies, w ith  good image contrast
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and contribute to a high degree of correlation between kV EPI- and CBCT-based 
match data. Agreement analyses (Table 4.9} showed that the bias ranged 
between -0.515mm and 0.266mm between modalities. Clinically, this appears to 
be small.
Correlation in random error between the three modalities CBCTdaiiy, CBCTweekiy 
and kV EPIweekiy was less strong than for systematic error (r  statistic 0.34 -  0.72, 
p < 0.005 in all cases except CBCTdaiiy vs kV EPIweekiy in the vertical direction (r 
statistic 0.59, p=0.0067} and CBCTweekiy vs kV EPIweekiy in the lateral direction (r 
statistic 0.34, p=0.1395} (Table 4.10}. However, in contrast, in general, 
agreement between these modalities for random error in all three directions was 
even stronger than for systematic error, ranging between -0.14mm and 
0.091mm, w ith  p values all greater than 0.005 (Table 4.11}, indicating that the 
null hypothesis (that bias equals zero} could not be rejected.
These results appear consistent w ith  the literature. A group from M.D. Anderson 
Cancer Center, Houston, compared 2D kV EPls w ith  kV CBCT (Varian OBI 
system} in twenty-one patients receiving radiotherapy for HNC [7]. Ninety-eight 
pairs of 20 kV EPls and CBCTs were studied. The authors reported that 
systematic and random errors were sim ilar (<1.6mm} for both imaging 
techniques and also that statistically significant correlations were observed in all 
three directions, for both 20 kV EPI and CBCTs. Despite the strong correlation, 
some instances were noted in which setup error of up to 8mm were noted from 
CBCT review but not from verification using 20 kV EPI. It was suggested that 
these discrepancies may have arisen from non-rigid or rotational anatomical 
changes such as a change in neck curvature which may be less apparent on 20 
kV EPls. Rotational changes were not specifically evaluated in this study. On 
review of our own data, there were two instances in which displacements of 
7mm were noted in the vertical direction on CBCT images compared w ith  5mm 
and 6mm on kV EPls. These differences would not have statistical significance 
but nevertheless remain clinically relevant.
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4.4.2. Impact on CTV to PTV margin
The PTV is defined as a geometric concept 'defined to select appropriate beam 
sizes and beam arrangements, taking into consideration the net effect of all the 
possible geometrical variations and inaccuracies in order to ensure that the 
prescribed dose is actually absorbed in the CTV' [3, 4]. In practical terms, the aim 
of a CTV to PTV margin is to account for setup error and internal organ motion in 
the delivery of therapeutic radiation to a defined CTV. Various groups have 
proposed 'margin recipes' which aim to achieve a minimum specified isodose to 
the CTV [5,12] (Table 4.13].
Table 4.13. Proposed CTV to PTV margin recipes.
Authors Minimum Minimum Margin recipe
dose volume of CTV
to CTV treated
Van Herk et a l[5] >95% 100% 2.5Z+ 0.7o
Stroom et a l[12] >95% >99% 2.0E+ 0.7o
Y,, population systematic error; a, random error
In order for each department to evaluate appropriate local CTV to PTV margins, 
it  is necessary to collect and m onitor setup data -  or risk underdosing target 
volumes or unnecessary irradiation of critical organs at risk (OARs). The 
significance of underdosing to the target volume has been modelled previously 
by Tome et al [13] who reported that cold spots in the target volume can have a 
detrimental impact on tumour control probability (TCP). The authors showed 
that i f  1% of the target volume was underdosed by 15%, this would lead to a loss 
in TCP of 4%. This loss of TCP appears relatively small, however, the loss in TCP 
increased sharply when underdosing of 1% of the target volume increased in 5% 
increments -  w ith  a loss in TCP of 11% and then 22% for dose deficits of 20% 
and 25% to the 1% volume dose bin, respectively. Hong et al evaluated the 
potential impact of daily setup variations on ten IMRT plans for patients w ith  
HNC [14]. Positional displacements were applied to each patient's corresponding 
IMRT plan which was then analysed for variations in dose volume histogram
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(DVH), equivalent uniform dose (EUD), mean total dose (mTd) and maximal total 
dose (MTD). The authors demonstrated that when positional displacement in all 
directions were converted into a mean composite vector offset and subsequently 
incorporated into an ÏMRT plan, that underdosing of the GTV was common and
that when the least and median offset histories were applied, the EUD decreased 
by 3 -  14%, and by up to 21% when the largest offset histories were applied.
In this department, when estimated systematic and random components of setup 
error were entered into the Van Herk margin recipe, the calculated CTV to PTV 
margin was approximately 5mm in the vertical and longitudinal directions and 
4mm in the lateral direction (Table 4.7), regardless of imaging method or 
frequency, i f  daily online setup positional corrections were not applied. These 
results appear comparable with published planning margins. Den et al [11] 
performed a prospective study of daily IGRT for patients w ith  HNC using CBCT 
acquired by an Elekta linac. Twenty-eight patients and 1013 CBCT scans 
(comprising daily pre-treatment CBCTs and m inimum weekly post-treatment 
CBCTs) were studied. CTV to PTV margins in the absence of daily CBCT image 
guidance were estimated to be 4.9mm, 4.1mm and 3.9mm in the vertical, 
longitudinal and lateral directions, respectively. A t least once weekly, post­
treatment CBCT scans were acquired to assess for residual error, results of 
which enabled an estimation of appropriate margins w ith  daily online IGRT. 
IGRT showed that margins could be reduced to 1.4mm, 2.1mm and 1.2mm in the 
vertical, longitudinal and lateral directions, respectively, representing a 
reduction of between 60 and 80% in margin size.
Systematic and random setup errors are incorporated into margin recipes but 
are themselves subject to other parameters such as the frequency of imaging 
protocol. Three main types of correction protocol affect margins: no correction, 
offline correction and online correction [15]. Offline correction protocols enable 
a reduction in the margin compared with no correction by accounting for 
systematic treatment preparation errors. An online protocol w ill additionally 
detect random patient setup error. Our results suggest that the frequency -  daily 
versus weekly - of verification imaging did not have a statistically significant
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impact on setup error. However, as shown by Den et al [11], residual error -  
comprising both systematic and random errors w ill s till remain even after online 
correction of setup but w ill lead to smaller CTV to PTV margins. Patient factors 
are also important and online daily image guidance has the potential to identify 
spurious large displacements, for example, due to physical fitness or 
psychological daily variation in the patient, which may lead to unpredictable 
changes in positioning which would not otherwise be identified by non-daily 
image verification. Zeidan et al [16] analysed setup data for twenty-four patients 
treated on a helical tomotherapy unit. The impact o f various correction protocols 
based on differing imaging frequency was simulated retrospectively. All 
protocols were effective in reducing the mean systematic error to less than 
1.5mm. In general, both systematic and random errors reduced w ith  increasing 
imaging frequency. The study concluded that residual setup errors also reduce 
w ith  imaging frequency, mainly due to the positive impact on random error. 
Velec et al also reported residual error as measured by 118 pre- and post­
treatment kV CBCT image pairs in a study of twenty patients treated w ith  either 
a standard or a skin-sparing immobilisation device [10]. The residual 
intrafraction random and systematic errors ranged between 0.3 and 0.9mm in all 
directions and the ir existence add further support to the on-going requirement 
for margins even when daily online IGRT is applied. Similarly, Wang et al 
performed online CBCT guided IMRT for twenty-two patients w ith  
nasopharyngeal cancer [9]. 505 pre-correction pre-treatment, 106 post- 
correction pre-treatment and 143 post-treatment CBCT scans were acquired. 
The setup errors derived from the in itia l CBCT scans are summarised in Table 
4.12 and are associated w ith  CTV to PTV margins of 3.5mm to 4.2mm in all 
directions. Post-correction data was associated w ith  smaller margins ranging 
between 1.6 and 1.8mm but interestingly, post-treatment setup errors resulted 
in estimated CTV to PTV margins ranging between 2.5mm and 3.0mm, indicating 
intrafractional changes.
Our data suggests that 2D versus 3D imaging did not have a significant impact on 
estimated CTV to PTV margins although as described above, data from our own 
study and from Li et al [7] suggest that unpredictable changes in positioning may
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occur that is less clearly demonstrated on 2D versus 3D imaging. However,
overall, i f  2D appears equivalent to 3D verification, this result is clinically 
relevant: CBCT imaging is associated w ith  increased radiation dose to the 
patient, requires training of radiographers who are accustomed to reviewing and 
verifying anatomical changes in 2D and potentially requires prolonged image 
review time compared w ith  standard 2D imaging.
The dosimetric impact of CBCT is associated w ith  effects on both additional risk 
of secondary cancer and increased dose to critical OARs in close proxim ity to the 
target volume. Kan et al [17] reported organ absorbed doses and effective doses 
measured during a head scan in standard mode using Varian OBI. The mean 
absorbed dose per scan to the spinal cord was 4.08cGy w ith  mean doses of 
6.22cGy and ll.OBcGy to lens and thyro id respectively. In the setting of daily 
online IGRT for a th ir ty  fraction treatment course, the increased doses to spinal 
cord, lens and thyroid would be 1.2Gy, 1.9Gy and 3.3Gy, respectively. W hilst the 
potential increases of absorbed dose to lens and thyroid are important, the 
increase in dose to spinal cord could be critical and i f  the absorbed dose could 
not be reduced by modification of scanning acquisition settings or other 
techniques, the potential increase in dose should be accounted for during the 
radiotherapy planning process. The authors also evaluated a low  dose scanning 
protocol which reduced absorbed dose to spinal cord to 0.875cGy per scan which 
would be clinically useful. W ith respect to the potential impact of effective dose, 
the study found that the effective dose from a head scan in standard mode was 
10.26mSv, compared w ith  2.10mSv in low dose mode. ICRP 60 and 103 have 
advised that the probability of inducing fatal cancer from a single radiographic 
exposure is 5% per Sv [18, 19]. This suggests that if thirty CBCT images were 
taken using the standard scan protocol, that the additional risk of secondary 
cancer would be approximately 2%. These data appear comparable with more 
recent data published by Cheng et al [20] who also presented absorbed dose and 
effective dose data for an updated version [Version 1.4.13) of the Varian OBI 
system and demonstrated large reductions in the absorbed dose per scan (spinal 
cord: 1.44cGy, lens 0.38cGy and thyroid 1.39cGy) by application of the updated 
version of software.
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Finally, our prospective study was designed to test the hypothesis that CBCT can 
be used to improve the accuracy o f IMRT deliver. This in turn lead to a potential 
improvement in local tumour control and a reduction in normal tissue toxicity. 
Chen et al [21] performed a retrospective study of 225 patients treated w ith  
daily image-guided IMRT for HNC. Either kV or MV volumetric imaging was used 
for image guidance. IMRT plans for the firs t 95 patients involved a 5mm CTV to 
PTV margin. Following institutional review of setup data, the CTV to PTV margin 
was reduced to 3mm for the subsequent 130 patients. Two-year estimates of 
overall survival, local-regional control and distant metastasis-free survival were 
76%, 78% and 81%, respectively. The CTV to PTV margin used did not influence 
any of these endpoints (p > 0.05 in all cases). The margin size also did not impact 
on recorded acute or late toxicity. The authors concluded that the planning 
margin can safely be reduced in the selling of daily IGRT.
4.5. Conclusion
Daily online CBCT image guidance can be used to improve the geometric and 
dosimetric accuracy of planned IMRT. Setup errors detected by CBCT appear 
sim ilar to those detected w ith  2D kV EPI but some variations in positioning may 
be more clearly demonstrated by volumetric data provided by CBCT. The CTV to 
PTV margin can be reduced with daily online CBCT image guidance.
4.6. Acknowledgements
Setup of the clinical study was supported by Angela Francis, Elizabeth Adams 
and Tom Jordan, Department of Radiotherapy and Radiotherapy Physics, Royal
Surrey County Hospital.
Online and offline matching of CBCT and kV EPls was performed by Kirsty 
Freeman, Ceri Jamieson, Marianne Dabbs and the radiographer team on LAI, 
Department of Radiotherapy, Royal Surrey County Hospital, Guildford.
Statistical analysis was supervised by Sabeena Sidhu, Department of 
Radiotherapy Physics, Royal Surrey County Hospital.
182
4.7. References
1. Grégoire, V., et al. Proposai fo r  the delineation o f the nodal CTV in the
node-positive and the post-operative neck. Radiother Oncol, 2006. 79(1): p.
15-20.
2. Grégoire, V., et al., de/ment/on node /eve/s ond re/oted
CTTs /n the node-ne^ot7ve neck; DAllANGl, EORTC 60RTEC NC/CRT06
consensus guidelines. Radiother Oncol, 2003. 69(3): p. 227-36.
3. International Commission on Radiation Units & Measurements, 1.1., ICRU
Report 50: Prescribing, Recording and Reporting Photon Beam Therapy 
1993, International Commission on Radiation Units & Measurements, Inc.
4. International Commission on Radiation Units & Measurements, I.I., ICRU
Report 62: Prescribing, Recording and Reporting Photon Beam Therapy 
[Supplement to ICRU Report 50) 1999, International Commission on 
Radiation Units & Measurements, Inc.
5. van Herk, M., et al.. The probability o f correct target dosage: dose- 
population histograms fo r  deriving treatment margins in radiotherapy. Int J 
Radiat Oncol Biol Phys, 2000.47(4): p. 1121-35.
6. Gupta, T., et al.. Assessment o f three-dimensional set-up errors in 
conventional head and neck radiotherapy using electronic porta l imaging 
device. Radiat Oncol, 2007. 2: p. 44.
7. Li, H., et al.. Comparison o f 2D radiographic images and 3D cone beam 
computed tomoprop/^ /o r posftzonmp heod-ond-neck rod/otheropy 
patients. In t J Radiat Oncol Biol Phys, 2008. 71(3): p. 916-25.
8. Pehlivan, B., et al., /nter^octzono/ set-up errors evu/uotzou hy duz/y 
electronic portal imaging o f IMRT in head and neck cancer patients. Acta 
Oncol, 2009.48(3): p. 440-5.
9. Wang, J., et al.. The clinical feasibility and e ffect o f online cone beam 
computer tomography-guided intensity-modulated radiotherapy fo r  
nasopharyngeal cancer. Radiother Oncol, 2009. 90(2): p. 221-7.
10. Velec, M., et al., Cone-beam CT assessment o f interfraction and intrafraction 
setup error o f two head-and-neck cancer thermoplastic masks. In t J Radiat 
Oncol Biol Phys, 2010. 76(3): p. 949-55.
183
11. Den, R.B., et al., Daily image guidance with cone-beam computed 
tomography fo r  head-and-neck cancer intensity-modulated radiotherapy: a 
prospective study. Int J Radiat Oncol Biol Phys, 2010. 76(5): p. 1353-9.
12. Stroom, J.C., et al., /nc/us/on p/ peometn'co/ uncertomt/es m rod/otheropy 
treatment p/unnmp hy means eoverape prohahdzty. Int J Radiat Oncol 
Biol Phys, 1999.43(4): p. 905-19.
13. Tome, W.A. and J.F. Fowler, On cold spots in tumor subvolumes. Med Phys, 
2002. 29(7): p. 1590-8.
14. Hong, T.S., et al.. The zmpact daz/y setzzp varzatzozzs ozi head-and-zzeck 
intensity-modulated radiation therapy. In t J Radiat Oncol Biol Phys, 2005. 
61(3): p. 779-88.
15. The Royal College of Radiologists, Institute of Physics and Engineering in 
Medicine, ed. On tnrpet; enszzrznp peometrze accuracy zn radzotherapy. 
2008, London: The Royal College of Radiologists.
16. Zeidan, O.A., et al.. Evaluation o f image-guidance protocols in the treatment 
o f head and neck cancers. In t ]  Radiat Oncol Biol Phys, 2007. 67(3): p. 670-
7.
17. Kan, M.W., et al.. Radiation dose from  cone beam computed tomography fo r  
image-guided radiation therapy. In t J Radiat Oncol Biol Phys, 2008. 70(1): 
p. 272-9.
18. ICRP, ICRP 60. Recommendations o f the International Commission o f 
Radzo/opzca/ Protectzon. 1991.
19. ICRP, The 2007 Recommendations o f the International Commission on 
Radiological Protection. Publication 103. Annals of ICRP, 2007. 37: p. 1- 
332.
20. Cheng, H.C., et al.. Evaluation o f radiation dose and image quality fo r  the 
Varian cone beam computed tomography system. Int J Radiat Oncol Biol 
Phys, 2011.80(1): p. 291-300.
21. Chen, A.M., et al. Evaluation o f the planning target volume in the treatment 
o f head and neck cancer with intensity-modulated radiotherapy: what is the 
appropriate expansion margin in the setting o f daily image guidance? Int J 
Radiat Oncol Biol Phys, 2011. 81(4): p. 943-9.
184
Chapter 5: Volum etric and dosimetric verification using cone beam  
computed tom ography (CBCT) in image-guided intensity m odulated  
radiotherapy (IG-IMRT) to  head and neck cancers (HNC)
A prospective p ilo t study was designed to evaluate the potential of image guided 
intensity modulated radiotherapy (IG-IMRT) using cone beam computed 
tomography (CBCT) to improve local tumour control and reduce side effects in 
patients w ith  head and neck cancer (HNC). Following Research Ethics 
Committee approval, twenty patients w ith  HNC who were to be treated w ith  
radical IG-IMRT were enrolled into the study. Daily online verification was 
performed using CBCT. Once each patient had completed a course o f IG-IMRT, 
the CBCT images were imported into the treatment planning system (TPS). The 
contralateral parotid gland was contoured on the CBCT scans from the firs t and 
final week of treatment by a single observer. The delivered treatment plan was 
recalculated and dose statistics for the contralateral parotid gland were 
recorded. The aim of this study was to evaluate how IG-IMRT using CBCT could 
be used to guide adaptive radiotherapy strategies in this department.
5.1. Objective of study
To evaluate the impact of variation in volume and dose to the contralateral
parotid gland during a course of image-guided intensity modulated radiotherapy 
(IG-IMRT) using cone beam computed tomography (CBCT).
5.2.IVIethodology
5.2.1. Patients
This study received Research Ethics Committee approval p rio r to the prospective 
collection of all patient data. Twenty patients w ith  histologically confirmed 
squamous cell carcinoma of the head and neck (HNSCC) who were to be treated 
w ith  IMRT w ith  curative intent were entered into the study. Patient recruitment 
was carried out during the period of June 2009 to July 2010, at St Luke's Cancer 
Centre, Royal Surrey County Hospital, Guildford, UK. Eligible patients were 
prospectively identified through the weekly Head and Neck M ultidisciplinary
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Meeting (MDM). IMRT was delivered w ith  a Varian linear accelerator w ith  
integrated On-Board Imager OBI (Varian Medical Systems, Palo Alto, CA).
5.2.2. Radiotherapy planning procedure
IMRT planning was performed as previously described in Chapter 4.
5.2.3. Image guidance
All patients were treated on the same dedicated research linear accelerator
(linac) fitted with an On-Board Imager (OBI) system (On-Board Imager, Varian 
Medical Systems, Inc., Palo Alto, CA). The OBI system comprised a kilovoltage 
(kV) source and an opposing silicon flat-panel detector mounted perpendicularly 
to the treatment beam axis. The flat-panel detector enabled the generation of 
either orthogonal 2-dimensional (2D) electronic portal images (EPls) or 3- 
dimensional (3D) cone beam computed tomography scans (CBCTs). Patients 
were imaged on a daily basis.
5.2.3.1. Cone Beam Computed Tomography
Following positioning of the patient on the treatment couch, the OBI system was
set to CBCT acquisition mode, following which the gantry rotated, acquiring a 
continuous series of kV images which were reconstructed to produce a 3D CBCT 
scan. The following parameters were used for acquisition of the CBCT scan: kVp, 
lOOkV; nominal milliamperes per frame, 20mA; nominal milliseconds, 20mS and 
total rotation angle, 200°.
5.2.3.2. Online 3D image verification
Online matching and correction using CBCT imaging was performed daily as
described in Chapter 4. A m inimum action level of 1mm was used, for corrections 
in all three directions of vertical (anterior-posterior), longitudinal (superior- 
in ferior) and lateral (right-left) directions. Floor rotation was assessed and 
corrected with a minimum action level of 1 degree.
5.2.4. On-treatment assessment
Patients were weighed on a weekly basis during treatment.
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5.2.5. Evaluation of contralateral parotid gland changes
5.2.5.1. Delineation of contralateral parotid gland
The CBCT scans were co-registered to the planning CT scans and imported into
the treatment planning system (Eclipse version 8.2, Varian Medical Systems, Palo 
Alto, CA) where a single observer contoured the contralateral parotid gland on 
the CBCT scans from the firs t and final week of treatment (Figure 5.1). For each 
patient, potentially a maximum total of ten CBCT scans were available for 
contouring from each fraction of daily treatment -  on a Monday to Friday basis - 
during week one and week six of treatment. In order to assess for intraobserver 
variability, the contralateral parotid gland was contoured on the same CBCT scan 
on ten separate occasions for one patient. On each occasion, the observer was 
blinded to the previous contours to reduce bias. Volumetric data was recorded.
Figure 5.1. Contralateral parotid contoured on: (a) contrast-enhanced 
planning CT scan (dark cyan) and on (b) CBCT scan (magenta).
5.2.5.2. Calculation of delivered dose
The clinical delivered IMRT treatment plan was set up on each CBCT dataset. If a
shift had been applied to correct for setup error, the registered isocentre on that 
day's corresponding CBCT scan was also shifted to simulate the delivered 
treatment. The plan was then recalculated. Dose statistics and dose volume
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histogram (DVH) data for the contralateral parotid gland were recorded (Figure 
5.2). The prescription entered into the TPS was the total dose for the six week 
course of treatment (65Gy in 30 fractions to the PTVl). This was to facilitate 
comparison w ith  standard dose tolerance of the parotid gland, which is most 
commonly considered in terms of total dose received across an entire treatment 
course, for example, a total tolerance dose of '24Gy' rather than as dose per 
individual fraction. In other words, 'week one' data for the contralateral parotid 
gland mean dose represented the total dose across a th ir ty  fraction course of 
treatment, based on the contralateral parotid gland contoured on the week one 
CBCT. This process was then repeated for the CBCT scans acquired during the 
final week of treatment.
Figure 5.2. Combination plan view of isodose coverage in axial dimension 
and DVH for recontoured contralateral parotid gland for Patient 15.
For the DVH analysis, cumulative DVHs were exported from the treatment 
planning system in csv (comma-separated-value) format. The DVHs were 
expressed in percentage of dose and volume, in 0.1% increments for both 
parameters. They were then imported into a Microsoft Excel spreadsheet and
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arranged side by side for each patient and grouped according to 'F irst week' or 
'Final week' category. Volume data for each dose increment was then averaged 
for either the firs t or final week o f treatm ent This produced two averaged DVHs 
per patient: one averaged DVH for the firs t week and another for the final week 
of treatment.
These summary DVHs were then compared by subtracting the average volume 
data from the firs t week from the average volume data from the final week, at 
each 0.1% dose increment, for each patient This produced a 'difference' DVH -  
where the difference in volume between the two averaged weekly DVHs was 
plotted against dose. The difference DVHs were then displayed as curves which 
provided visual means of comparing DVHs between the two time points in 
treatment [as depicted in figure 5.7).
5.2.5.3. Radiobiological modelling
BioSuite 8, a radiobiological software package, was used to generate estimates of
tumour control probability [TCP) and normal tissue complication probability 
[NTCP) for the contralateral parotid gland in terms of late xerostomia, defined as 
a reduction o f 25% or more in stimulated individual parotid salivary flow. 
Biosuite 8 is an updated version of Bioplan, an earlier version of a radiobiological 
software package developed by the same research group [1, 2]. For NTCP 
modelling, the Lyman-Kutcher-Burman model was used. A literature search was 
performed to obtain the parameters for late xerostomia required for NTCP 
modelling as shown below in Table 5.1 [3]. The definition of late xerostomia was 
defined as a reduction in stimulated individual parotid gland flow rates of 25% 
at one year following radiotherapy.
Table 5.1. NTCP parameters for late xerostomia.
Parameter Late xerostomia
m (slope) 0.4
TD50 39.9Gy
n (volume effect) 1
alpha/beta 3
m, steepness of curve; TD50, uniform dose leading to 50% complication 
probability
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5.2.6. Statistical analysis
Student’s two-tailed t-test was performed to evaluate the significance of the
differences in volumetric and dosimetric changes between the contralateral 
parotid glands in the firs t and final weeks of treatment.
5.3. Results
5.3.1. Patients
Twenty eligible patients were recruited for study participation and treated 
between June 2009 and August 2010. Data was collected prospectively. Patient 
characteristics are as shown in Table 5.2.
Table 5.2. Patient characteristics.
Patient
no.
Gender Age
(years)
TNM Primary
site
Histology Concomitant
platinum
chemotherapy
1 Male 69 T2N2b Scalp see No
2 Female 63 T2N2b OPX sec Yes
3 Female 39 T0N2b UKP sec No
4 Male 54 T0N2b UKP sec Yes
5 Male 60 T2N1 LNX sec Yes
6 Male 59 T0N2b UKP sec Yes
7 Male 61 T4bNl OPX sec Yes
8 Male 59 T2N2b OPX sec Yes
9 Male 65 T3N0 OPX sec Yes
10 Male 54 T2N2c OPX sec Yes
11 Male 62 TlN2b OPX sec Yes
12 Male 58 T2N2b OPX see Yes
13 Male 72 T4aN2c OPX sec Yes
14 Male 52 TlN2b OPX sec Yes
15 Male 62 T4N1 OPX sec Yes
16 Male 52 T4N2b HPX sec Yes
17 Male 70 T4N2b OPX sec Yes
18 Female 44 T4N1 OPX see Yes
19 Female 47 T4N2b OPX sec Yes
20 Male 66 T4aN2b OPX sec Yes
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Abbreviations used in Table 5.2: OPX, oropharynx; UKP, unknown primary of 
head and neck origin; LNX, larynx; HPX, hypopharynx; SCC, squamous cell 
carcinoma
5.3.2. Intraobserver variability
The CBCT scan for one particular patient (Patient 13) was selected as
representative of showing typical soft tissue definition across all the available 
CBCT scans. The contralateral parotid gland was then contoured on ten separate 
occasions by the same observer. The median difference in volume from the mean 
was 0.37%, with a 95% confidence interval o f-5.15% to 5.15%, with a p value of 
0.2310. These results indicated consistency within the observer’s contouring 
technique.
5.3.3. Volumetric analysis
Each of the twenty patients potentially had five daily CBCT scans from the first
week and five daily CBCT scans from the final week of treatment available for 
evaluation of the contralateral parotid gland. The maximum total number of 
scans potentially available for recontouring and recalculation would have been 
two hundred. However, a variety of issues were identified including breakdown 
of the data transfer link between OBI linac and data storage, flickering in couch 
position of sub-millimetre or sub-degree magnitude leading to misalignment of a 
small number of voxels which resulted in an inab ility  to recalculate dosimetry, 
and practical issues such as routine machine service necessitating treatment on a 
non-OBI-fitted linac, all of which contributed to a reduced number o f suitable 
CBCT scans for recontouring and recalculation purposes.
For the volumetric analysis, all the scans for one patient had data processing 
problems and therefore this patient was excluded from the analysis. A total of 62 
CBCT scans collected during the firs t week of treatment for the remaining 
nineteen patients were subjected to recontouring, w ith  65 CBCT scans evaluated 
from the final week of treatment for the same patients, making a sum total of 127 
CBCT scans included in the analysis.
Each patient's body weight was recorded weekly during treatment. The average 
change in weight between the final and the firs t week was -4.4% (median -5.1%, 
range -10.2 to +3.7). Only three patients (Patient 2, weight gain of 0.8%, Patient
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11 (3.7% gain] and Patient 15 (2.0% gain)) experienced modest weight gain 
during treatment.
Table 5.3. Volum etric data for contralateral parotid  gland for each patient.
Median (range) contralateral 
parotid gland volume
Difference 
(Final week - First week)
(tient n First week n Final week Absolute
(cm3)
% Weight
change
1 5 33.6 cm3 
(29.2-34.6)
1 30.8 cm3 
(30.8-30.8)
-2.8 -8.3% -5.7%
2 3 20.6 cm3 
(17.0-21.5)
4 18.2 cm3 
(17.6-18.5)
-2.5 -11.9% +0.8%
3 4 13.8 cm3 
(13.2-14.3)
3 10.8 cm3 
(10.3-12.3)
-3.0 -21.9% -8.8%
4 3 28.3 cm3 
(24.8-31.6)
4 24.2 cm3 
(23.7-25.1)
-4.2 -14.7% -9.1%
5 3 37.2 cm3 
(35.4-40.9)
2 30.9 cm3 
(30.8-30.9)
-6.4 -17.1% -1.6%
6 4 33.3 cm3 
(30.5-35.4)
5 27.8 cm3 
(25.1-29.3)
-5.5 -16.5% -5.2%
7 3 39.9 cm3 
(39.3-40.1)
2 37.3 cm3 
(37.2-37.5)
-2.5 -6.3% -2.3%
8 4 48.5 cm3 
(48.3-50.7)
4 46.9 cm3 
(44.6-48.5)
-1.7 -3.4% -6.2%
9 2 29.2 cm3 
(28.0-30.3)
3 23.6 cm3 
(21.7-23.8)
-5.6 -19.3% -2.9%
10 3 32.2 cm3 
(31.3-35.5)
2 29.1 cm3 
(27.6-30.6)
-3.1 -9.5% -3.5%
11 1 22.3 cm3 
(22.3-22.3)
2 19.7 cm3 
(18.3-21.1)
-2.6 -11.7% +3.7%
12 3 26.6 cm3 
(23.9-28.8)
3 23.2 cm3 
(21.7-23.4)
-3.3 -12.5% -9.5%
13 3 38.0 cm3 
(29.0-40.9)
2 33.2 cm3 
(32.7-33.6)
-4.8 -12.8% -3.0%
14 0 na 0 na na na Na
15 1 20.2 cm3 
(20.2-20.2)
5 16.2 cm3 
(14.0-16.7)
-4.1 -20.0% +2.0%
16 2 25.8 cm3 
(24.0-27.5)
4 16.0 cm3 
(14.5-17.8)
-9.8 -37.9% -10.2%
17 4 20.3 cm3 
(18.1-23.1)
5 20.3 cm3 
(19.0-22.7)
0.0 -0.2% -4.9%
18 4 13.4 cm3 
(12.7-14.7)
5 10.9 cm3 
(10.7-11.1)
-2.4 -18.3% -6.9%
19 5 12.9 cm3 
(12.1-14.1)
5 10.8 cm3 
(10.1-12.0)
-2.1 -16.2% -3.1%
20 5 32.2 cm3 
(31.9-34.7)
4 28.1 cm3 
(27.2-30.6)
-4.1 -12.7% -5.9%
n, number of CBCT scans available for analysis; na, data not available
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Figure 5.3. Median volume of contralateral parotid gland in first versus 
final week of IG-IMRT for nineteen patients.
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As demonstrated in Figure 5.3, all nineteen patients except one patient [Patient 
17, overall no change noted after contouring nine CBCT scans] experienced 
shrinkage of the contralateral parotid gland o f up to 37.9%. The mean absolute 
difference in contralateral parotid gland volume was -3.7cm^, in other words, 
mean gland shrinkage of 3.7cm^. The standard deviation was Z .llcm ^, standard 
error, 0.48 w ith  a 95% confidence interval of [-4.73 cm^ to -2.69 cm^]. Student’s 
two-tailed paired t-test indicated that this shrinkage was strongly statistically 
significant, w ith  a two-tailed p-value of <0.0001.
The mean absolute difference in contralateral parotid gland volume [-3.7cm^] 
translated into a mean proportional change of -14.28%. The standard deviation 
was 8.04% w ith  a 95% confidence interval of [-18.16% to -10.41%).
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5 .3 .3 .1 . Effect o f w eight loss on contralateral parotid  gland  
volum e
Nine patients were noted to have lost 5% or greater of body weight between the 
firs t and final week of treatment [median -6.90%, range -10.21% to -5.24%). For 
these patients, the mean proportional change in contralateral parotid gland 
volume was -16.26%, w ith  a standard deviation of 9.74% and 95% confidence 
interval of [-23.75% to -8.77%). These results did not achieve statistical 
significance [p value of 0.270).
Spearman’s rank correlation coefficient [rho) was also calculated to assess the 
association between proportional volume change and proportional weight 
change for the nineteen patients. No correlation was found [rho 0.16, 95% 
confidence interval -0.32 to 0.57, two-tailed p value of 0.5185).
Patient 16 had a diagnosis of T4N2b SCC of the hypopharynx. This patient lost 
the greatest proportion of body weight over treatment [10.2% reduction) and 
was also found to have the greatest reduction in gland volume of 37.9%.
Median weight change for the ten remaining patients was -2.62% [range-4.87% 
to +3.69%). Mean proportional contralateral parotid gland volume change for 
these patients appeared smaller than for those patients w ith  5% or greater 
weight loss w ith  an average volume change o f -12.50% [95% confidence interval 
o f -16.89% to -8.12%), versus -16.26%, respectively, p value of 0.628). The 
corresponding scatter plot is shown below in Figure 5.4[a).
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Figure 5.4. Scatter plots showing (a) proportional per-treatm ent weight 
change (% ) against proportional change in contralateral parotid gland 
volume (% ) and (b) mean absolute contralateral parotid gland dose (Gy) 
based on the contours and CBCT scans of week one against proportional 
change in contralateral parotid gland volume (% ).
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5.3.3.2. Effect of high contralateral parotid gland mean doses on 
volume
Patients 1, 4, 6, 10, 12, 15, 18, 19 and 20 had median contralateral parotid gland 
mean doses of 30Gy or greater in the firs t week of treatment [Table 5.4). In 
these nine patients, a mean absolute difference of -3.50cm^ [translating to a 
proportional change of -14.31%) was noted between the firs t and final week, 
w ith  a 95% confidence interval of -4.32 to -2.69. This reduction in volume was 
statistically significant, w ith  a two-tailed p value of <0.0001.
Spearman's rank correlation coefficient was calculated to assess the relationship 
between contralateral parotid gland mean dose in the firs t week and 
proportional change in contralateral parotid gland volume between the firs t and 
final weeks of treatment for all nineteen patients. No relationship was found, 
w ith  a rho statistic of -0.22, 95% confidence interval of -0.61 to 0.26 and a two-
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tailed p value of 0.3710. The corresponding scatter p lot is shown above in Figure 
5.4(b).
5.3.4. Dosimetric analysis
5.3 4.1. Contralateral parotid mean dose analysis
In total, 110 CBCT scans (57 scans for the firs t and 53 scans for the final week of
treatment) were available for contouring and recalculation o f IMRT plans for 
eighteen patients. Mean dose for the contralateral parotid gland have been 
reported as total projected dose over the full course of treatment, based on the 
parotid volume recontoured on the CBCT scans of either week 1 or week 6. 
Results for median (range) contralateral parotid gland mean dose are shown in 
Table 5.4 below.
Table 5.4. Median (range) contralateral parotid gland projected total mean 
dose (Gy) for each patient.
Median (range) contralateral parotid  
gland projected total mean dose
Patient First week Final week
Difference in mean 
dose
(Final - First week) 
Absolute %
1 38.8Gy (38.5-39.5) 39.4Gy (39.4-39.4) 0.6Gy 1.5%
2 28.5Gy (27.7-29.3) 24.4Gy (21.9-27.7) -4.1Gy -14.2%
3 26.0Gy (25.3-27.8) 28.3Gy (27.8-28.8) 2.2Gy 8.6%
4 36.3Gy (35.9-40.0) 37.2Gy (31.8-37.3) 0.9Gy 2.4%
6 29.8Gy (29.3-34.0) 27.9Gy (25.2-32.7) -1.9Gy -6.3%
7 22.7Gy (19.4-28.6) 22.7Gy (22.7-22.7) O.OGy 0.0%
8 23.8Gy (22.9-24.4) 25.7Gy (24.8-27.3) 1.9Gy 7.9%
9 27.9Gy (27.9-27.9) 26.9Gy (26.2-27.7) -0.9Gy -3.4%
10 49.2Gy (48.7-49.6) 50.0Gy (49.7-50.3) 0.9Gy 1.7%
11 20.0Gy (20.0-20.0) 19.7Gy (18.6-20.7) -0.3Gy -1.7%
12 32.2Gy (31.1-33.3) 29.8Gy (28.5-31.1) -2.5Gy -7.6%
13 26.3Gy (25.7-26.9) 29.7Gy (28.8-30.7) 3.5Gy 13.1%
15 47.9Gy (47.9-47.9) 45.2Gy (41.1-46.7) -2.6Gy -5.5%
16 29.2Gy (28.7-29.6) 27.8Gy (24.2-30.4) -1.3Gy -4.6%
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17 29.2Gy (26.1-33.2) 30.2Gy (29.0-31.2) l.OGy 3.4%
18 39.9Gy (37.2-41.3) 38.3Gy (37.6-39.0) -1.6Gy -3.9%
19 42.9Gy (41.7-43.9) 42.6Gy (41.6-43.8) -0.3Gy -0.7%
20 40.0Gy (38.8-42.2) 40.7Gy (40.1-41.5) 0.8Gy 2.0%
Mean (range) contralateral parotid gland mean dose was 32.8Gy (20.0 to 49.2) in 
the firs t week and 32.6Gy (19.7 to 50.0) in the final week of treatment.
The mean absolute reduction in contralateral parotid gland dose was 0.2Gy, w ith  
the change in mean dose ranging between -4.1Gy and +3.5Gy. This corresponded 
to proportional changes o f -14.2% and +13.1%, respectively and was associated 
w ith  a 95% confidence interval of -1.16Gy to +0.73Gy. These changes were not 
statistically significant (two-tailed Student's t-test p value of 0.6416).
Contralateral parotid gland mean dose data calculated on the original planning 
CT scan IMRT plan was also compared w ith  the median data from the firs t 
week's CBCT scans. The mean difference in mean dose was an increase of 0.12Gy 
for the glands recontoured on CBCT scans compared w ith  those contoured on 
the original planning CT scans, w ith  a 95% confidence interval of -2.41 to 
+2.65Gy. The difference in mean dose was not statistically significant (two-tailed 
p value of 0.9224).
5.3 .4 .I.I. Effect of weight loss on mean contralateral 
parotid gland dose
Nine patients (Patients 1, 3, 4, 6, 8,12, 16, 18 and 20) experienced weight loss of 
at least 5% (see Table 5.3). Changes in median contralateral parotid gland mean
dose for these patients are shown in Figure 5.5. The mean change in dose 
between the final and firs t week of treatment was -O.lGy, 95% confidence 
interval, -1.43Gy to +1.23Gy. Statistical significance was not achieved (p value 
0.8687).
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Figure 5.5. Changes in median contralateral parotid gland mean dose with  
treatment in nine patients experiencing greater than 5% body weight loss.
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Spearman’s rank correlation coefficient rho was -0.15 w ith  a 95% confidence 
interval of -0.58 to 0.34 and a two-tailed p value of 0.5479 for the eighteen 
patients, indicating no relationship between weight loss and change in mean 
dose. The corresponding scatter p lot is shown below in Figure 5.6(a).
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Figure 5.6. Scatter plots showing (a) proportional per-treatm ent weight 
change (% ) against proportional change in contralateral parotid gland 
mean dose (Gy) and (b) mean absolute contralateral parotid gland dose 
(Gy) in week one against proportional change in contralateral parotid 
gland mean dose (%).
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5.3.4.I.2. Effect of high contralateral parotid gland mean 
doses on changes In mean dose
Patients 1, 4, 6, 10, 12,15,18, 19 and 20 had median contralateral parotid gland
mean doses of 30Gy or greater in the first week of treatment (Table 5.4). As seen 
in Section 5.3.3.2., a high mean dose was associated with a statistically significant 
mean reduction of 3.50Gy, or 14.31%, in gland volume. The data for these nine 
patients was also examined to measure the effect on mean dose by the final week 
of treatment. In this aspect, a high parotid gland mean dose in the firs t week had 
no effect on the final week median parotid gland mean dose, w ith  a mean change 
of -0.64Gy and a two-tailed p value of 0.2339.
No relationship was found between parotid mean dose in week one and per- 
treatment proportional changes in mean dose for eighteen patients. Spearman's 
rank correlation coefficient, rho, was -0.20, 95% confidence interval -0.61 to 0.30 
and two-tailed p value 0.4282.
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53.4.2. Contralateral parotid dose volume histogram (DVH) 
analysis
Cumulative dose volume histograms [DVHs] expressed in percentage of dose and 
volume were obtained from the treatment planning system for the contralateral 
parotid gland for each recalculated fraction in the firs t and final week of 
treatment. A total of 110 DVHs were compared, from eighteen patients. Averaged 
DVHs were calculated as described earlier and 'difference DVHs’ -  the difference 
in relative volume at each dose increment - were produced for each patient. The 
resulting 'difference DVH’ curves are shown in Figure 5.7, below.
Figure 5.7. Changes in dose volume histogram (DVH) between the first and 
final week of treatm ent for eighteen patients.
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Figure 5.7 shows for most patients, the changes in DVH were w ith in  -5% and 
+5% of the contralateral gland volume. The m ajority of curves appeared to lie 
w ith in  the negative volume change region (below 0% volume], suggesting a 
trend to a reduction in the contralateral parotid gland volume receiving specified 
incremental doses by the final week of treatment.
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On further inspection of individual 'difference DVH' curves, the 'difference DVH' 
for Patient 8 showed a more striking increase in the volume (around 10% 
volume increase] of contralateral parotid gland receiving approximately 30% 
dose by the final week of treatment. Consequently, the mean contralateral 
parotid gland dose increased by 7.9% (see Table 5.4.). Patient 13 also showed an 
increase in mean contralateral parotid gland mean dose of 13.1%. In contrast, for 
Patient 15, 15% less volume of the gland received 90% dose by the final week of 
treatment.
The corresponding cumulative averaged DVH curves for the firs t and final week 
of radiotherapy for Patients 8 and 15 are shown below in Figure 5.8. For Patient 
8, the final week DVH curve shifts to the right for most of the gland, but the 
portion of the gland receiving approximately 62% or more reduced by the final 
week of treatment, w ith  the DVH curve shifting to the left. In the case of Patient 
15, the entire DVH curve for the final week shifted to the left of the firs t week 
DVH, indicating that all of the gland received less dose in the final week 
compared w ith  the firs t week of treatment.
Figure 5.8. Cumulative DVHs for the contralateral parotid gland in the first 
and final week of treatm ent for Patients 8 and 15.
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5.3.4.2 .I. Effect of weight loss on averaged DVH curves for 
contralateral parotid gland
Nine patients (Patients 1, 3, 4, 6, 8,12, 16, 18 and 20) experienced weight loss of
at least 5% (see Table 5.3). Weight loss of 5% or more did not have a statistically 
significant impact on mean dose to the contralateral parotid, as discussed earlier, 
and as can be seen from Figure 5.9, no obvious impact on the changes in DVH can 
be seen.
Figure 5.9. Changes in dose volume histogram (DVH) curves for patients 
experiencing greater than 5% weight loss (dotted line) and patients with  
less than 5% weight loss (solid line) between the first and final weeks of 
treatment.
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5.3.5. Normal tissue complication probability (NTCP) analysis
Estimations of normal tissue complication probability (NTCP) for late
xerostomia, defined as a 25% or greater reduction in stimulated individual
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parotid salivary flow, generated using Biosuite, a radiobiological software 
package, are shown in Table 5.5.
Table 5.5. NTCP estimations for late xerostomia for the contralateral 
parotid gland.
Median (range) NTCP for late 
xerostomia
Difference in median 
NTCP (Final - First 
week)
Patient First week Final week Absolute %
1 46.6% (45.4-49.0) 48.5% (48.5-48.5) 1.9 4.1%
2 15.6% (14.4-16.7) 10.2% (8.0-14.4) -5.4 -34.7%
3 13.3% (12.2-15.8) 16.6% (15.5-17.7) 3.3 24.8%
4 34.8% (33.9-45.3) 37.3% (24.6-38.2) 2.5 7.2%
6 17.3% (16.9-26.1) 13.3% (11.2-15.1) -4.0 -23.1%
7 9.6% (6.5-17.3) 9.5% (9.5-9.5) -0.1 -1.0%
8 9.9% (9.0-10.6) 11.7% (10.7-13.7) 1.8 18.2%
9 15.9% (15.9-15.9) 14.6% (13.4-15.7) -1.4 -8.5%
10 66.9% (65.6-68.1) 69.5% (68.7-70.2) 2.6 3.9%
11 6.6% (6.6-6.6) 6.6% (5.7-7.4) 0.0 -0.8%
12 24.3% (21.7-26.5) 19.6% (17.1-22.1) -4.7 -19.3%
13 13.6% (12.7-14.4) 19.2% (17.5-20.8) 5.6 4&8%
15 64.7% (64.7-64.7) 56.8% (44.7-60.7) -7.9 -12.2%
16 17.1% (16.4-17.7) 15.5% (10.7-19.4) -1.6 -9.1%
17 20.9% (19.3-23.9) 18.5% (16.3-20.0) -2.4 -11.5%
18 41.1% (34.7-44.5) 37.4% (34.9-39.8) -3.8 -9.1%
19 48.0% (44.4-50.7) 47.3% (44.5-50.5) -0.7 -1.5%
20 41.8% (38.9-48.2) 44.5% (42.3-46.3) 2.7 6.3%
NTCP, normal tissue complication probability
Mean NTCP estimates for late xerostomia were 28.21% (standard deviation 
19.03) and 27.57% (standard deviation 18.93) for the firs t and final weeks of 
treatment, respectively. The average difference in median NTCP between the
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final and firs t week of treatment was -0.64%, w ith  a 95% confidence interval of - 
2.41% to +1.13%. No statistical significance was achieved (two-tailed p value of 
0 .4 5 2 9 ).
5.3.5.1. Effect of high mean dose on estimated NTCP for late 
xerostomia
Nine patients (Patients 1, 4, 6, 10, 12, 15, 18, 19 and 20) had median 
contralateral parotid gland mean doses of 30Gy or greater in the firs t week of 
treatment (Table 5.4). There was no statistically significant impact on estimated 
NTCP for late xerostomia (mean difference, -1.27%, two-tailed p value of 
0 .3 5 3 2 ).
5.4. Discussion
The prim ary objective in the curative treatment of patients w ith  head and neck 
cancer (HNC) using therapeutic radiation is to achieve tum our control whilst 
m inim ising toxicity to the nearby organs at risk (OARs). Several groups have 
investigated the potential of intensity modulated radiotherapy (IMRT) to deliver 
this goal in the setting o f HNC, including two m ulti-institu tional studies which 
have reported high tum our control rates combined with reduced salivary gland 
toxicity [4, 5].
Image guidance and adaptive radiotherapy (ART) are two strategies which have 
the potential to improve outcomes achieved using IMRT. Earlier work reported 
by this student in Chapter 4 demonstrated that image-guided IMRT (IG-IMRT) 
using CBCT imaging can be used to improve the geometric accuracy in delivering 
IMRT in HNC.
The study reported in this chapter aimed to evaluate how IG-IMRT using CBCT 
might be used to improve dosimetric accuracy and quality of treatment. The 
results would inform  potential adaptive radiotherapy (ART) strategies in 
patients w ith  HNC.
Current conventional radiotherapy planning techniques involve designing a 
course of treatment based on a single planning CT dataset -  a 'snapshot' of 
patient anatomy. For the m ajority of patients receiving radical treatment for
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HNC, a typical course of treatment extends over six to seven weeks. Changes in 
patient or tumour anatomy, position, shape or size during treatment -  internal 
patient setup error - cannot specifically be accounted for w ith  this approach. 
Dose gradients in IMRT plans are often steep to achieve required dose coverage 
to target volumes or dose m inimisation to OARS. This strategy is however 
susceptible to internal changes w ith in  the patient or tum our which in turn have 
the potential to impact negatively on the dosimetric quality of an IMRT plan.
ART is a potential solution for the issue of per-treatment changes in patient or 
tumour. Various strategies have been proposed [6], usually involving re­
assessment of soft tissue anatomy by volumetric imaging during treatment and 
then re planning of treatment. A major obstacle to the implementation of this 
strategy is the considerable impact on resources in terms of staff time and 
expertise, additional scanning requirement and patient impact. It is therefore 
im portant to evaluate which patients might be predicted to benefit most from 
this strategy and also the potential gains in terms of tum our control or reduction 
in normal tissue complications.
This study evaluated the potential of CBCT imaging to identify anatomical change 
leading to volumetric and dosimetric variation during treatment. The results 
provided an opportunity to identify potential factors which might highlight 
which patients would be most like ly to benefit from adaptive planning strategies.
5.4.1. Volumetric changes
Several groups have evaluated changes in target volumes (TVs) and OARs during
treatment for HNC. Modes of per-treatment imaging include repeat diagnostic kV 
CT, both w ith  or w ithout contrast [7-9], in-room kV CT [10,11], and MV CT using 
Helical Tomotherapy [9, 12]. Published findings have been summarised below in 
Table 5.6.
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Table 5.6. Reported per-treatment volumetric changes in target volume 
and OAR structures in the literature.
Author n Concom Weight 
chemo change
Imaging Structure Volumetric
change
Barker 14 12 -7.10% kVCTin-room GTV -70%
et al Parotid Median -
[10] 28.1% 
(range -5.9 
to -53.6%]
Hansen 13 13 -4.0 to kVCTdlag Defined external -6.40%
et al -14.0% skin surface
[7] volume 
Parotid - right 
Parotid - left 
PTV-GTV 
PTV-CTV
-15.6% 
-21.5% 
+ 11.6% 
-7.5%
Bhide 20 20 na kVCTdiag Parotid - ipsilat —38.0% by
et al week 5
[8] Parotid - contralat —30.0% by 
week 5
Broggi 54 67 -8.0% MVCT Parotid -26.0%
et al (median)
[9] 33 kVCTdiag
Lei 19 18 -5.10% kV CBCT Parotid - contralat Mean - 
14.3%
;-3
...^
(range - 
37.9% to -
j'liS
02%d
n, number of patients; concom chemo, concomitant chemotherapy; na, not 
available; kV, kilovoltage, CT, computed tomography, CTdiag, diagnostic CT; MV, 
megavoltage, GTV, gross tumour volume; CTV, clinical target volume; PTV, 
planning target volume; ipsilat, ipsilateral; contralat, contralateral; grey highlight 
region, student's own data.
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Results from this student's study [highlighted in grey) appear comparable with 
published literature. The m ajority of patients received concomitant 
chemotherapy and all patients experienced weight loss ranging between a 
reduction of 4% and 14% compared w ith  baseline during treatment.
W ith respect to the parotid gland, details of la terality were not always reported 
but all groups reported mean or median reductions in parotid volume ranging 
14.3% to 38%.
In this study, the contralateral parotid gland was shown to undergo an average 
of 14.3% reduction in volume by the final week of treatment. Recommended 
mean dose constraints for the parotid gland to minimise the risk of late 
xerostomia are 26Gy to 30Gy [3, 4,13]. Wherever possible, parotid-sparing IMRT 
was performed in these patients and therefore the contralateral gland was of 
clinical interest, w h ilst the ipsilateral parotid gland nearly always received a 
mean dose exceeding 30Gy. Volumetric data for the ipsilateral parotid gland was 
not collected for all patients in this study and are not reported here. Such data 
might have been of interest to compare w ith  published data, which in most cases 
did not differentiate between ipsi- and contralaterality. Bhide et al showed that 
the ipsilateral parotid undergoes greater shrinkage (38%) than the contralateral 
parotid (30%), suggesting that possible volumetric changes in the ipsilateral 
parotid gland might have shown greater reductions than for the contralateral 
gland. Although results from this study suggest a smaller reduction in volume 
than in the w ork reported by Bhide et al, reported parotid volume shrinkage 
from the other groups was also smaller and ranged 15.6% to 28.1%.
Per-treatment weight loss is commonly observed during a course of 
chemoradiation for HNC. In this study, weight loss did not have a significant 
effect on parotid volume changes during treatment.
Finally, in this study, 127 CBCT scans performed during the firs t and final weeks 
of treatment for nineteen patients were evaluated. The number of scans 
evaluated contributes to the robustness of the data. Up to five CBCT scans were 
evaluated for each of the firs t and final week of treatment. In contrast, in most of
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the reported literature, per-treatment imaging was performed only once per 
week.
5.4.2. Dosimetric changes
In this study, no statistically significant dosimetric changes were demonstrated
between the firs t and final weeks of treatment. Weight loss and starting mean 
dose of contralateral parotid gland did not show any correlation w ith  dose 
changes during treatment. The absolute mean change in contralateral gland 
mean dose was -0.2Gy [range -4.1Gy to +3.5Gy]. These results appear 
comparable w ith  those published in the literature [Table 5.7).
Table 5.7. Reported per-treatm ent dosimetric changes in target volume 
and OAR structures in the literature.
Author n Concom Weight Imaging Structure Dosimetric change
Hansen 13 13 -4  to kVCTdiag Parotid right Mean dose: -0.6Gy
et al [7] -14% [-3.9%), V26: +10.9%
Parotid left Mean dose: -3.1Gy
[-2 0 .4 % ), V26: -3.0%
PTV-GTV V93%: 92.5% in 2nd
CT vs. 99.5% in
original plan
PTV-CTV V93%: 90.5% in 2nd
CT vs. 98.7% in
original plan
O'Daniel 11 na na kVCTin- Parotid - Mean dose +3.0Gy
et al [11] room ipsilat
Parotid - Mean dose +1.0Gy
contralat
GTV No change
CTV- high No change
dose
Lee et al 10 10 na MVCT Parotid Daily mean dose
[12] change: +15%
Bhide et 20 20 na kVCTdiag Parotid - Mean dose +2.8Gy
al [8] ipsilat [+7.3%)
Parotid - Mean dose +1.0Gy
contralat [+4.1%)
Lei 18 18 -5 .10%  kV CBCT Parotid - Mean -0.2Gy (range
contralat -4.1Gy to +3.5Gy),
corresponding to
proportional mean
change -0.4% (range
-14.2% to +13.1%)
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Abbreviations for Table 5.7.: n, number of patients; concom chemo, concomitant 
chemotherapy; na, not available; kV, kilovoltage, CT, computed tomography, 
CTdiag, diagnostic CT; MV, megavoltage, GTV, gross tum our volume; CTV, clinical 
target volume; PTV, planning target volume; ipsilat, ipsilateral; contralat, 
contralateral; grey highlight region, student's own data.
Changes in parotid gland mean dose in the literature do not show great 
consistency. Three of the five groups reported increases in mean dose, two of 
whom performed kV CT and found increases ranging between 2.8Gy and S.OGy 
for the ipsilateral parotid gland[8, 12] and an increase o f l.OGy in mean 
contralateral parotid gland dose. Another group performed a study using MVCT 
(Helical Tomotherapy] and reported an increase in mean dose of 15% at the end 
of treatment. However, only ten patients were assessed and differences in soft 
tissue contrast between MV imaging and kV imaging may be a factor. In contrast, 
Hansen et al reported reductions in mean dose of 0.6Gy and S.lGy for the right 
and left parotid glands, respectively.
In this study, the average change in mean dose was small (-0.2Gy) w ith  a 95% 
confidence interval of -1.16Gy to +0.73Gy. These results were based on 110 
CBCT scans, providing some robustness to the data. A 'real-time' picture of dose 
was estimated by applying that day's recorded setup corrections to 
corresponding shifts of the plan isocentre on the CBCT scan. The student 
calculated estimated normal tissue complication probabilities (NTCP) for late 
xerostomia to evaluate the possible relevance of dosimetric change in the 
contralateral parotid gland. Overall, no significant difference was noted. The 
average difference in median NTCP between the final and firs t week of treatment 
was small (-0.64%), with a 95% confidence interval of -2.41% to +1.13%. This 
suggests that although changes in the parotid gland are noted during treatment, 
such changes may not be associated w ith  a change in the rate of late xerostomia.
The DVH analysis in Section 5.3.4.2 included averaged 'difference DVHs' for 18 
patients. Patients 8 and 13 showed increases in dose and volume, whilst Patient 
15 -  and also Patient 2 -  showed reductions in dose and volume. Interestingly, 
volumetric parotid gland data and patient weight change, as reported in Table
5.3, showed that the increase in dose and volume for both Patients 8 and 13
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appeared to correspond w ith  reductions in median gland volume and reductions 
in patient body weight over the course of treatment. More specifically, median 
contralateral parotid gland volume changes for Patients 8 and 13 were -3.4% 
and -12.8%, respectively, w ith  body weight changes o f -6.2% for Patient 8 and - 
3.0% for Patient 13. The contralateral parotid gland for Patient 8 shrank less 
(3.4%) than the reported mean contralateral parotid gland shrinkage of 14.28% 
and was also the largest gland contoured of all twenty patients (median absolute 
volume 48.5cm^ in week 1 of treatment compared w ith  46.9cm^ by the final 
week). However, the weight change of -6.2% for Patient 8 was greater than the 
mean weight change for the population of 20 patients (mean change -4.1%, 
range -10.2% to +3.1%). This may suggest that the greater than average weight 
loss seen in this patient may have been associated w ith  a reduction in soft tissue 
in the head and neck region w hilst the parotid gland retained the bulk of its 
volume, hence receiving an increased dose due to reduced beam attenuation.
Similarly, but to a lesser extent. Patient 13’s gland shrank by 12.8%, also less 
than the average gland shrinkage (14.28%). Although the contralateral parotid 
gland for Patient 13 was not as large as Patient 8's gland, the median absolute 
gland volume for Patient 13 in week 1 was 38.0cm^ and reduced to 33.2cm^ in 
the final week, in other words, it  was s till one of the larger glands contoured. 
The weight change for Patient 13 was -3.0% which was closer to the population 
mean (-4.1%). It is perhaps more difficult to infer the reason for the increase in 
difference DVH and this highlights one of the weaknesses of averaging DVH 
statistics and producing 'difference DVHs'. Unless there is a strong trend -  and 
even i f  there is -  in DVH curves for a patient, the detail regarding which part of 
each contoured gland volume receives a specified dose is blurred and lost. In this 
patient's case, examining the 3-dimensional (3-D) dose distributions (axial, 
coronal and sagittal viewing) for each gland contoured and for each treatment 
fraction, each delivered at different timepoints may potentially reveal the 
mechanism as to how this occurred: one possible explanation could be that 
although there was shrinkage of 12.8% w ithout large body weight reduction 
(which in turn  may infer less change in beam attenuation), that the parotid gland 
may have contracted in a medial direction, thus moving closer to the high dose 
target volume and receiving an increase in dose. Examining the individual DVH
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curves for each treatment fraction, rather than the averaged 'difference DVH' 
curves, would also be valuable.
In contrast, for Patient 15, approximately fifteen per cent less volume of the 
contralateral parotid gland received approximately ninety per cent of the dose 
by the final week of treatment. The mean dose reduced by 5.5% (Table 5.4). The 
median volume of the gland decreased by 20.0% (population average shrinkage 
14.28%) and Patient 15 was one of only 3 patients who gained weight during 
treatment, w ith  a weight gain of 2.0% by the final week (Table 5.3). The mean 
gland dose for Patient 2 reduced even more (14.2%) but w ith  a more modest 
shrinkage of gland (11.9%) and was associated w ith  weight gain of just 0.8% 
(although Patient 2 was also one of the only 3 patients to gain weight during 
treatment). As above, examination of the 3-D dose distribution and individual 
DVH curves would be useful and may show contraction of the parotid gland 
towards the contralateral side, away from the region of high dose target volume.
5.4.3. kV CBCT as a substitute for standard diagnostic contrast
enhanced kV CBCT
Radiotherapy planning for treatment to HNC requires a diagnostic contrast 
enhanced kV CT as standard. Repeating this form of imaging during treatment 
adds cost in terms of additional dose, staff, resource and patient time which are 
im portant issues in the running of a busy clinical department.
5.4.3.1. Image quality
The image quality o f CBCT imaging and suitab ility of the data for dose calculation
are issues that are yet to be resolved. In this study, it  was noted that the image 
quality of CBCT scans varied from fraction to fraction, for each patient. Figure 10 
shows an example o f the quality and variab ility of CBCT imaging w ith in  the same 
patient. Figure 10(b) was taken from a CBCT performed on the firs t day of 
treatment. W hilst the image quality is in ferio r to the diagnostic contrast 
enhanced CT (Figure 10(a)), structures can be seen w ith  definition between 
tissue planes. Two days later, however, the CBCT image quality has deteriorated 
(Figure 5.10 (c)), w ith  poor tissue definition and increased streak artefact. A 
formal evaluation of image quality and imaging parameters is currently being
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performed by radiation physicists in this department but one potential factor 
that has been identified is the relationship of image quality to the time of day at 
which the CBCT is performed, suggesting that the warm-up period for the 
machine may need to be increased p rio r to performing CBCT for this purpose.
Figure 5.10. Transverse, coronal and sagittal views in the same plane 
showing parotid glands for Patient 13. (a) Diagnostic contrast enhanced 
planning CT, (b) kV CBCT taken on fraction one, (c) kV CBCT taken on 
fraction three of treatment.
Aside from the variab ility  in image quality, it  was found that the contrast in soft 
tissue was not sufficient for reliable identification of target volume structures. It 
was frequently d ifficu lt to identify even large nodal masses and this is a 
lim itation of CBCT for direct replanning strategies. Another lim ita tion is the issue 
of missing data. Imaging modes for the OBI include a head scan mode which has 
been optimised to image this region and was used in this study. Nodal volumes in 
HNC typically extend down both sides of the neck, to below the level of the 
clavicles. Unfortunately, the head scan mode is not optimised for imaging regions 
w ith in  the most in ferior part of the neck or infraclavicular region, as 
demonstrated in Figures 5.10(a) and (b). Manual contouring and bulk override 
approaches can account for this but are labour intensive and prone to added 
uncertainties. When clinically indicated due to uncertainty regarding setup in the 
lower neck, CBCT imaging of the lower neck was performed in addition to a head
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scan, using the thorax imaging mode. This provided reasonable image quality 
w ith in  this region. Digital 'stitching' of the two imaged regions was attempted 
using in-house software to produce one continuous anatomically imaged region 
but could not be successfully imported back into the treatment planning system 
due to manufacturer restrictions.
5.4.3.2. Dose calculation
Mean doses to the recontoured contralateral parotid were calculated on CBCT data
using an appropriate calibration curve in the TPS [14] and were compared with original 
mean doses calculated on the original contrast enhanced diagnostic CT. There was no 
statistically significant difference. Lee et al performed a dose reconstruction study on 
five patients with HNC who underwent serial CBCT imaging during a course of 
radiotherapy [15]. The original IMRT plan was reconstructed on corresponding CBCT 
scans. The reconstructed dose distribution, dosimetric endpoints and DVHs were then 
compared with the IMRT treatment plan. The authors reported that for most treatment 
sessions, the CBCT-based dose reconstructions yielded DVHs of the target that were 
within 3% to that of the original treatment plan. The conclusion was that dosimetric re- 
evaluations of treatment could be made using per-treatment CBCT imaging to inform 
decisions about the necessity for re-planning. A similar study was performed by Ding et 
al involving both patient and phantom subjects [16]. The authors also reported that 
target and OAR doses recalculated on CBCT images agreed within 1-3% with those 
calculated on planning CT images.
5.5. Conclusion
IG-IMRT using CBCT can inform  on volumetric and dosimetric variation during 
treatment and may be used to improve dosimetric accuracy and quality of 
treatment by early detection of these changes. Despite poor image quality of the 
CBCT scans, parotid gland delineation was performed w ith  little  intraobserver 
variab ility  and a high degree of clinical confidence. This study shows that there 
are changes in volume that translate into changes in dosimetry. These changes, 
however, are small and do not translate into significant changes of NTCP. It is 
highly unlikely that these would translate into a clinically significant difference 
and therefore mean parotid dose on the planning CT scan remains a good 
predictor of salivary function outcome.
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The current image quality and length of patient anatomical imaging w ith in  one 
CBCT scan appears suboptimal for replanning purposes alone and remains an 
unresolved issue at the present time. The w ork performed w ill serve as a 
platform for further w ork which would ideally investigate changes on a weekly 
basis during treatment to identify changes in other parameters such as spinal 
cord dose changes and anatomical changes such as patient thickness. This 
information may in turn  provide guidance in identifying in advance those 
patients who may require replanning strategies.
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Chapter 6: Summary and conclusions
6.1. Summary of introduction and aims of thesis
A radiation dose-response relationship has been demonstrated for HNSCC.
Radical radiotherapy can cure early stage HNSCC but for locally advanced 
disease, locoregional failure is common. The site of failure frequently occurs 
w ith in  the high dose target volume. This suggests that current approaches to 
delineating the high dose target volume are reasonable and also suggests the 
existence of a population of relatively radioresistant tum our cells in this region. 
Various strategies to widen the therapeutic window include the addition of 
radiosensitisers and the application of modified fractionation.
Until recently, radiation dose escalation using conventional radiotherapy 
techniques has been lim ited due to the risks of increased normal tissue toxicity. 
IMRT offers an opportunity to deliver increased doses o f radiation to specified 
tumour subvolumes w h ilst maintaining or even reducing the doses received by 
surrounding tissues. This technique has been termed dose-painting w ith  IMRT.
Various strategies have been explored to inform  on the optimal method of 
identifying a dose-painting target. PET imaging may be an ideal tool to evaluate 
for this purpose. PET is w idely available and a large range of tracers are under 
evaluation. Quantification of tracer uptake may be used as a surrogate to identify 
potentially radioresistant cell populations. The m ajority of published evidence 
for dose-painting with IMRT to HNSCC has involved FDG-PET. The ideal method 
of FDG-PET image segmentation that has practical value in the clinic is an 
im portant and as yet unresolved issue.
The accuracy of treatment delivery is of fundamental importance in all forms of 
radiotherapy. Geometric and dosimetric accuracy is of particular relevance when 
delivering dose escalated highly conformai treatment techniques such as dose- 
painting w ith  IMRT, as the potential consequences of unintentionally under- or 
over-treating the tissues may be more significant. Standard treatment 
verification has been performed using 2D in-room imaging. More recently, 3D in ­
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room imaging has become available and may be used to increase confidence in 
the quality o f geometric and dosimetric accuracy of treatment delivery.
The overall aim of this thesis was to evaluate the potential benefits that m ight be 
achieved through the incorporation of advanced imaging techniques in 
combination w ith  IMRT to HNSCC. Chapter 2 reported a comparison of five 
different FDG-PET segmentation methods. The results contributed to the 
methodology design of a pre-clinical study. This pre-clinical study aimed to 
evaluate whether dose-painting w ith  IMRT to an FDG-avid subvolume would be 
feasible and used radiobiological modelling to estimate the likely impact on TCP 
and NTCP. The results are discussed in chapter 3. Chapters 4 and 5 evaluated 
potential applications of 3D in-room CBCT imaging. A clinical p ilo t study of 
twenty patients was performed in which IMRT was delivered using CBCT image 
guidance. Chapter 4 compared CBCT image guidance against standard 2D EPI 
image guidance and evaluated the optimal imaging frequency and impact on 
appropriate CTV to PTV planning margins. Parotid sparing IMRT is a technique 
which has been shown to widen the therapeutic w indow by reducing late toxicity 
whilst maintaining tum our control. A planning study was performed to evaluate 
the potential applications of using CBCT scans acquired during treatment to 
inform on per-treatment volumetric and dosimetric changes in the contralateral 
parotid gland and is reported in Chapter 5.
6.2. Summary of thesis findings by chapter and discussion
6.2.1. Chapter 2 -  FDG-PET segmentation
FDG is a surrogate marker of glucose metabolism and is currently the most
commonly used PET tracer in clinical use. Although many groups have explored 
FDG-PET segmentation in the setting of HNSCC, the optimal technique remains 
unresolved. Accurate and consistent delineation of tumour is essential i f  FDG- 
PET is to be included in planning dose-painting w ith  IMRT. The ideal method 
should be free from in tra- and inter-observer variability, simple to use and 
consistent across different centres in which different PET scanners may be used.
218
The five different FDG-PET segmentation techniques investigated in this work 
can be broadly grouped into three main types (generated volume shown in 
brackets):
a) visual interpretation inform ing manual delineation (GTVbM),
b) fixed threshold of FDG uptake -  using an a rb itra rily  fixed percentage of 
signal intensity (PMSI) (for example, the GTVb36%), a fixed value of 2.5 of 
standard uptake variable (GTVbsuvz.s) or a semi-adaptive approach using 
a PMSI value based on individual patient source-to-background ratio 
(GTVbsBR),
c) fu lly adaptive -  using a fuzzy locally adaptive Bayesian algorithm -  the 
GTVbpLAB.
Since visual interpretation is the most commonly used approach currently in
clinical practice, the GTVbM was selected as the reference technique against 
which the other generated GTVb volumes were compared.
6 .2 .1 .1 . Fixed threshold based on PMSI
Of the various PMSI thresholds selected for evaluation, the PMSI of 36% -
GTVb36% appeared most sim ilar to the GTVbM for the ten patients in the study. 
Conformity indices were reasonable: an absolute volume index (AVI) of 1, a 
Jaccard coefficient (JC) of 0.64 -  the highest JC value of all the segmentation 
techniques evaluated and reasonable mean distance to conformity (MDC) and 
shift in centre of mass (SCM) results (45.46 and 2.55, respectively). Wilcoxon 
rank testing showed that the GTVb36% was one of only a few volumes to show 
sim ilarity to the GTVbM (p=0.770). Bland Altman testing showed small bias 
(0.893) and narrow 95% lim its o f agreement (-9.351 to 11.137).
The threshold of 36% has undergone histopathological validation w ith  
pharyngolaryngectomy specimens [1]. However, despite the encouraging results 
for this threshold, the largest problem is that it  is not possible for a single 
threshold of uptake to be applicable to all HNSCC tumours, for all patients. W hilst 
a PMSI o f 36% was validated, so too were PMSI values ranging up to 73%, for the 
small nine-patient sample evaluated by Daisne et al. Limitations of our study 
include the small sample size, only one pair of clinical oncologist and nuclear 
medicine physician contoured the reference GTVbM and using scans acquired
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from only one PET scanner. However, fixed thresholding based on a PMSI value 
is a simple and in tuitive technique which can easily be applied in a number of 
centres and could be a reasonable starting point for future work. Therefore the 
GTVb36% was selected for evaluation in the pre-clinical dose-painting study 
reported in chapter 3.
6 2.1.2. Fixed threshold of SUV 2.5
The GTVbSUV2.5 was significantly larger than the GTVbM [Wilcoxon rank 2-
tailed p value of 0.02) and was associated w ith  the largest bias of all methods of 
30.998 and wide 95% lim its of agreement (-73.081 to 135.077). Conformity 
indices indicated poor conformity and a large amount of overcontouring 
(MDC(O) 1420.15).
This result was interesting since this threshold of SUV is often used in FDG-PET 
review in lung cancer. A possible explanation is that whilst lung tumours are 
usually surrounded by air, in other words, regions of low FDG background 
uptake, this is not the case for HNSCC, where the surrounding tissues are 
frequently muscle or other structures w ith  higher physiological FDG uptake. 
Higher thresholds of SUV may be more applicable for HNSCC and could be 
explored in the future.
6.2.1.3. Fixed threshold based on source-to-background ratio 
(SBR)
Results for the GTVbsBR compared to GTVbM were similar although in general, 
modestly improved, to those of the GTVbsuvz.s and once again indicated
overcontouring compared w ith  the GTVbM. This technique was also validated by 
Daisne et al [2] and in theory seems more promising than a fixed PMSI for all 
patients as it  adapts by varying according to the SBR of individual patients. This 
finding may be related to differences in acquired PET image datasets and also the 
resolution and slice thickness of the CT component, as in our study, the CT 
component from the co-registered PET/CT scans was used and for example, the 
slice thickness was approximately 4mm compared with 2mm slice thickness 
used in standard radiotherapy planning CT. This may impact on volume 
calculation by the TPS due to the partial volume effect and analysis tools on the 
contouring station. Reconstruction of slices into smaller thicknesses would be
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useful for further clarification. Our experience found that considerable resources 
in terms of staff expertise and time, scanner time and cost of FDG were required. 
The parameters generated were scanner specific and may change if  PET scanner 
protocols or models are updated over time, necessitating repetition of the work. 
This technique may have been validated but may not be easily translated to 
routine clinical practice in all centres.
6.2.1.4. Segmentation based on fully adaptive fuzzy locally 
adaptive Bayesian algorithm (FLAB)
The GTVbpLAB was significantly smaller than the GTVbM (median difference
5.205cm^, Wilcoxon rank p value 0.010) but showed reasonable values of bias (- 
5.648) and agreement (95% lim its of agreement, -16.898 to 5.602). The JC was 
unremarkable (0.47) but the MDC of 3.03 was small compared to other methods. 
This technique appeared promising for further studies but our experience 
revealed that a major lim ita tion was the numerous challenges involved with 
im porting a foreign -  externally generated [3] -  contour into a commercial 
treatment planning system (TPS). Only a special collaboration w ith  a 
radiotherapy software designer produced a solution for im porting the GTVb FLAB 
into the TPS [4]. This is an im portant consideration for algorithms under 
development by other groups and also application to differing commercial TPSs.
6.2.1.5. Discussion
The manually delineated volume (GTVbM) was selected to be the reference
volume in this study. This choice was made to reflect current standard practice 
w ith  respect to tumour volume delineation. In 2010, the International 
Commission in Radiation Units and Measurements (ICRU) updated 
recommendations to reflect the IMRT treatment technique. The report stated 
that: 'gross tumour volumes (GTV) are delineated on a 3D basis using clinical 
(e.g., physical examination), anatomical (e.g. CT or MRl), and/or functional 
imaging modalities (e.g., PET or functional MRI).' The GTV has been defined by 
the ICRU as the 'gross demonstrable extent and location o f the tumour'. It is 
w idely accepted that the most accurate method to determine the extent of the 
GTV is by histopathological, microscopic examination of the surgical specimen. 
This approach, however, is precluded w ith  prim ary radical radiotherapy and
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represents the key challenge to designing the most accurate tum our delineation 
strategy. Clinical oncologists therefore take a m ulti-m odality approach, 
combining clinical evaluation skills w ith  interpretation of both anatomical and 
functional imaging modalities in an effort to estimate the 'true' GTV.
Visual interpretation by clinicians is prone to in tra- and inter-observer 
variability. Riegel et al reported clinician variability in delineating the GTV for 
head and neck cancer treatment planning [5]. Two radiologists and two radiation 
oncologists contoured the prim ary tumour GTV on 16 patients, firs t on the basis 
of CT alone, and then on PET/CT fusion. W hilst significant disagreement was 
noted between radiation oncologists, no differences were found between the 
volumes contoured by radiologists and the volumes contoured by oncologists, 
regardless of whether based on CT or PET/CT. Near-significant differences [p =
0.09) and statistically significant differences [p = 0.0002) were identified 
between the contours based on CT (G T V cr), and PET/CT (GTVpET/cr), 
respectively. In general, for each physician, composite or union volumes [G T V ct 
U  GTVpET/cr) formed from the GTVcT and GTVpET/CT tended to be larger in size 
than corresponding G T V ct volumes. The same group later developed a GTV 
contouring protocol and a sim ilar study was performed, during which the same 
two radiologists and two radiation oncologists were asked to re-contour the 
G TVs for the sixteen originally investigated patients [6]. The region of overlap 
between the four physicians' volumes increased significantly following use of the 
protocol (Wilcoxon signed-rank, p < 0.05). This finding supports the use of 
contouring protocols to reduce inter-observer variab ility w ith  respect to GTV 
contouring using FDG-PET/CT.
A Canadian group performed a sim ilar study in which six oncologists and two 
radiologists experienced in the management of head and neck cancer were asked 
to delineate prim ary tumour G TVs on CT scans both w ith  and w ithout contrast 
enhancement and FDG-PET/CT scans for ten patients w ith  head and neck cancer 
[7]. Intra- and inter-observer variab ility  was least w ith  contrast-enhanced CT 
scans and greatest for FDG-PET/CT. The authors concluded that these 
differences were likely to be related to the more lim ited experience when using 
FDG-PET/CT to identify the prim ary tumour extent. In contrast to Riegel and
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Berson et al, no trend for systematic contouring of larger volumes as a result of 
using different imaging modalities, was found. The effect of physician discipline, 
that is, radiology versus oncology, was not discussed. It was estimated that 
approximately 60 observer-hours had been required to generate the data for this 
study, w ith  each physician spending at least 7.5 hours perform ing the contouring 
exercise.
In the work reported in chapter 2, a clinical oncologist and radiologist jo in tly  
contoured the GTVbM. The number of patients was small (ten) and the 
radiologist lacked familiarity w ith  the radiotherapy contouring workstation, 
whilst the oncologist had lesser experience in interpreting FDG-PET/CT imaging 
than the radiologist. No differences between oncologist and radiologist approach 
to contouring can be inferred. In future work, a similar contouring exercise 
would be repeated, using FDG-PET/CT imaging data from patients w ith  HNC 
acquired at a selection of PET centres nationally and requesting clinical 
oncologists and radiologists from a number of institutions each separately to 
contour the GTVbM. The results could then be used as a basis for a national 
contouring guideline w ith  the aim to minimise intra-, inter-observer and inter- 
institutional variability. A key challenge, as commented by Breen et al [7], is the 
intensive staffing resource required. In addition, different institutions use 
different viewing platforms all associated w ith  the ir own commercial software 
image analysis tools; these factors may increase variab ility  in visual 
interpretation.
The results from this study suggest that in this centre, the segmentation 
technique which generated volumes that were most sim ilar to those generated 
manually by clinicians (GTVbM) was the fixed threshold based on PMSI, in 
particular, the fixed threshold of 36%. This finding, however, only approximates 
the contours for a small sample of patients, which were jo in tly  performed by a 
single institution's clinical oncologist and radiologist pair, on the imaging 
datasets from one single PET scanning machine. It is possible that these results 
could be different i f  a sim ilar study were to be performed, in a m ulti-institu tion 
setting. Although in our case, the PMSI of 36% appeared the most practical and 
sim ilar to the manually produced contour, a semi- or fu lly  adaptive segmentation
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technique seems more attractive, as the threshold for including or excluding 
voxels would vary according to individual patient FDG-PET/CT scan 
characteristics. Data produced from a m ulti-institu tion study would be extremely 
valuable in developing more automated segmentation techniques and hence 
reducing variation in FDG-PET/CT interpretation.
6.2.2. Chapter 3: FDG-PET guided dose-painting with IMRT to 
oropharyngeal tumours -  a pre-clinical study
A pre-clinical study was performed using the same ten patients' co-registered
FDG-PET/CT datasets which were evaluated in the FDG-PET segmentation work. 
Increasing dose levels were dose-painted to the GTVbM volume using IMRT, w ith  
conventional dose prescription to the standard planning volumes. Dosimetric 
comparison and radiobiological estimations of the potential gain in TCP against 
potential increase in NTCP were performed. The relevance of FDG segmentation 
technique was evaluated by comparing estimated TCP values associated w ith  the 
non-optimised GTVb volumes against values for the GTVbM.
6.2.2.1. Feasibility of dose-painting with IMRT to the FDG-avid 
subvolume (GTVb) and relevance of results
These pre-clinical results showed that dose-painting w ith  IMRT to the FDG-avid
subvolume was technically feasible w ithout exceeding dose constraints to organs 
at risk including the parotid gland. The D2% should ideally receive less than 
107% of the prescribed dose [8, 9]. For the GTVbM, the maximum D2% value 
was less than 103% at all dose levels but for the PTVl, the D2% was 110% of the 
PTVl prescribed dose at both DL3 and DL4. This relates to the dose gradient 
between the GTVbM and the PTVl and suggests that a pragmatic approach might 
be required.
It was not always possible to dose escalate the entire GTVbM volume, 
particularly for those patients w ith  large tumours. The GTVbM for eight patients 
ranged from 1.95cm^ to 20.63cm^ but two patients had large GTVbM volumes 
(67.69cm3 and 81.18cm3) (see Appendix 1). The D95% objective of 95% of the 
DL was possible for all dose levels. The target V100% objective for the GTVbM 
was 100%. At DL3 and DL4, it  was not possible to optimise clinically acceptable 
plans to achieve this. This highlights the difficu lty in planning dose escalation to
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larger volumes. Duprez et al reported a dose-painting w ith  IMRT study which 
found that acute grade 3 toxicity was more common in patients receiving 80.9Gy 
to a larger volume (mean 73.1cm^] than a higher dose of 85.9Gy to a smaller 
volume (mean IS .lcm ^] [9].
This raises an im portant question for dose escalation -  what lim it should be 
placed on the maximum size of the dose-painting target and whether it  should 
vary according to the level of dose escalation? Pre-clinical w ork could include 
another planning study in which a number of plans at different dose levels are 
optimised but w ith  the addition of modifying the GTVb volume through 
application of shrinking or enlarging concentric margins. Radiobiological 
comparison using TCP and NTCP should then take place in comparison w ith  the 
IMRT plans optimised to dose-paint the unmodified original GTVb volume.
Other w ork could consider another approach to IMRT plan optimisation. The 
most commonly used approach is based on setting dose parameters which are 
used to drive IMRT plan optimisation. Innovative approaches include the 
incorporation biological cost functions into the optimisation process. The 
biological volume effect of structures suggests that higher radiation doses may 
be tolerated when the irradiated volumes are smaller. Each structure or organ is 
associated w ith  a different response to dose per fraction has its own particular 
volume effect. These properties can be used to drive IMRT plan optim isation to 
obtain a dose distribution [10]. Commercial IMRT planning systems are already 
available and may present different solutions to the question of the upper limit 
of size of dose-painting target than results from conventional IMRT planning 
driven by more purely dosimetric parameters.
This pre-clinical study found that DL3 -  dose-painting a dose of 71.5Gy in 30 
fractions to the GTVbM volume - was associated w ith  an increase in estimated 
TCP of 8% and an increase in estimate NTCP for late dysphagia of 20.1% (36.1%
at DL3 compared w ith  16.0% at D L l). Hence, treatment at DL3 was associated 
w ith  a TCP of 69.7% versus a TCP of 61.7% at D L l (table 3.10]. This appears a 
reasonable choice for clinical evaluation in the context of a phase 1 clinical study.
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The reported increases in TCP in the literature vary. Tome and Fowler modelled 
the effect of selective boosting of dose to tum our subvolumes [11]. Their results 
showed that for a population o f relatively radiosensitive cells, that a boosted 
dose of 115% achieved an estimated 11% increase in TCP. Our results, w ith  
dosepainting of an additional 10%, associated with an estimated increase of 8% 
in TCP, seem reasonable.
Thorwarth et al reported a planning study investigating different dose-painting 
strategies involving thirteen patients w ith  head and neck cancer [12]. Three 
IMRT plans were created for each patient: a conventional IMRT plan, an 
additional uniform dose escalation (uniDE] of 10% to the FDG-avid subvolume, 
and a dose-painting by numbers [DPBN] plan. Estimated TCPs were 55.9%, 
57.7% and 70.2%, respectively. This translates to an increase in TCP of 3.2% 
when comparing conventional dosing w ith  a 10% boost to the FDG-avid 
subvolume. The numerical value of the estimated TCPs appears low at only 
55.9% at a standard dose equivalent to 70Gy, compared w ith  our result which 
suggested a TCP of 61.7% at a 70Gy equivalent dose. One possible explanation is 
that the median size of the GTVbM volume was 10.78cm^ (range: 1.95-81.18) 
(table 2.6) and much smaller than the corresponding size of the FDG-avid 
subvolumes in the w ork of Thorwarth et al: median 31.67cm^, range 7.32-94.34). 
The authors reported that it  was more difficu lt to treat the entire target volume 
w ith  boost dose when the target was large due to the enhanced risk of acute 
reactions. However, with the DPBN approach, only small areas received 
comparable radiation doses and therefore desired dose escalation, w ith  
increases in estimated TCP, were possible whilst maintaining isotoxicity.
Differences in reported TCP estimates can further be explained by differences in 
chosen radiobiological parameters. Thorwarth et al based the ir model on 
parameters derived from dynamic i^F-fluoromisonidazole (FMISO) studies in 
which real patient dynamic FMISO data was correlated w ith  treatment outcome 
[12, 13]. The authors acknowledge that the model was based on a small (fifteen) 
patient sample which may be prone to errors. Thorwarth et al reported using a 
tumour cell sensitivity parameter alpha of 0.4Gy^with a clonogen density of 10^ 
cm-3. Alpha values in the literature range between 0.2 and 0.5Gy i  and clonogen
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density values range 10^ to 10^ cm'^ [14-17]. W ith respect to radioresistant 
tumour cell subpopulations, Fenwick reviewed available data and suggested that 
the alpha value of the most radioresistant subpopulation was only half that of the 
mean alpha value for that tumour. It has been proposed that certain clonogen 
subpopulations have greater impact in determining tumour control. These 
subpopulations may be small and justify values below 10^ cm-3. In the work 
presented in this thesis, a more conservative approach was adopted w ith  respect 
to the chosen radiobiological parameters and therefore an alpha of 0.27 G y i and 
clonogen density of 10^ cm'  ^were used for the purpose of TCP estimation and 
may have contributed to the lower estimates of TCP compared w ith  the 
literature.Published evidence supports the hypothesis that dose escalation using 
IMRT has the potential to improve locoregional control rates w ithout increasing 
late toxicities. Guerrero Urbano et al reported results from a phase 1 study of 
dose-escalated chemoradiation in SCC of the larynx and hypopharynx [18]. Two 
radiation dose levels (DL) were tested: D Ll at a dose equivalent to 70Gy in 35 
fractions and DL2 which involved a dose equivalent to a 9% dose escalation to 
the prim ary tumour. Fifteen patients were treated in each dose level. Complete 
response rates were 80% in D L l and 87% in DL2. These clinical results are 
superior to the estimated TCP values generated in this thesis (table 3.10], in 
which D L l was associated w ith  a median estimated TCP of 61.7% and DL3 
(equivalent to a 10% dose escalation to the GTVbM) w ith  a median estimated 
TCP of 69.7%.
The higher rate of tumour control observed in the phase 1 study mentioned 
above may be associated w ith  the neo-adjuvant use of two cycles of cisplatin and 
5-fIuorouracil chemotherapy followed by two doses o f concomitant cisplatin 
w ith  radiation. A well-known meta-analysis has shown that concomitant 
chemotherapy is of significant benefit with respect to loco-regional failure 
(hazard ratio (HR) 0.74 (0.70-0.79), p<0.0001) [19]. It is therefore like ly to have 
contributed to the high response rate observed in the phase 1 study.
Radiobiologists have attempted to quantify the therapeutic contribution of 
chemotherapy to local tumour control. Plataniotis and Dale reviewed clinical 
data from randomised controlled trials of concomitant chemoradiotherapy for
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cervical cancer [20]. In tumour w ith  intermediate radiosensitivity w ith  alpha 
ranging 0.22-0.28Gy h it  was proposed that the addition of concomitant 
chemotherapy corresponded w ith  between 1.2 and 2.6Gy of extra dose, in 2Gy 
fraction sizes. W ith respect to the pre-clinical study reported in this chapter, i f  
the contribution of concomitant chemotherapy is proposed to be approximately 
2Gy, compared w ith  the standard D L l o f 70Gy in 2Gy fractions, this would 
correspond effectively to an increase in dose of 2.9%. In turn, the addition of 
chemotherapy might translate to an increase in dose to 112.9% when DL3 
(71.5Gy in 30 fractions, equivalent to 110% of D L l) is applied. From table 3.10, it 
can be seen that at a dose escalation of 115% (DL4), the median estimated TCP 
value was 73.0% (range: 67.0-78.4%), compared with 61.7% (range 51.9-69.6%) 
at DLl.
Miah et al reported a phase l / I l  dose escalation study in which an increase in 
biologically equivalent dose of 9% (DL2, translating to 76Gy in 2 Gy fractions) 
was delivered to the prim ary tumour, preceded by two cycles of induction 5- 
fluorouracil (5FU) and cisplatin chemotherapy followed by concomitant cisplatin 
w ith  IMRT [21]. Acute grade 3 dysphagia was increased by 28% w ith  dose 
escalation but only 8% (two out of twenty-four) of patients were found to have 
late grade 3 (one patient) or 4 (one patient) dysphagia compared w ith  5% at the 
standard dose. The two-year locoregional progression-free survival rate was 
78.4% w ith  the DL2 group compared w ith  64.2% for DLl. The authors 
developed a m ulti-institutional phase 111 study, ART-DECO -  Accelerated 
RadioTherapy-Dose Escalation versus Conventional dose), on these findings 
which is now open to recruitment and which w ill provide im portant tumour 
control and toxicity data for the dose escalation technique.
Another group, Madani et al, have also reported clinical data which 
demonstrated that FDG-PET-guided dose escalation w ith  doses to either the GTV 
(72.5Gy in 32 fractions, dose level 1) or 77.5Gy in 32 fractions to the FDG-avid 
subvolume (lim ited to a maximum size of lOcm^) was well-tolerated [22]. At a 
minimum of six months after the end of treatment, one patient out of ten (10%) 
had late grade 3 dysphagia compared w ith  three patients out of twenty (15%) in
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the lower dose arm. There was no incidence of grade 4 late toxicity. There was 
no significant difference in tumour response between the two interventions.
6.2.2.2. Translation of pre-clinical work to a phase I clinical study
- considerations
The pre-clinical study reported in this thesis has been translated into a clinical 
phase I study. It is anticipated that, if, as pre-clinical data suggests, the phase I
study demonstrates that this technique is feasible, the next step would be to 
develop a multi-institutional phase 111 clinical study. The use of induction 
chemotherapy p rio r to radical chemoradiation for HNSCC is reasonably 
prevalent in the UK compared w ith  the rest o f Europe. This consideration may 
impact decisions regarding the optimal tim ing of the FDG-PET/CT scan in the 
radiotherapy planning pathway, especially if induction chemotherapy is to be 
given, when designing the phase 1 study. It would not be appropriate to perform 
the FDG-PET/CT scan prio r to embarking on two three-weekly cycles (the 
standard regimen] of chemotherapy since tumour and patient anatomy are likely 
to change as a result of time and chemotherapeutic intervention by the time the 
patient proceeds to radical chemoradiation, six weeks later. I f  the FDG-PET/CT 
planning scan was performed immediately p rio r to chemoradiation, however, 
there is a risk that tum our FDG-uptake might be greatly reduced and provide 
poor quality information regarding a dose-painting target. Definitive data w ith  
large sample sizes investigating the effect of a single cycle of induction 5FU and 
cisplatin chemotherapy is not currently available. Yoon et al reported changes in 
maximum SUV as seen on FDG-PET performed at baseline and at two to four 
weeks following completion of two to three cycles of three-weekly induction 
cisplatin and an oral fluoropyrim idine [23]. Reductions in maximum SUV in the 
prim ary tumour ranged from 45.9% to 93.6% w ith  the median maximum SIV 
being 3.2 (range 1.0 to 6.4). For four out of seventeen patients, the maximum 
SUV reduced to less than 2.0.
Moule et al investigated FDG-PET segmentation techniques during a course of 
radical radiotherapy to HNSCC. FDG-PET/CT scanning was performed at
cumulatively acquired radiation doses of 0, 10, 44 and 66Gy delivered in 2Gy 
fraction sizes [24]. W ith respect to measured SUV, no statistically significant
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effect was seen before a m inimum cumulative dose of 36Gy [w ith  six out of ten 
patients receiving concomitant cisplatin chemotherapy). It seems reasonable to 
conclude that it  would appear unlikely that a single cycle of cisplatin and 5FU 
chemotherapy could have an equivalent effect to a cumulative dose of 36Gy, w ith  
or w ithout concomitant chemotherapy. It could therefore be anticipated that the 
number of patients in whom, following a single cycle of induction cisplatin and 
5FU, the degree of FDG uptake compared to pre-treatment uptake reduces such 
that an FDG-avid target volume cannot be adequately demonstrated, is likely to 
be small.
Furthermore, standard radiotherapy planning pathways can require up to 28 
days as so many steps and staff groups are involved: production of an 
immobilisation device, planning scans, delineation, optimisation and quality 
assurance [QA) procedures. A pragmatic compromise would be to perform the 
FDG-PET/CT planning scan on the same day, immediately p rio r to 
administration o f the second cycle of induction chemotherapy.
Another im portant consideration to be incorporated in the design of the clinical 
study is the FDG-PET/CT scanning protocol. This w ill need to address a number 
of issues. In our pre-clinical study, due the differences in positioning between 
diagnostic PET scans used for the study and the actual radiotherapy department 
planning CT scan, it  was not possible to co-register the PET scan with the 
planning CT scan w ith  accuracy. For the purpose of the study, the CT component 
of the FDG-PET/CT scan was therefore used for the study. Quality assurance 
(QA) procedures of the CT component of the PET scanner were performed by the 
radiotherapy physics team with satisfactory results with respect to the image 
datasets. In a future clinical study, the patient w ill need to be scanned positioned 
on a couch setup identical to that in the radiotherapy treatment room and w ith  
immobilisation in place. Rigorous QA of the CT component of the scanner to 
radiotherapy department standard must be completed. Radiation protection of 
staff must be considered. PET technologists have undergone training w ith  
respect to handling radioactive tracers but pre-treatment radiographers who 
w ill be involved w ith  positioning patients whilst 'hot' on the PET scanner bed 
w ill not have undergone the same rigorous training. Jarrit et al reported a p ilot
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study incorporating FDG-PET/CT for radiotherapy planning for patients w ith  
lung cancer [25]. The average staff dose per patient was approximately 3.0 -  3.5 
pSv. These doses are comparable w ith  those obtained by diagnostic staff 
throughout the entire imaging process. PET scanning protocols differ between 
centres and therefore collaboration w ith  a national body such as the National 
Cancer Research Institute [NCRl) PET Research Network is im portant [26].
6.2.3. Chapter 4: Image-guided intensity modulated radiotherapy (IG- 
IIVIRT) using cone beam computer tomography (CBCT) in patients 
with head and neck cancer (HNC) -  a clinical study
A p ilo t study involving twenty patients was performed to evaluate potential
applications of CBCT w ith  respect to patients receiving IMRT for HNC. CBCT was 
new technology to the department and not in clinical use at the time of the study. 
2D verification using electronic portal imaging (EPl) was standard practice in 
this department. The results from this study enabled a comparison of 3D -  CBCT 
-  image guidance w ith  standard 2D guidance, informed on the ideal frequency of 
imaging and provided a basis for appropriate update of planning margins for this 
group of patients. Four verification strategies were used to measure 
displacement:
1. Daily CBCT using automatic matching, CBCTdaiiy, auto
2. Daily CBCT using therapy radiographer matching, CBCTdaiiy
3. Weekly kV EPl using therapy radiographer matching, kV EPlweeWy
4. Weekly CBCT using therapy radiographer matching, CBCTweekly
The results showed that both systematic and random components of set-up 
error were small for all four verification strategies. A statistically significant 
difference was noted between the automatic and manual techniques, as m ight be 
expected and the remainder of the comparison was performed between the 
three remaining manual matching techniques.
Regarding systematic errors, these were calculated to be: vertical direction -  
1.49 to 1.68mm, longitudinal direction 1.37 to 1.76mm and lateral direction -  
1.10 to 1.14mm for all strategies. Random errors in the vertical, longitudinal and
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lateral directions were 1.64 -  1.74mm, 1.39 -  1.55mm and 1.19 -  1.37mm, 
respectively. Reassuringly, these results were small and also comparable w ith  
data from other centres (table 4.12). Correlation between verification strategies 
was good (r statistic 0.76 -  0.96, p < 0.0001) for systematic error and reasonable 
for random error (r  statistic 0.34 -  0.72, p < 0.0050).
Appropriate CTV to PTV margins were calculated by applying the 'Van Herk 
margin recipe' [27]. Results are summarised below:
Table 4.11. Planning target volume (PTV] margins in mm calculated using 
setup error recorded by various imaging strategies.
Vertical Longitudinal Lateral
CBCT daily, auto 2.75 3.53 3 .14
CBCTdaiiy 4.87 4.52 3.73
CBCTweekly 5.42 4 .91 3.68
kVEPIweekly 5.27 5.37 3.72
As systematic and random components of setup error were sim ilar for all 
techniques, the calculated margins did not differ greatly according to verification 
strategy. CTV to PTV margins in the vertical and longitudinal direction were all 
approximately 5mm and 4mm in the lateral direction. These margins would 
apply i f  no correction at all had been performed. Current planning margins in 
this department are 3mm for the patients wearing head and neck immobilisation 
devices. The minimum action level for positional correction is 3mm. These 
results provide clinical confidence that the currently used CTV to PTV margin is 
appropriate.
Overall, the three verification strategies appeared to be similar and share good
agreement, w ith  the net result that the CTV to PTV margins were approximately 
the same. The next question is which technique and which frequency to apply? 
The kV EPl and CBCT appeared to be consistent in measuring displacements. The 
main reason for this is that matching was still performed according to vertebral 
bodies, which are clearly imaged on simple kV EPls. However, CBCT provides
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greater detail regarding soft tissues and also provides a slice-by-slice view. There 
were occasionally some discrepancies between displacements recorded by CBCT 
versus kV EPl and although this did not occur w ith  such frequency that it 
affected set-up error, could have been clinically relevant to that patient on the 
day that the discrepancy would have occurred (for kV EPl, only offline review 
was performed for the purpose of the study).
Online daily matching is able to reduce random error. Even w ith  daily online 
CBCT matching, however, residual error may remain after appropriate 
correction of displacement before treatment delivery. Den et al showed that 
residual errors measured 0.9mm +/- 0.9 in the vertical and longitudinal 
directions, and 0.7mm + /- 0.8 in the lateral direction [28]. The temptation w ith  
3D in-room imaging such as CBCT is to assume that if online matching is 
performed, the planning margin can be minimised. This is dangerous, as shown 
by the residual error reported by Den. The couch geometry is lim ited and 
precision of movement is between 1 and 2mm. Organs in the head and neck 
region -  even w ith  head and neck/shoulder immobilisation -  may still move 
during the treatment beam on time.
There is an assumption that the quality of image review is identical for each 
therapy radiographer but this is not always easy to deliver in realtime. Finally, 
compromises are sometimes made to find a ‘best f it ’ -  prioritis ing the match in a 
critical region of dose to provide safety to radiation-sensitive critical organs such 
as the spinal cord, but then having to accept a compromise of slightly inferior 
matching to a target volume. The cervical spine region has a very large number 
of degrees of freedom which can lead to rotational displacements of up to 4 
degrees [29]. In IMRT, there are frequently regions of steep dose gradient 
between the target volumes and the cervical spinal cord. The treatment couch in 
our department was only able to correct for floor rotations but rotational 
displacements were noted -  and appeared more clearly demonstrable on 
volumetric than planar imaging -  in the vertical and longitudinal direction. 
Treatment couches which allow correction of rotation in six degrees of freedom 
are commercially available which w ill provide the opportunity to estimate the 
dosimetric consequences of rotational displacement.
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This p ilo t study in which CBCT volumetric guidance was used to deliver radical 
IMRT to patients w ith  HNC was successful. Staff reported that it  was an ideal way 
to introduce new technology in clinical practice, as patients were treated in 
dedicated research slots which provided longer appointment times [th irty  
minutes), w ith  senior radiographer and clinical oncology medical staff present to 
support the therapy radiographer, who were in itia lly  somewhat apprehensive of 
perform ing matches in three dimensions rather than two. Online matching did 
not prove overly onerous in terms of linac time or in terms of stress to the staff. 
An evaluation of the impact of online matching on room-time was performed. 
The average room-time was 21 minutes per patient -  including time data 
acquired from treating the very first patient in the study. The standard treatment 
slot was twenty minutes and therefore, online matching using 3D image 
guidance only required one minute more than standard 2D guidance treatment 
slots.
In conclusion, daily online CBCT image guidance is feasible in clinical 
departments and offers the optimal opportunity to minimise set-up error.
6.2.4. Chapter 5: Volumetric and dosimetric verification using CBCT in 
IG-IIVIRT to HNC
This study aimed to evaluate how CBCT image guidance could be used to guide 
adaptive radiotherapy strategies. Adaptive radiotherapy is an exciting treatment 
strategy in which the radiotherapy plan is modified during treatment according 
to changes in the patient or tumour anatomy or behaviour. As discussed in 
chapter 3, it  was not always possible to deliver dose-painting IMRT to the entire 
biological target volume (GTVb) for two patients who both had large FDG-avid 
subvolumes of greater than 65cm^ in size. Adaptive radiotherapy potentially 
offers a solution in the case where the tum our volume responds to treatment and 
shrinks during a course of treatment. Replanning can then be performed, 
providing an opportunity to improve the dose distribution and even potentially 
to reduce dose to nearby tissues.
In this work, CBCT scans from the firs t and last week of treatment were imported 
into the TPS. The contralateral parotid gland was contoured on the CBCT 
datasets. The corresponding fraction's correctional shifts were applied before
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setting up the IMRT plan on the CBCT and calculating the plan. Volume and dose 
data were recorded. NTCP estimates were also performed to estimate the 
probability of late xerostomia. The results showed that the contralateral parotid 
gland reduced in volume by a mean of 14.3% [range -37.9% to -0.2%) which 
appears comparable w ith  published data. In addition, some of the published data 
relates to reassessment of parotid glands based on diagnostic quality CT. Volume 
shrinkage results from this study lie comfortably in the range of data reported in 
the literature and also compared well w ith  original planning CT volume data for 
the parotid glands for the corresponding patients in this study. This adds to 
confidence in using this technique for volumetric and dosimetric verification, 
providing the organs can be adequately visualised.
Our experience showed that CBCT can be used to inform on changes in volume
and dosimetry during a course of radical radiotherapy. The image quality of 
CBCT scans is of insufficient quality to visualise soft tissues to the standard 
required for IMRT planning but were sufficiently adequate, that the 
intraobserver variab ility  in contouring the parotid glands was small. This 
suggests that CBCT, apart from being an in-room tool to detect positional 
displacements, may also have the potential application to detect early volumetric 
and dosimetric changes which may in turn  facilitate replanning approaches, 
where appropriate.
6.3. Concluding remarks
The firs t part of this thesis provided a basis for a future phase 1 clinical study to
evaluate the feasibility of dose-painting IMRT to squamous cell carcinoma of the 
oropharynx. Radiobiological estimation suggested that an 8% increase in TCP
might be possible w ith  an associated increase in NTCP for late dysphagia of 
around 20%. The FDG segmentation w ork showed that methodology for 
identification o f the dose-painting target is im portant and can vary widely. 
Although a single fixed threshold of FDG uptake cannot be applied to all clinical 
situations, it  is however simple, intuitive, reduces inter-observer variab ility  and 
should be available in most centres, unlike institutional-specific algorithms. High 
dose radiotherapy treatments require a high degree o f precision in delivering 
this treatment. The second part of this thesis reviewed the implementation of
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new volumetric in-room image guidance. CBCT could be used w ith  success to 
provide confidence in not only the geometric accuracy of delivery but could also 
be used inform  on per-treatment volumetric and dosimetric changes w ith in  the 
patient.
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